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Abstract 
Stem cell therapy demonstrates much promise for the replacement of damaged 
tissue in several diseases, including spinal cord injury.  However, challenges around 
the control of stem cell fate in situ still hinders effective recovery of the normal tissue 
function.  Stem cell encapsulation permits their immobilization within biocompatible 
scaffolds, allowing for a better control of parameters such as proliferation, 
integration, migration and differentiation within the host tissue.  A customized 
microfluidic device was developed for the production of alginate microcapsules.  The 
diameter of such microcapsules could be easily controlled by the modification of the 
fluids flow rates, allowing for the reproducible production of highly monodisperse 
microcapsules.  This microfluidic method was then successfully applied for the 
encapsulation of two different types of stem cells: (i) Neural Stem Cells and (ii) Dental 
Pulp Stem Cells.  Both cell types demonstrated survival within the alginate 
microcapsules for up to three weeks in culture.  However, an early egress of cells 
from inside to outside of the microcapsules was observed 3 days post-encapsulation.  
In order to delay such cell escape, alginate microcapsules were modified through the 
addition of type I collagen.  The alginate-collagen microcapsules permitted similar 
rates of cell survival and permitted the delay of cell egress until 10 days after 
encapsulation.  Stem cells demonstrated a retention of their stem cell and neuronal 
differentiation properties upon selective release from alginate-collagen 
microcapsules, as demonstrated by high proliferation rates and the production of 
stem cell and neuronal markers.  When cell-laden microcapsules were transplanted 
into an ex vivo SCI model the microcapsules were able to effectively retain the 
transplanted stem cells at the site of implantation.  Transplanted cells survived up to 
10 days in culture after transplantation and demonstrated the production of 
neuronal markers within the cord cultures.  The results presented in this thesis 
demonstrate the ability of stem cells to retain their viability and neuronal 
differentiation capacity within alginate-collagen microcapsules, thereby providing a 
promising future therapy for the treatment of spinal cord injury.  
 
  
 
 
 XV 
 
Aims of the Project 
The main objective of this thesis was to attempt to encapsulate stem cells within 
biocompatible scaffolds for further application in regenerative medicine, specifically, 
in spinal cord injury (SCI) repair.  It was hypothesized that the encapsulation of stem 
cells within biocompatible scaffolds would permit a better control of stem cell 
parameters, such as proliferation, migration, integration and differentiation.  Hence, 
the aims of this thesis can be described as follows: 
1) The development of a customized microfluidic device for the production of 
alginate and alginate-collagen microcapsules and the optimisation of 
microfluidic parameters to reproducibly produce polymer microcapsules with 
diameters < 500µm 
2) The application of the microfluidic device for the viable, long-term 
encapsulation of stem cells  
3) To compare the behaviour of encapsulated stem cell types, including cell 
viability and proliferation and the maintenance of stem cell and neuronal 
differentiation potential upon release from microcapsules 
4) To study the behaviour of encapsulated cells within an ex vivo SCI model as a 
precursor to future (outside of this thesis), pre-clinical studies  
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The field of regenerative medicine offers the potential to treat a multitude of 
debilitating and deadly conditions such as myocardial infarction (Bai et al. 2011), 
diabetes (Acarregui et al. 2014) and spinal cord injury (Fan et al. 2017), by replacing 
and regenerating lost or damaged tissue.  Stem cells are ideal candidates to 
regenerate injured tissues, due to their potential to become into different cell 
lineages.  However, the poor control of stem cell fate in situ and the loss of 
transplanted cells due to immune responses limit their clinical application (Li et 
al.2016).  Hence, the immobilization of stem cells within biocompatible scaffolds has 
gained great attention over the last decades in the field of regenerative medicine 
(Asghari et al. 2017).  Immobilized cells within biomaterials permits their protection 
from potential harmful agents at the site of implantation, while allowing for a better 
control of cell parameters, including integration, migration, proliferation and 
differentiation (Banerjee et al. 2009; Jun et al. 2013).  
It has been demonstrated that the physico-chemical properties of 
biomaterials have a profound influence in the stem cell behaviour mechanisms.  
Hence, the selection of the biomaterial is of a key importance to guarantee the 
correct performance of the grafted cells.  Alginate is one of the most used scaffolds 
in regenerative medicine due to its biocompatibility, low toxicity, relatively low cost 
and mild gelation conditions (Lee & Mooney 2012).  Its versatility permits the 
modification of its mechanical properties depending on the desired application.  
However, despite these advantageous features, alginate itself may not be an ideal 
material, since it is unable to specifically interact with mammalian cells (Rowley et al. 
1999).  Cell anchorage is critical in many cellular functions including migration, 
proliferation and differentiation.  Hence, alginate has been usually combined with 
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other biomaterials, such as collagen.  Because collagen is the main component of the 
extracellular matrix, it is also one of the most used biomaterials for cell 
immobilization.  The high content of amino acids, makes collagen a biologically active 
material which promotes excellent cell adhesion and growth.  Furthermore, collagen 
is biodegradable and so allow immobilized cells, over time, to produce their own 
extracellular matrix and replace the degraded scaffold. 
Among the biomaterials geometry, microcapsules are often the preferred 
format for cell immobilization due to their high surface area to volume ratio, which 
enhances mass transfer through the polymer membrane (Liu et al. 2014).  Because 
the reproducibility of the size of microcapsules is critical in clinical application, 
microfluidics has gained the attention of researches to produce cell-laden 
microcapsules (Jang et al. 2016).  This technology offers a tight control of the 
parameters governing the formation of microcapsules and allows to work in a sealed 
environment, thereby avoiding potential cross-contamination.   
Thus, previous research has reported that the therapeutic delivery of 
encapsulated stem cells is a promising approach for increasing cell survival in tissue 
regeneration.  Therefore, the overall aims of this thesis were to develop a customized 
microfluidic device for stem cell encapsulation within alginate or alginate-collagen 
microcapsules, and further application into an ex vivo SCI model. 
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1.1 Spinal Cord Injury 
Spinal cord injury (SCI) involves devastating neurological deficits resulting in 
permanent functional motor and sensory loss.  The lack of effective treatments to 
overcome this condition explains the increasing interest among the scientific 
community to investigate and develop novel therapies (Zeb et al. 2016; Karsy & 
Hawryluk 2017).  
There are different causes of SCI, generally grouped into (i) non-traumatic and 
(ii) traumatic causes.  Non-traumatic causes include arthritis, cancer, inflammation, 
infections or disk degeneration (Prasad & Schiff 2005; Ward et al. 2015).  These 
conditions provoke a compression on the spinal cord leading to the loss of its normal 
function.  Traumatic causes involve the physical disruption of the spine due to traffic 
accidents, acts of violence, falls and sports injuries, amongst others (Chen et al. 2013).  
 
1.1.1 Anatomy and Physiology of the Spinal Cord 
The spinal cord (SC) is a bundle of nerves that extends from the brain down to 
the lumbar region of the vertebral column.  The interior of the cord is made of grey 
matter, forming a butterfly-shaped cross-sectional area that is mainly composed of 
cell bodies.  It is surrounded by white matter, which is formed by myelinated axons, 
named tracts.  The spinal cord is covered by the meninges, a group of fibrous 
membranes including the dura mater, arachnoid and the innermost pia mater, that 
give support and protection to the spinal cord (O’Rahilly et al. 2004) (Figure 1.1A).  
Along with the brain, the spinal cord forms the Central Nervous System (CNS), and it 
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enables the transmission of information between the brain and the peripheral 
nervous system (PNS), controlling both somatic and autonomic reflexes (Figure 1.1B).  
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Figure 1.1.  Schematic representation of the spinal cord anatomy and function.  A) The SC is 
made of grey matter, mainly composed of cell bodies.  This is surrounded by white matter, 
which is formed by myelinated axons (tracts).  SC is protected by the meninges (dura mater, 
arachnoid and pia mater).  B) SC enables the transmission of information between the brain 
and the PNS, controlling both somatic and autonomic reflexes.  Adapted from Mescher 
(2016) 
A
B
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Among the different types of neuronal cells in the spinal cord, neurons are 
responsible for the transmission of electrical signals between the CNS and the PNS 
through a highly connected neuronal network.  Neurons are identified by the 
expression of β-III tubulin, microtubule associated protein 2 (Map2) (Caceres et al. 
1986) and diverse types of neurofilaments (NF) (Lee & Cleveland 1996).  Their 
multipolar morphology allows neurons to receive chemical signals from other 
neurons and transmit them via axonal projections (synapses) over long distances.  
There are several types of neurons and each of them plays a different role in the 
transmission of an electrical signal.  Sensory neurons bring information from the 
receptor to the spinal cord and link, through the interneurons, with the motor 
neurons that carry impulses out to the effector, such as muscles or glands (Sheerin 
2004).  
Neurons have a characteristic electrically excitable membrane that allows the 
generation of action potentials and therefore, the transmission of information along 
the spinal cord.  At resting state, neurons contain high intracellular concentration of 
K+ and low concentration of Na+ and their neuronal membranes are held at a low 
potential.  Chemical stimulation provokes the membrane depolarization to its 
threshold potential, which in turn leads to the opening of voltage-activated ion 
channels and the entrance of Na+ ions into the cell, starting an action potential.  The 
action potential travels along the neuron as Na+ channels open.  As soon as 
depolarization is complete (peak action potential), Na+ channels inactivate and K+ 
channels open, allowing K+ to leave the cell, bringing the membrane potential to 
more negative values than the cell's normal resting potential (hyperpolarization).  
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Passive diffusion of the extra K+ ions out of the cell through the potassium leakage 
channels, allows the cell to return to its resting membrane potential (Figure 1.2). 
In order to achieve an efficient action potential transmission over long 
distances, axons are covered by myelin sheaths.  Myelin acts as an insulator 
preventing current loss from the axons and increasing the speed of the axon potential 
conduction.  There are specific areas in the axon uncovered by myelin, called nodes 
of Ranvier (Tasaki & Mizuguchi 1948).  These myelin sheath gaps are highly rich in Na+ 
and K+ channels, allowing the regeneration of the action potential repeatedly along 
the axon, accelerating the action potential transmission.  Since action potentials 
"jump" from one node to the next, this process is known as saltatory conduction 
(Purger et al. 2016) (Figure 1.3).  
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Figure 1.2.  Action potential transmission along the axon.  (1) A chemical stimulus causes the 
neuronal membrane depolarization toward the threshold potential.  (2) When the threshold 
of excitation is reached, Na+ channels open and the membrane depolarizes.  (3) At the peak 
action potential, K+ channels open and there is an efflux of K+ out of the cell.  Simultaneously, 
Na+ channels close. (4) The membrane becomes hyperpolarized as K+ ions continue to leave 
the cell.  (5) The K+ channels close and K+ leaves the cell by passive diffusion through 
potassium leakage channels.   
 
Figure 1.3.  Schematic representation of the action potential propagation through saltatory 
conduction.  The transmission of action potentials over long distances is enabled by axons 
myelination.  Nodes of Ranvier allow the regeneration of action potentials repeatedly, 
“jumping” from one node to the next (saltatory conduction).  Adapted from Siddique & 
Thakor 2013. 
Neuron
Node of Ranvier
Myelin sheath
Oligodendrocytes
Saltatory conduction of 
action potential
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Oligodendrocytes synthesize myelin providing insulation to axons, but also, 
they provide trophic support to neurons by the production of glial cell line-derived 
neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF) and insulin-
like growth factor-1 (IGF-1) (Bradl & Lassmann 2010).  Numerous processes extend 
from the body of oligodendrocytes, allowing one single cell to myelinate multiple 
axons (Watkins et al. 2008).  Oligodendrocytes are identified by the expression of 
myelin-associated proteins such as myelin basic protein (MBP), 
myelin/oligodendrocyte specific protein (MOSP) or galactocerebroside (GalC) 
(Buchet & Baron-Van Evercooren 2009). 
The CNS possesses its own set of immune cells, called the microglia.  These 
cells are identified by the expression of cell surface markers such as CD11b, CD45 and 
ionized calcium binding adaptor molecule 1 (IBA-1) (Sedgwick et al. 1991).  Microglia 
form a network of cells distributed throughout the central nervous system.  They act 
as macrophages, phagocytosing and scavenging the CNS for damaged or unnecessary 
neurons and infectious agents (Gehrmann et al. 1995).  Furthermore, microglia play 
a key role in inflammation, releasing active molecules that activate a cascade of 
inflammation events as a response after damage or infection (Aloisi 2001). 
Homeostatic support to neuronal cells is provided by astrocytes.  These star-
shaped cells are identified by the expression of glial fibrillary acidic protein (GFAP) 
and S100b calcium-binding protein (Nolte et al. 2001; Ogata & Kosaka 2002).  As part 
of their supporting role in the CNS, they provide biochemical support to endothelial 
cells that form the blood–brain barrier, supply nutrients to the nervous tissue and 
maintain the extracellular ion balance.  They are also responsible for the scarring 
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process following SCI (Kimelberg & Nedergaard 2010).  Hence, a highly controlled 
coordination of all the neuronal cell types is of a key importance in the maintenance 
of the proper function of the spinal cord. 
 
1.1.2 Pathophysiology 
Spinal cord injuries can cause the permanent loss of motor and sensory 
function.  Depending on the location and severity of the damage, injury can be 
complete, leading to a total loss of function, or incomplete, where some motor and 
sensory function remains in the organism.  SCI creates a highly complex inhibitory 
environment with a multitude of obstacles that limit the recovery.  When the spinal 
cord is injured, there is a physical disruption of axons, cell membranes and blood 
vessels, which occurs as the direct result of the mechanical trauma.  This primary 
injury provokes a cascade of cellular and biochemical reactions that leads to further 
damage and the significant expansion of the injury site, known as secondary injury 
(Fleming et al. 2006). 
Primary injury occurs as a result of blunt impact, compression or penetrating 
trauma.  Blunt impact leads to concussion, contusion, laceration, transection or 
intraparenchymal haemorrhage, whereas hyperflexion, hyperextension, axial 
loading, and severe rotation might be caused by cord compression.  Penetrating 
trauma can occur as a result of gunshots and stab wounds.  Immediately after 
mechanical trauma, cell membranes become disrupted leading to cell necrosis at the 
point of impact (Hulsebosch 2002).  The physical insult of the cord also leads to the 
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disruption of the blood-spinal cord barrier, allowing immediate neutrophil invasion 
into the neural tissue and activation of resident microglia (Fleming et al. 2006). 
In a secondary injury, activated microglia release pro-inflammatory molecules 
attracting blood monocytes to the lesion site and hence, increasing the inflammation 
(Donnelly & Popovich 2008).  The release of proteolytic and oxidative enzymes by 
activated microglia leads to DNA and protein damage, which subsequently drives cell 
death and disruption of neuronal signalling (Fleming et al. 2006).  Activated microglia 
also release neurotransmitters, such as glutamate, causing their accumulation and 
the loss of homeostasis, thereby provoking cell death via excitotoxic mechanisms 
(Yanase et al. 1995).  Oligodendrocytes are damaged by macrophages at the lesion 
site after the injury and continue to undergo apoptosis in the neural tissue for many 
weeks after SCI (Comalada et al. 2012).  The result of the loss of oligodendrocytes is 
the demyelination of axons (Hains et al. 2003).  During the process of demyelination, 
axons are directly exposed to damaging effects such as inflammatory cytokines and 
free radicals, leading to neuronal loss.  As a result, demyelination leads to delays in 
conduction or even its total disruption (McTigue 2008).  
Activation of an inflammatory response contributes to the formation of axonal 
growth-inhibitory glial scar and the production of pro-inflammatory radicals, leading 
to a harsh environment at site of injury which is responsible for the limited 
regeneration capacity of the injured spinal cord (Rolls et al. 2008).  Several days after 
the primary injury, astrocytes migrate towards the injury site and proliferate forming 
a tight interwoven called the glial scar (Kawano et al. 2012).  The glial scar is regarded 
as a mechanically obstructive barrier, preventing the infiltration of immune cells and 
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inflammatory molecules to restrict the damage area (Cregg et al. 2014).  The 
expression of inhibitory molecules, such as chondroitin sulphate proteoglycans, 
contributes to the glial scar inhibiting axonal regrowth (McKeon et al. 1991).  
However, recent studies have demonstrated that astrocytes express multiple axon-
growth-supporting molecules suggesting that, contrary to the widely stablished 
consideration, astrocyte scar formation might aid rather than prevent axon 
regeneration in the central nervous system (Anderson et al. 2016).   
 
1.1.3 Tissue engineering approaches for SCI 
Microglia activation following SCI is maximal between 3 and 7 days post-injury, 
causing widespread cell damage and deterioration of the extracellular matrix 
(Sinescu et al. 2010).  These inflammatory events in the first week after SCI create a 
hostile environment, which is lethal to transplanted cells.  This explains the low 
effectivity of cell replacement therapies during this period of time (Okano et al. 2003; 
Coyne et al. 2006).  Hence, researches have attempted different strategies for the 
successful grafting of transplanted cells.  Most of these therapies centre on cell 
injection following the acute phase of SCI, when the release of inhibitory and lethal 
molecules has ceased.  However, the already formed glial scar hinders the integration 
of the transplanted cells within the host tissue, preventing regeneration of damaged 
tissue (Coyne et al. 2006; Cregg et al. 2014). 
The variety of processes inhibitory to axonal regeneration caused by SCI 
creates a multitude of obstacles limiting recovery, which together hinder the 
effectiveness of single therapeutic interventions.  This challenge has encouraged the 
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development of combination strategies that work together synergistically to improve 
recovery.  Seemingly, the most effective approach should incorporate the integration 
of scaffolds along with therapeutic molecules and/or cells into the site of injury.  
Scaffolds help direct and organize the grafted cells providing a bridge through which 
the regenerating axons can be properly guided through the injury gap, at the same 
time that grafted cells and therapeutic molecules provide trophic support to 
regenerating axons.  This increases the healing effects of the scaffold.  Several 
scaffolds have been successfully utilized as support for transplanted cells, including 
matrigel (Pinzon et al. 2001), fibrin (Meijs et al. 2004) and poly(α-hydroxy acids) (Teng 
et al. 2002).  However, only collagen and alginate constructs will be introduced in 
detail in this section, since these are the hydrogels utilized in this thesis.  
Due to the versatility of alginate, this hydrogel has been utilized for the 
immobilization of numerous cell types in different construct shapes.  Alginate 
sponges supported the migration, differentiation and integration of foetal rat 
hippocampus neurospheres into the injured spinal cord (Wu et al. 2001).  In another 
study, alginate microcapsules containing BDNF promoted the growth of regenerating 
axons through the implanted microcapsules, leading to functional improvement of 
the affected limbs in a rat in vivo SCI model (Tobias et al. 2005).  In a different 
approach, NSCs immobilized within alginate fibres migrated into injured spinal cord 
of mice and they differentiated towards the three neural cell types, neurons, 
oligodendrocytes, and astrocytes (Sugai et al. 2015). 
Like alginate, the ease of manipulation of collagen into various 
shapes/structures has permitted its application to fill the gap invoked after SCI, 
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thereby providing support to wound healing cells.  Application of cross-linked 
collagen and collagen filaments has been studied in animal models of SCI and 
demonstrated to increase regenerative activity in the spinal cord with a subsequent 
improvement in the functional disability (Yoshii et al. 2004).  The use of collagen gels 
as vehicles to transplant neonatal astroglial cells into the injured spinal cord of the 
adult rat allowed the precise application of these cells into the lesion gap (Joosten et 
al. 2004).  The presence of transplanted neonatal astroglial cells demonstrated a 
significant increase in the number of ingrowing neurofilament-positive fibres, 
resulting in a modest but temporary improvement of locomotor recovery.  More 
recently, a collagen construct bound to epidermal growth factor receptor (EGF) 
antibody Fab fragment was transplanted into an acute rat SCI model (Fan et al. 2017).  
By neutralization of the myelin inhibitory molecules, the construct promoted 
neurogenesis of endogenous injury-activated neural stem cells (NSCs).  NSCs 
differentiated into mature functional neurons that were able to reconnect the injured 
gap.  
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1.2 Stem Cells 
Stem cells are unspecialized cells with an enhanced renewal capacity and the 
potential to differentiate towards multiple lineages, depending on external stimuli 
controlled by the stem cell niche (Moore & Lemischka 2006).  These unique features 
make stem cells ideal candidates for use as a renewable source for cell therapy in 
regenerative medicine, repairing or replacing damaged tissues.  Depending on the 
tissue of origin, stem cells are classified as embryonic or adult stem cells.  
 
1.2.1 Embryonic Stem Cells 
Embryonic stem cells (ESCs) are isolated from the inner cell mass of the 
blastocyst, an early stage embryo produced about 5 days after fertilization (Evans & 
Kaufman 1981; Martin 1981).  These cells have the potential to differentiate into any 
cell type within the three germ layers: ectoderm, mesoderm and endoderm, and 
thus, they are pluripotent stem cells.  This pluripotent state is conserved through 
regulatory networks composed of transcription factors and signalling cascades, 
where Oct4, Nanog and Sox2 have essential roles in maintaining ESCs self-renewal 
capacity.  Alterations in these signals promote differentiation towards specific cell 
types (Boyer et al. 2005).   
Oct4 expression is restricted to pluripotent cells and thus, a loss of 
pluripotency in ESCs is often accompanied by Oct4 downregulation (Thomson et al. 
2011).  Oct4 must be present at appropriate levels to maintain pluripotency, since an 
increase causes differentiation towards endoderm and mesoderm lineages, and a 
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decrease leads to the formation of the outer cell mass of the blastocyst, the 
trophectoderm (Niwa et al. 2000).  Nanog is another key regulator of pluripotency.  
Like Oct4, its expression is restricted to pluripotent cells and is downregulated upon 
differentiation.  It plays a critical role in regulating the cell fate of pluripotent ESCs, 
preventing differentiation (Chambers et al. 2003).  High levels of Nanog can maintain 
mouse ESCs self-renewal capacity independent of extrinsic signals (Chambers et al. 
2003) and enables human ESCs grow in feeder-free conditions (Darr et al. 2006).  
Together with Oct4 and Nanog, regulation of Sox2 expression levels is essential in the 
maintenance of ESCs pluripotency.  Adachi and co-workers reported that both 
upregulation and downregulation of Sox2 led to a decrease in Nanog and Oct4 
expression, causing trophectoderm differentiation (Adachi et al. 2010).  
During embryonic development, the blastocyst is reorganized into a laminar 
structure called gastrula in a process known as gastrulation.  The gastrula contains 
the three primary germ layers: ectoderm, mesoderm, and endoderm that further 
differentiate into different tissues.  Endoderm, the most internal germ layer, forms 
the lining of digestive system and respiratory system.  Ectoderm, the most exterior 
germ layer forms the epidermis, and the neural crest, which later forms the nervous 
system.  Mesoderm, the middle germ layer, forms muscle, the skeletal system, and 
the circulatory system.  As the embryo develops, stem cells capacity to differentiate 
into more specialized cells becomes more restricted towards the tissue of origin 
(Nichols & Smith 2012).  
Mouse embryonic stem cells can be isolated and propagated indefinitely 
without undergoing cell senescence in vitro when cultured in the presence of 
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leukaemia inhibitory factor (LIF) (Smith et al. 1992).  Upon removal of LIF, mouse ESCs 
spontaneously differentiate towards progenitor cells of the three embryonic germ 
layers: mesoderm, endoderm, and ectoderm (Keller 2005).  These findings highlight 
the enormous potential of ESCs for the treatment of a variety of diseases due to their 
ability to differentiate into any cell type within the three germ layers.  However, the 
therapeutic application of human ESCs is still debated due to ethical concerns derived 
from the fact that their isolation involves the destruction of the embryo.  Also, their 
application in human therapy is controversial due to problems of allogeneic rejection 
and concerns about uncontrolled development of malignancies (Hentze et al. 2007).   
 
1.2.1.1 Neural Stem Cells 
NSCs are present in both embryonic and adult tissues.  Isolation of NSCs from 
the adult mammalian central nervous system was first described by Reynolds & Weiss 
in 1992 using a novel serum‐free culture system, the neurosphere assay (NSA).  The 
same procedure can be applied for the isolation of embryonic NSCs (Azari et al. 2011).  
After isolation, NSCs can be cultured in vitro in the presence of EGF and/or basic 
fibroblast growth factor (bFGF).  Cells proliferate giving rise to neurospheres which 
can be passaged over extended periods of time, demonstrating long-term self-
renewal and multipotency capacities (Zhao et al. 2005).  However, upon removal of 
growth factors, neurosphere-derived cells are induced to differentiate towards the 
three neuronal phenotypes: neurons, astrocytes and oligodendrocytes (Pagano et al. 
2000; Guo et al. 2012).   
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NSCs are typically characterised by the expression of nestin and musashi.  
Nestin is an intermediate filament protein expressed by NSCs (Morshead et al. 1994).  
Upon differentiation, nestin becomes downregulated and is replaced by tissue-
specific intermediate filament proteins (Michalczyk & Ziman 2005).  Musashi is an 
RNA-binding protein that regulates the translation of target mRNAs during neural 
development.  This marker contributes to the maintenance of mammalian adult 
neural stem cell populations (Sakakibara et al. 2002).   
 
1.2.2 Adult Stem Cells 
Most of the differentiated cells in adult tissues have a relatively short life span 
and are continuously replaced by new cells generated from stem/progenitor cells.  In 
the adult mammalian organism, stem cells are found in almost all tissues and play a 
key role in maintaining cell genesis and renewal in different tissues and organs during 
the life span of the animal as part of the natural aging process, or after cell loss due 
to injury or disease (Pessina & Gribaldo 2006).   
One of the main differences between embryonic and adult stem cells (ASCs) is 
their ability to differentiate into different cell types; that is, their potency.  Whilst 
ESCs are pluripotent, ASCs are multipotent or unipotent, in that their differentiation 
potential is more restricted and depends on their tissue of origin (Wagers & 
Weissman 2004).  However, several observations proved that these tissue-specific 
stem cells are able, under suitable conditions, to “transdifferentiate” towards a wider 
range of cell types, regardless whether these tissues are derived from the same germ 
layer or not (Anderson et al. 2001).  This observation opens a new spectrum of 
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possibilities for adult stem cells to be used in regenerative medicine.  In fact, a 
relatively new source of ASCs with pluripotency capacity was discovered in 2006, 
referred to as Induced Pluripotent Stem Cells (iPSCs) (Takahashi & Yamanaka 2006).  
These cells were reprogrammed from adult fibroblasts through the addition of 
defined factors and demonstrated to have the primary properties of ESCs.  Thus, 
iPSCs can be developed from autologous somatic cells, avoiding ethical and immune 
problems.   
As outlined at the beginning of this section, ASCs can be found in the majority 
of tissues within the organism.  Amongst these tissues, the bone marrow is the most 
widely used source for the isolation of stem cells (Soleimani & Nadri 2009; Huang et 
al. 2015).  There are two stem cell types derived from the bone marrow: 
Hematopoietic Stem Cells (HSCs), that give rise to all blood cell types (Eaves 2015) 
and Mesenchymal Stem Cells (MSCs; also known as Mesenchymal Stromal Cells), 
which are the source of osteocytes, chondrocytes, and adipocytes (Gimble et al. 
2008).  However, the painful and invasive procedures involved in the isolation of 
BMSCs from bone marrow have encouraged researches to seek alternative sources 
of stem cells (Pendleton et al. 2013).   
 
1.2.2.1 Dental Pulp Stem Cells 
The dental pulp is the soft tissue found in the inner part of the tooth, which is 
mainly formed of connective tissue, blood capillaries, nerves and several cell types, 
including fibroblasts, odontoblasts and immune cells (Liu et al. 2006).  The dental pulp 
acts as a sensory organ through nerves that perceive changes in temperature and 
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pressure.  It constitutes a protectant part of the tooth, triggering immune responses 
against oral pathogens (Jontell et al. 1998).  During tooth development, dental pulp 
is the responsible for the formation of primary dentin through the production of 
odontoblasts.  After completion of root development, secondary dentin is produced 
through life at a slower rate.  In cases of mild injury, odontoblasts produce 
reactionary dentin (Smith et al. 1995).  However, after severe trauma, such as caries 
or fracture, odontoblasts are damaged and subsequently die.  Hence, newly 
produced odontoblast-like cells migrate towards the injured dentine surface and 
secrete reparative dentin, providing a protective barrier to the dental pulp (Liu et al. 
2006). 
The ability to create new odontoblasts throughout life in response to damage 
suggested the existence of a source of stem cells within the dental pulp.  Gronthos et 
al. in 2000 isolated a clonogenic, rapidly proliferative population of cells from adult 
human dental pulp, which were termed Dental Pulp Stem Cells (DPSCs).  After 
comparison with BMSCs, both cell types shared a similar immunophenotype in vitro 
but they showed different cell fate in vivo.  When DPSCs were first described, it was 
suggested that their differentiation potential was restricted towards odontoblast-like 
cells, as demonstrated by the ability to form a dentin-like structure in vivo (Gronthos 
et al. 2000).  However, further studies showed their potential to differentiate into 
adipocytes and neuronal-like cells, suggesting that DPSCs are an easily accessible 
source of multipotent stem cells (Gronthos et al. 2002).   
More recently, a set of markers has been described which characterise DPSCs 
(Kawashima 2012).  These markers include STRO-1, CD29, CD44, CD73, CD90, CD105, 
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CD146, CD166 and CD271, which are typically expressed by MSCs.  Hence, DPSCs are 
generally classified under this cell type.  However, DPSCs represent a heterogeneous 
population of cells, and their marker expression profile vary depending on their 
isolation source (Graziano et al. 2008; Karaöz et al. 2010).  This can be explained due 
to the existence of two different origins for these stem cells, the neural crest and the 
mesoderm (Komada et al. 2012).  In fact, DPSCs can be isolated from different stem 
cell niches within the pulp, giving rise to stem cell populations with different 
proliferative and differentiation potentials (Shi & Gronthos 2003; Løvschall et al. 
2005; Lizier et al. 2012).  This heterogeneity has been investigated in our lab in 
respect of their potential for neuronal differentiation (Young et al. 2016).  These 
results led to the conclusion that the expression of nestin by some clonogenic 
populations of DPSCs could be used as a marker to identity cell populations with 
neuronal differentiation potential. 
Due to the expression of mesenchymal (Ponnaiyan & Jegadeesan 2014) and 
ESC markers (Kerkis et al. 2007), various studies have been performed to evaluate 
the differentiation potential of DPSCs, revealing that they have the ability to produce 
many kinds of cell populations and tissues (Tatullo et al. 2015).  However, due to the 
wide repertoire of possibilities of DPSCs in regenerative medicine, only the potential 
for neuronal differentiation and repair will be considered in this thesis.  
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1.2.2.1.1 Neuronal Regenerative potential of DPSCs 
Several protocols have been developed for in vitro differentiation of DPSCs 
into neuronal cells, based on the differentiation mechanisms of NSCs in vitro.  NSCs 
are maintained as multipotent cells in culture in the presence of mitogens such as 
bFGF and EGF.  However, removal of these growth factors from the culture medium 
leads to the differentiation of NSCs towards neuronal cells (Pagano et al. 2000; Guo 
et al. 2012).  Based on this method, DPSCs have been differentiated into neuronal-
like cells (Hisham et al. 2013).  When cultured in serum and growth factor free 
medium, DPSCs ceased proliferation and differentiated into neuronal-like cells as 
demonstrated by the development of multiple neurites and the expression of 
neuronal markers such as nestin, map2 and β-III tubulin.   
Nonetheless, expression of neuronal markers is only a pre-requisite for 
neuronal differentiation.  In order to successfully apply DPSCs for the treatment of 
CNS diseases, differentiated cells must be proven functionally active.  Patch-clamp 
electrophysiology recording techniques have been applied to assess the functionality 
of neuronal-like cells differentiated from DPSCs (Arthur et al. 2008; Király et al. 2009; 
Gervois et al. 2015).  Among the protocols developed for neuronal differentiation of 
DPSCs, only a few have demonstrated the production of functionally active neurons.  
Kanafi et al. (2014) demonstrated for the first time that it was possible to produce 
functional dopaminergic neurons from DPSCs when the cells were cultured under the 
presence of midbrain cues, including sonic hedgehog (SHH), fibroblast growth factor 
8 (FGF8) and bFGF.  Functional activity of differentiated DPSCs was demonstrated by 
the secretion of dopamine upon stimulation with KCl and ATP, and the intracellular 
Ca2+ influx in the presence of KCl. 
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The differentiation of DPSCs towards functionally active neuronal cells has 
been also achieved following a two-step protocol (Gervois et al. 2015).  Neuronal 
induction was acquired through the formation of neurospheres when DPSCs were 
cultured with mitogenic growth factors in low-adherence plates.  In a second step, 
cells underwent neuronal maturation based on cAMP and neurotrophin-3 (NT-3) 
signalling after seeding on poly-l-ornithine (PLO)/laminin coated plates.  Patch-clamp 
assessment showed that differentiated cells were able to set a single action potential, 
demonstrating functional activity. 
In addition to the ability of neuronal lineage differentiation, DPSCs have the 
potential for secretion of trophic factors, affecting the behaviour of neighbouring 
cells.  Nosrat et al. (2004) compared the behaviour of dopaminergic neurons cultured 
in vitro with and without DPSCs in the absence of exogenous neurotrophic factors.  
Results revealed that neurons developed elaborate neurites only when they were co-
cultured with DPSCs, suggesting the key role of DPSCs in the growth and maintenance 
of neurons in vitro by the release of growth factors.  Also, the release of 
neurotrophins by DPSCs promoted the neuronal differentiation of stem cells in a 3D 
culture system (Soria et al. 2011).  These findings suggest new criteria for the design 
of cell therapy experiments in animal models to assist the repair of lesions in the CNS, 
based not only on the direct cellular replacement, but also on the application of 
DPSCs as trophic support for regenerating cells.   
The promising results obtained in vitro have encouraged researches to assess 
the regeneration potential of DPSCs within the CNS in vivo.  The capacity of DPSCs to 
promote growth and differentiation of stem cells through the release of growth 
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factors has been observed after injection in the mouse hippocampus (Huang et al. 
2008).  The grafted DPSCs promoted proliferation, cell recruitment and maturation 
of endogenous stem cells through modulation of the local microenvironment by 
promoting growth factor signalling.  A similar behaviour was observed in a rodent 
stroke model (Leong et al. 2012).  The intracerebral transplantation of human DPSCs 
resulted in significant improvement in forelimb sensorimotor function several weeks 
after treatment.  However, a low percentage of the grafted cells survived, suggesting 
that functional improvement was more likely to be mediated through DPSC-
dependent paracrine effects than direct cellular replacement.  However, when DPSCs 
were transplanted into rats’ spinal cords after complete transection, they promoted 
the regeneration of transected axons through three major neuroregenerative 
mechanisms, including cellular replacement (Sakai et al. 2012).  It was observed that 
transplanted DPSCs differentiated into mature oligodendrocytes, replacing lost cells 
after SCI.  But also, the grafted cells prevented apoptosis of endogenous neural cells 
and inhibited multiple axon growth inhibitors, improving the preservation of 
neuronal filaments and myelin sheaths.   
DPSCs provide an easily available source of stem cells with promising potential 
for the treatment of neurodegenerative diseases.  Their isolation through a minimally 
invasive procedure, offers some benefits when compared with BMSCs.  Unlike the 
use of ESCs, DPSCs also provides benefits in that their use does not raise ethical 
concerns.  Finally, these ASCs can be isolated from patients for autologous 
transplantation without risk of immunological rejection, avoiding the use of 
immunosuppressants and hence, preventing damage to vital organs due to the use 
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of these drugs (Halloran 2004).  Hence, all the benefits mentioned above justify the 
increasing interest for clinical use of DPSCs in the treatment of a number of diseases.   
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1.3 Cell encapsulation  
As outlined in the previous section, stem cells are potent therapeutic tools to 
treat several diseases based on their ability to differentiate towards a desired lineage, 
or, by providing trophic support to regenerating tissues.  However, it is difficult to 
control the behaviour and cell fate within an organism.  It is also necessary to find a 
suitable stem cell delivery system in order to control cell parameters in situ, such as 
proliferation, migration, integration and differentiation.  To this end, cell 
encapsulation technology has arisen as a method for cell immobilization within a 
biocompatible and semipermeable scaffold, protecting the encapsulated cells from 
an adverse environment post-grafting.  
The first reported attempt of cell immunoisolation was made in the early 
1930s (Bisceglie 1933).  Bisceglie filled a gelatine membrane with tumour cells 
harvested from a mouse carcinoma, which was then inserted into the peritoneal 
cavity of a guinea pig.  Upon removal of the graft 12 days after implantation, it was 
observed that the cells within the membrane were still alive.  Although the focus of 
the experiment was to investigate tumour immunology, this observation led to the 
discovery of a new methodology for cell implantation.  
Cell encapsulation has been the focus of many researchers in order to protect 
the enclosed biological material from potential hazardous processes (Freimark et al. 
2010).  Specifically, cell microencapsulation represents a strategy that aims to 
overcome the present difficulties related to whole organ graft rejection, and 
consequently, the requirements for use of immunosuppressive drugs.  In the case of 
autologous transplantation, where the patient receives cells from themselves, 
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cellular rejection is not an issue.  However, grafted cells might still need protection 
from the adverse environment created at the damaged site, as in SCI (Fleming et al. 
2006).  Also, cell encapsulation has been demonstrated to be useful in directing the 
cell fate of immobilized cells, suggesting that cell fate can be controlled by the 
composition/structure of the encapsulation matrix (Ghasemi-Mobarakeh 2015).  
 
1.3.1 Requirements of cell encapsulation systems 
The microcapsule system must meet some distinct requirements in order to 
guarantee both the survival of the encapsulated cells and a successful clinical 
outcome.  These requisites include capsule stability, permeability and diffusion.  
 
1.3.1.1 Stability 
The mechanical stability of the microcapsules needs to be such that it can 
withstand the shear stress induced during production, handling and application 
during a surgical procedure.  The desired mechanical properties of microcapsules 
depend on their application.  For example, applications such as bone and cartilage 
grafts, or, sustained release of therapeutic molecules over extended periods of time, 
requires a long-term stability of the polymer microcapsules (Zhu & Marchant 2011; 
Tiwari et al. 2012).  In these cases, degradation of capsules due to chemical changes 
is undesirable, since capsules will quickly lose integrity, the graft will be lost and 
hence, the therapeutic effect will be interrupted.  In other applications, 
microcapsules are utilized as vehicles for cell and/or drug delivery (Santoro et al. 
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2014).  Under these conditions capsules should provide protection from the immune 
response but they should progressively degrade as inflammation decreases to allow 
for the delivery of the encapsulated material.  The mechanical strength can be 
controlled by changing the polymer concentration, polymerization conditions, or by 
introducing various functional groups (Coutinho et al. 2010).   
 
1.3.1.2 Permeability 
In the situation whereby the application involves the transplantation of 
encapsulated cells, the capsule membrane should be impermeable to antibodies and 
immune cells, thereby providing protection for the encapsulated cells from the 
immune response after grafting.  However, this will depend upon the type of 
transplantation.  Autografts should not trigger any immune response since the 
transplanted biological material derives from the same patient.  In the case of 
allografts, where cells from an individual are transplanted to a different individual, it 
is potentially enough to prevent contact between immune cells of the host and the 
donor cells through a physical barrier, such as that provided by the capsule 
membrane (Duvivier-Kali et al. 2001).  However, simple systems are not effective in 
the case of xenografts (cross species transplantation), where biological material from 
one specie is transplanted into a patient of a different specie, i.e. from animals to 
humans.  Transplants across different species barriers are subject to strong 
immunologic rejection, hindering the success of xenogeneic transplantation (Yang & 
Sykes 2007).  Xenogeneic cells contain pathogen-associated molecular patterns 
(PAMPs) that are recognized by the host and activate the innate immune cell system 
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that, in turn, activates the classical complement pathway.  This activation leads to the 
production of antibodies that accumulate on the surface of the implanted capsules, 
triggering the mobilization of cells and producing inflammatory mediators towards 
the implantation site (Wang & Yang 2012).  During these responses, many cytokines 
that are small enough to pass through the capsule membrane are produced, further 
contributing to the failure of the encapsulated cells (Juste et al. 2005).  The final result 
of this cascade is the envelopment of the capsules by inflammatory cells and 
fibroblasts that scavenge almost all oxygen and nutrients and lead to ischemic 
compromise of the surviving cells in the capsules.  Under ischemia conditions, cells 
produce specific factors that lead to a progressive fibrosis, and gives rise to a further 
loss of cell functionality (Sun et al. 2009).   
As a consequence of the vigorous immunological responses triggered in 
xenogeneic transplantation, stricter encapsulation requirements should be 
considered.  In these cases, additional coating of the capsule membrane is then 
required to block the entrance of cytokines. The xenotransplantation of rat islets in 
diabetic minipigs without immunosuppressive therapy was successfully achieved by 
means of cell encapsulation in a membrane system that included an additional barrier 
between the capsule membrane and the interface with the recipients (Neufeld et al. 
2013).  In a different approach, a multifunctional hydrogel-based scaffold consisting 
of murine cell-loaded alginate-poly-l-lysine-alginate (APA) microcapsules and 
dexamethasone (DXM)-loaded poly(lactic-co-glycolic) acid (PLGA) microspheres 
embedded in alginate hydrogel was injected in an in vivo rat model (Acarregui et al. 
2014).  The system did not trigger inflammation responses and it allowed for the 
continuous and localized release of DXM.  
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1.3.1.3 Diffusion 
Another parameter that should be controlled in order to increase the survival 
chance of the encapsulated cells is the diffusion of molecules in and out of the 
capsule.  The encapsulation material should permit the bidirectional diffusion of 
oxygen and nutrients inside the capsule and the efflux of waste products and 
therapeutic molecules, such as growth factors.  In this sense, membrane permeability 
can be tailored depending on the polymer composition.  Thus, by controlling the 
molecular weight and degree of cross-linking of the polymer, the pore size can be 
modified in order to allow the bidirectional diffusion of molecules (Vaithilingam & 
Tuch 2011).  The diffusion rate of a molecule through a membrane is determined by 
its size and charge, and the charge of the polymer membrane (Danysh et al. 2010).  
Hence, these are factors to consider when selecting the appropriate encapsulation 
material.  In order to ensure the survival of encapsulated cells, oxygen and nutrients 
not only have to pass through the polymer membrane, but also need to reach the 
centre of the capsule to provide nutrition to every cell.  Hence, capsules of 
appropriate diameter must be produced in order to guarantee an effective 
oxygenation and nutritional regime for the encapsulated cells (Ogbonna et al. 1991).  
Also, it has been demonstrated that the diameter of the capsule could influence the 
immune response against the grafting.  Sakai et al. (2006) observed that 
inflammatory reaction was much lower when employing smaller microcapsules 
(100µm), in comparison to larger sized microcapsules (300 – 1000µm).  In this 
respect, the selection of the encapsulation technology is crucial to achieve 
monodisperse microcapsules with a controllable diameter. 
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1.3.2 Applications of cell encapsulation 
Advances in the fields of cell therapy and biomaterials have triggered the 
increased interest and progress of cell encapsulation technology (Burdick et al. 2016).  
This technique was first utilised to overcome the problems related to organ graft 
rejection and the need to use immunosuppressive drugs.  However, the versatility of 
this technique, born from the great number of biomaterials and cell types that can 
be combined, has allowed its application in other fields, such as in vitro culture (Mei 
et al. 2014; Chen et al. 2015) or controlled release of drugs and growth factors 
(Qutachi et al. 2013; Nam et al. 2016). 
 
1.3.2.1 Immunoisolation in transplantation therapy 
Cell encapsulation has been widely applied for the immobilization of 
allogeneic or xenogeneic cells in a semipermeable but immunoprotective membrane 
to suppress immune rejection after grafting (Lee & Bae 2000; Emerich & Winn 2001; 
Hao et al. 2005).  Pancreatic islet transplantation has shown improved graft function 
in the treatment of type I diabetes.  However, adequate long-term therapeutic effect 
has not yet been demonstrated, and patients still require immunosuppression to 
prevent rejection (Van Belle & Von Herrath 2008).  Cell encapsulation offers a 
transplantation means to avoid the need for toxic immunosuppressives, while 
increasing the chances of graft function and survival.  Thus, islet encapsulation has 
proven to be effective in many studies, including allogeneic and xenogeneic 
transplantation (Duvivier-Kali et al. 2001; Neufeld et al. 2013).  Microencapsulation 
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of therapeutic cells also represents a promising therapy for the treatment of other 
diseases, such as haemophilia B.  Immunoisolation of myoblasts secreting factor IX 
(FIX) and further transplantation into mice permitted the improvement of FIX plasma 
levels without the activation of the immune response (Wen et al. 2007). 
 
1.3.2.2 Local and systemic controlled release of drugs and growth factors 
Living cellular systems can provide unlimited release of active compounds.  
Hence, encapsulation of therapeutic cells offers a tuneable method for an effective 
and controlled drug delivery.  Encapsulated delivery systems present numerous 
advantages compared to conventional dosage forms, including improved efficacy, 
reduced toxicity and improved patient convenience (Singh et al. 2010).  
Microcapsules offer an effective protection of the encapsulated active agent against 
degradation.  Also, by controlling the degradation rate of the polymer membrane it 
is possible to accurately control the release rate of the active compound (Kamaly et 
al. 2016).  Furthermore, the small size of microcapsules offers an easy and minimally 
invasive administration methodology.  For example, the systemic delivery of 
therapeutic factors represents an issue in the treatment of CNS conditions, where 
the blood/brain barrier hinders their administration (Pardridge 2005).  In this case, 
immunoisolated cellular implants that produce therapeutic drugs could be directly 
implanted into the region of interest, providing continuous drug delivery (Emerich & 
Thanos 2006).  The application of this technology has led to the establishment of 
some patented works.  For example, the implantation of encapsulated PC12 cells into 
individuals suffering from Parkinson's disease slowed or prevented the degenerative 
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processes of the disease by releasing dopamine and other factors (Emerich et al. 
1998). 
 
1.3.2.3 3D culture systems 
The viability, renewal and differentiation of stem cells towards a particular 
lineage are dependent on the properties of the cellular microenvironment or niche 
(Discher et al. 2009).  Cell microencapsulation provides the cells with a three 
dimensional structure similar to that found in vivo, which allows for in vitro 
investigation of the influence of microenvironments on cell behaviour and fate.   
Cell proliferation within microcapsules can be controlled by modification of 
the polymer concentration.  This is dependent upon the cell type and the 
encapsulation material.  For example, it was determined that the viability and 
proliferation of ESCs were optimum within 1% (w/v) alginate hydrogels, whereas 
higher or lower concentrations gave rise to a decrease in cell viability and 
proliferation rate (Wang et al. 2009).  The degree of cell attachment can be also 
controlled depending on the polymer composition.  Modification of alginate 
hydrogels with arginine-glycine-aspartic acid (RGD) residues increased cellular 
attachment and elongation, forming a dense network of cells (Markusen et al. 2006).  
A similar effect was observed in encapsulated cardiomyocytes within alginate-
collagen microcapsules, where the cells spread and proliferated giving rise to 
functional multilayer heart-like tissues (Bai et al. 2011).   
Stem cell differentiation can be guided through the interaction of 
encapsulated cells with the encapsulation polymer.  The influence of alginate 
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encapsulation parameters on ESC phenotype has been investigated (Wilson et al. 
2014a).  Results revealed that cell encapsulation delayed the differentiation process, 
regardless of alginate composition.  However, encapsulation within alginates with a 
high content of mannuronic residues promoted differentiation towards a primitive 
endoderm phenotype.  In a different approach, alginate microcapsules were loaded 
with retinoic acid, leading to neural lineage differentiation of the encapsulated ESCs 
(Li et al. 2011).  The differentiation within microcapsules can be also mediated 
through cell-cell interactions.  For instance, ESCs were induced to hepatic 
differentiation through the formation of cell aggregates within alginate/poly-L-lysine 
(PLL) microcapsules, which was controlled by the initial seeding density (Maguire et 
al. 2007).  
 
1.3.3 Cell encapsulation techniques 
Microencapsulation within spherical microparticles offers many benefits over 
other encapsulation geometries, including a high surface area to volume ratio, a high 
resistance to mechanical stress, a relatively short diffusion path length and access to 
a number of implantation sites by injection (De Vos et al. 2006).  However, in order 
to apply cell encapsulation technology in clinical therapies, the production of uniform 
capsules with excellent repeatability and reproducibility is required.  Formation of 
monodisperse droplets is of a great importance in order to accurately estimate the 
cell/drug dosage.  Hence, the development of new technologies aims for the 
continuous production of polymer microcapsules similar in size and morphology.  
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The simplest technique to produce polymer droplets is by conventional 
emulsification.  In this method, an aqueous polymer solution containing cells is 
rapidly stirred with an immiscible phase containing cross-linking agents to form small, 
spherical droplets of one phase within the other (Poncelet et al. 1992).  The method 
does not require the use of sophisticated equipment.  However, one of the main 
problems of this technique is the production of microcapsules with very different size 
and shape, which hinders its application in clinical therapies (Hoesli et al. 2011).   
Interfacial polymerization represents an alternative to conventional 
emulsification methods in which the size of the capsule can be easily controlled.  In 
this method, one phase containing the cell suspension and a reactive monomer is 
dispersed into a second immiscible phase to which is added a second monomer.  Both 
monomers react at the droplet surface (interface) forming a polymeric membrane 
(Neufeld et al. 2014).  However, this technique requires the use of organic solvents 
that are harmful to cells, compromising their viability (Khademhosseini et al. 2005).  
A different approach to obtain high monodispersity droplets is electrostatic 
extrusion.  In this method, a narrow stream of polymer containing cell suspension is 
extruded through a small needle or nozzle, whereupon it breaks up into droplets 
which are collected in a gelling bath.  In order to enhance droplet formation, an 
electrostatic potential is established between the needle and the gelling bath, thus 
attracting the droplets towards the bath.  This method permits the production of 
microcapsules down to 50μm in diameter (Bugarski et al. 1994).  In contrast to 
emulsion techniques, this technology is reproducible, controllable, and produces 
beads that are uniform in size.  Further, the production process is performed under 
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mild stress conditions without the use of any organic solvents that can inhibit cell 
activity and cause serious damaging effects.  However, the use of a high electric field 
might affect cell survival (Vaithilingam & Tuch 2011). 
Amongst the techniques described above, droplet extrusion represents one of 
the most widely used methods for cell encapsulation due to the benefits over other 
conventional techniques.  However, polymer cross-linking takes place in a second 
step upon collection in a gelling bath.  Under these conditions, gelation occurs in an 
uncontrolled manner and only the outer layer of the capsule is cross-linked, leading 
to a capsule with a solid shell and a liquid core, which affects the mechanical stability.  
Hence, although the droplets size can be accurately selected, cross-linking in the 
gelling bath is not precisely controlled, leading to capsules with random uncontrolled 
shapes where the gelation of different capsules from the same batch may vary 
(Capretto et al. 2008).  
Microfluidic technology overcomes the limitations mentioned above.  This 
technique generates cell-laden microcapsules offering the capability for high-
throughput variation in their diameter and mechanical properties by supplying 
multiple flows of precursor fluids at varying relative flow rates and concentrations 
(Velasco et al. 2012).  Microfluidic platforms allow work in a sealed environment 
protected from the atmosphere, thereby eliminating the risk of cross-contamination 
from bacteria or small molecules.  In addition, microfluidic cell encapsulation can be 
easily carried out in inexpensive, sterile, dust-free, and disposable devices (Morgan 
et al. 2016).  The principles and biomedical applications of microfluidic technology 
will be further explained in Section 1.5.  
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1.4 Biomaterials 
A biomaterial is defined as a material intended to interface with biological 
systems to evaluate, treat, augment or replace any tissue, organ or function within 
the body (Williams 1999).  In order for it to be used as scaffold for tissue engineering, 
a biomaterial should be biocompatible, that is, the biomaterial should not interact 
with biological systems in the host leading to inflammation or any adverse response 
(Williams 2015).  Depending on the application, the material should have specific 
mechanical properties and a controllable degradation rate, as well as an appropriate 
microstructure to allow for the performance of the biological function of the 
encapsulated system, for example cells or macromolecules (Lee & Mooney 2001).   
Several categories of biomaterials have been developed and tested for tissue 
engineering purposes over the last few decades (O’Brien 2011).  However, only 
alginate and collagen will be discussed in relation to this thesis. 
 
1.4.1 Alginate 
Alginate is one of the most used biomaterials in biomedical applications such 
as drug delivery, wound healing and tissue engineering (Lee & Mooney 2012).  This is 
due to its favourable properties, which include biocompatibility, mild gelling 
conditions, easy manipulation, low toxicity, relatively low cost and a three-
dimensional structure in vitro which is similar to that found in vivo.  The wide variety 
of patterns in which alginate can be prepared, such as microcapsules 
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(Zhang & He 2009), sponges (Shapiro & Cohen 1997), foams (Andersen et al. 2012) 
and fibres (Xu et al. 2017) explains its numerous applications. 
 
1.4.1.1 General properties 
Alginate is a naturally occurring anionic and hydrophilic polysaccharide 
typically extracted from brown algae (Hirst 1965).  It is a linear block copolymer 
formed by (1, 4) linked β-d-mannuronate (M) and α-l-guluronate (G) residues (Figure 
1.4).  The G/M ratio, the length of each block, and the molecular weight are 
dependent on the initial source of the material . 
 
 
Figure 1.4. Chemical structure of alginate.  Alginate is a linear block copolymer formed by (1, 
4) linked β-d-mannuronate (M) and α-l-guluronate (G) residues.  Adapted from Wallace et al. 
2010.   
 
Only the G-blocks are believed to participate in ion cross-linking with divalent 
cations.  Therefore, the G/M ratio and sequence are key factors affecting the physical 
properties of alginate and its hydrogels.  Alginates with high ratios of G blocks provide 
stiffer hydrogels with high viscosities.  On the other hand, alginates with a high 
content in M blocks have a better long-term stability, since M blocks decrease the 
M G
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number of reactive positions available for hydrolysis degradation (Sun & Tan 2013).  
Molecular weight also plays a key role in the physical properties of alginate hydrogels.  
High molecular weight alginates provide gels with greater mechanical properties 
(Kong et al. 2004). 
The factors affecting alginate biocompatibility are still unclear.  It has been 
reported that biocompatibility depends on the G/M ratio, suggesting that high M 
content alginates are immunogenic (Otterlei et al. 1991).  However, more recent 
studies demonstrated no host cell adhesion on high M content alginates after 
implantation in the peritoneal cavity of mice (Tam et al. 2011).  Since alginate is 
isolated from natural sources, its toxicity might be due to the impurities that may 
remain after alginate purification, such as heavy metals, endotoxins, proteins and 
polyphenolic compounds (Dusseault et al. 2006).  The reduction of protein content in 
alginate hydrogels induced significantly less pericapsular cell adhesion when 
implanted into mouse peritoneum (Ménard et al. 2010), suggesting that purification 
methods are crucial in order to eliminate any potential cytotoxic agent 
 
1.4.1.2 Hydrogel formation and biodegradation 
A hydrogel is a three-dimensional network of cross-linked hydrophilic polymer 
chains with a high water content.  The physicochemical properties of hydrogels 
depends upon the precise cross-linking method employed, the degree of cross-
linking, the molecular weight, and chemical composition of the polymers (Lee & 
Mooney 2012).  Whilst alginate hydrogels can be prepared by using different cross-
linking methods, covalent cross-linking involves permanently bonded alginate chains.  
Chapter 1: Introduction 
62 
Ionic cross-linking allows the reversion of the process, which is desirable in numerous 
biomedical applications.  
 
1.4.1.2.1 Ionic cross-linking 
Ionic cross-linking is the most commonly used strategy to produce alginate 
hydrogels.  The method involves the combination of an alginate solution with divalent 
cations (Sun & Tan 2013).  These ions are believed to specifically bind G blocks of the 
alginate chains, since their spatial disposition allows a greater degree of coordination 
(Draget et al. 1997).  Coordinated alginate chains overlay on adjacent chains, forming 
an “egg-box” structure (Grant et al. 1973) (Figure 1.5). 
 
Figure 1.5.  Representation of alginate ion cross-linking into an “egg-box” structure.  Divalent 
cations specifically bind G blocks.  Coordinated alginate chains overlay on adjacent chains 
forming an “egg-box” structure.  
 
The most common cation used to form alginate hydrogels is Ca2+.  This cation, 
in the form of CaCl2, has been extensively used for alginate external gelation (Yang et 
al. 2000; Knezevic et al. 2002; Shintaku et al. 2007).  In this approach, calcium salt is 
dissolved in an aqueous phase and brought into contact with alginate solution.  
Ca2+ Ca2+
Alginate solution Cross-linked alginate chains
“Egg-box” structure
Overlaid alginate chains
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Calcium chloride is highly soluble in water, giving rise to very quick, but poorly 
controlled gelation (Liu et al. 2006; Shintaku et al. 2007).  In order to delay gelation, 
and therefore have a better control over the gelation rate, researchers have utilised 
an internal gelation strategy.  Low soluble calcium salts, such as CaSO4 and CaCO3, are 
dispersed in the alginate solution and, upon reduction of the pH, calcium ions are 
released, provoking alginate cross-linking and formation of the gel structure in a more 
controlled manner (Branco da Cunha et al. 2014; Schmitt et al. 2015).  Slower gelation 
times, involving a more controlled cross-linking, leads to hydrogels with a greater 
degree of uniformity with enhanced mechanical properties (Kuo & Ma 2001).  
The main feature of ionically cross-linked alginate hydrogels is their limited 
long-term stability.  However, whilst this could be considered as a drawback for some 
applications, it might actually be beneficial for others.  Alginate hydrogels have been 
utilised as vehicles to protect transplanted cells from an adverse immune response, 
and to control cell parameters such us cell migration, proliferation and differentiation 
at the site of implantation (Banerjee et al. 2009; Jun et al. 2013).  Therefore, alginate 
hydrogels can provide therapeutic effects while degrading as the cellular system 
replaces the artificial matrix.  Ionically cross-linked alginate gels can be easily 
dissolved by ionic interchange reactions with monovalent ions.  This situation 
naturally occurs in vivo, where calcium ions are interchanged with sodium ions 
(Guarino et al. 2015).  However, a tight control of alginate degradation is required for 
this type of application, to control cell viability and therapeutic effect after 
implantation. 
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1.4.1.2.2 Covalent cross-linking 
The need for improving the long-term stability of alginate hydrogels for some 
applications in tissue engineering gave rise to the development of new methods for 
cross-linking.  Covalent cross-linking with poly(ethylene glycol)-diamines provides 
alginate hydrogels with improved mechanical properties due to permanent bonds in 
carboxylic groups from the G blocks.   
The stress applied on alginate hydrogels has different effects depending on 
the cross-linking method.  The bonds in an ionic cross-linked alginate are dissociated, 
which can provoke a plastic deformation, leading to the loss of its water content and 
the re-formation of random bonds.  By contrast, covalently cross-linked hydrogels do 
not experience any bond dissociation, and the stress relaxes mainly through 
migration of water, giving rise to elastic deformation (Zhao et al. 2010).  The 
mechanical properties of covalently cross-linked alginate hydrogels depend on the 
number of cross-linking molecules.  It has been reported that the use of bifunctional 
molecules, such as poly(acrylamide-co-hydrazide) or adipic acid dihydrazide, provides 
multiple attachment points in the gel, thereby enhancing its mechanical properties 
and delaying the degradation rates (Lee et al. 2004).  However, the main drawback 
of covalent cross-linking is the potential toxic effect of unreacted molecules, involving 
a necessary washing step after gel formation (Chan et al. 2015).   
As an alternative to chemical cross-linking, photo cross-linking has been also 
applied as a covalent method for alginate gelation (Bruchet & Melman 2015).  
However, the technique has some limitations when applied to the production of 
scaffolds for tissue engineering.  Cells are exposed to ultraviolet light, the 
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photoinitiators used may be cytotoxic and the use of organic solvents is often 
required to dissolve these photo initiators (Bruchet & Melman 2015).  Nonetheless, 
alternative methods that minimize the exposure to UV light and the use of organic 
solvent have been investigated, allowing the application of photo cross-linking 
hydrogels for cell immobilization (Rouillard et al. 2011). 
 
1.4.1.2.3 Alginate biodegradation  
Alginate is non-degradable in mammals since they lack the enzymes 
responsible for cleavage of the polymer chains (alginate lyases).  But, as mentioned 
above, ionically cross-linked alginate hydrogels can be dissolved by diffusion of 
calcium ions to the surrounding medium and interchange with other monovalent 
cations.  However, although hydrogels can dissolve, the average molecular weight of 
released alginate strands is typically above the renal clearance threshold, and 
therefore, they are not completely removed from the organism (Al-Shamkhani & 
Duncan 1995).  In vivo degradation of alginate hydrogels is desirable in some 
applications including drug delivery and cell transplantation.  This has contributed to 
the modification of alginate chemistry in order to render it as a biodegradable 
material (Yang et al. 2011).  One such approach consists of the partial oxidation of 
alginate chains with sodium periodate, leading to a water degradable polymer 
(Boontheekul et al. 2005).  
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1.4.1.3 Alginate applications in biomedical science 
The favourable properties of alginate hydrogels have allowed for their 
numerous applications in different areas within the biomedical field, such as wound 
healing, drug delivery, tissue engineering, and cell culture.  Unlike traditional 
dressings, alginate hydrogels maintain a moist microenvironment and minimize 
bacterial infection at the wound site, promoting wound healing by rapid 
epithelialization (Suzuki et al. 1998; Wang et al. 2015; Babavalian et al. 2015).  
Alginate hydrogels have the ability to adjust to the shape of the wound, which 
permits their implantation into the body in a minimally invasive manner, and filling 
irregularly shaped cavities (Thornton et al. 2004).  The incorporation of cells and 
bioactive molecules within the hydrogels permits their application in tissue 
engineering therapies, providing restoration of damaged tissues (Fragonas et al. 
2000; Di et al. 2016).   
Alginate hydrogels have been also used in 3D cell culture systems (Andersen 
et al. 2015).  Since alginate does not promote cell adhesion by itself, due to the lack 
of mammalian cell receptors and its low protein adsorption, alginate hydrogels have 
been modified to include molecules to promote cell attachment (i.e., cell-interactive 
alginates), for example, RGD sequences (Alsberg et al. 2001).  Sequences can be 
introduced in alginate chains by water-soluble carbodiimide chemistry (Rowley et al. 
1999).  Such modifications have been demonstrated to promote cell proliferation and 
differentiation (Alsberg et al. 2001; Rowley & Mooney 2002; Markusen et al. 2006;). 
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1.4.2 Collagen 
Along with alginate, collagen is one of the most widely reported biomaterials 
(Parenteau-Bareil et al. 2010).  The main advantage of collagen over other synthetic 
biomaterials is its tolerance within the organism.  Its application in the biomedical 
field is due to its characteristics such as weak antigenicity, cell attachment ability, 
biodegradability and biocompatibility (Silvipriya et al. 2015). 
 
1.4.2.1 General properties 
Collagen is the most abundant protein in animals constituting 30% of all 
protein found in the body and the main component of the extracellular matrix.  
Collagen plays important cohesion roles in tissues and organs, providing hydration, 
resistance, elasticity and flexibility (Muiznieks & Keeley 2013).  Collagen also affects 
the biological functions of cells such as cell survival, proliferation and differentiation 
(Pickering 2001).  
A collagen molecule is made up of three polypeptide chains arranged in the 
form of a triple helix wrapped around one another in a right-handed helical structure 
(Pauling & Corey 1951; Ramachandran & Kartha 1954).  The high content of the three 
amino acids, glycine, proline, and hydroxyproline, is responsible for the helix 
formation, that maintains the strands by the formation of hydrogen bonds between 
adjacent -CO and -NH groups, and also by covalent bonds (Lodish et al. 2000) .  
Collagen is packed into hexagonal and quasi-hexagonal shapes forming fibrillar 
collagen types.  
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To date more than twenty types of collagen within the organism have been 
discovered (Silvipriya et al. 2015).  Whilst all types of collagen have a characteristic 
triple helix, the length of the helix and the size and nature of non-helical portion 
varies dependant on the type (Miller 1984).  Type I collagen is the most abundant and 
the most utilised collagen type in biomedical applications (Zhang et al. 2011).   
 
1.4.2.2 Isolation, cross-linking and degradation 
1.4.2.2.1 Natural sources of collagen 
Collagen can be found within the tissues of numerous animals.  Bovine skin 
and bone have represented the main industrial source of collagen (Silvipriya et al. 
2015).  However, due to the outbreak of diseases, such as transmissible spongiform 
encephalopathies, and the high costs related to collagen extraction and purification, 
alternative sources of collagen have been considered.  Collagen isolation from rat tail 
is a cost-effective technique and guarantees the isolation of a high reproducible 
concentration of collagen (Rajan et al. 2006).  As such, rat tail collagen (type I) is 
extensively utilized in biomedical engineering research (Chan et al. 2010; Guo & Kong 
2002; Meghezi et al. 2015).  Also, researchers have considered a relatively new source 
of collagen.  It has been demonstrated that marine collagen from fish scales, skin, and 
bone has excellent bioactive properties such as biocompatibility, low antigenicity, 
high biodegradability, and cell growth potential (Phanat et al. 2010; Addad et al. 
2011; Cho et al. 2014).   
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1.4.2.2.2 Collagen cross-linking 
Like alginate, there are two types of cross-linking methods frequently 
employed for improving the mechanical stability of collagen scaffolds: physical 
methods and chemical methods.  Physical methods include the use of photooxidation 
(Choi et al. 2013), dehydrothermal treatments (Haugh et al. 2009) and ultraviolet 
irradiation (Davidenko et al. 2016).  However, the mechanical stability provided by 
physically cross-linked collagens is poor (Ma et al. 2004).  Hence, when higher cross-
linking degrees are required, chemical cross-linking becomes the favoured option.   
Traditionally, glutaraldehyde has been the most used agent for covalent cross-
linking of collagen (Cheung, et al. 1985; Roe et al. 1990; Ruijgrok et al. 1994; Xuemei 
et al. 2007).  At neutral pH, glutaraldehyde reacts with amino groups bridging two 
adjacent polypeptide chains and enhancing the biological stability of collagen.  
However, it has been reported that glutaraldehyde induces cytotoxicity due to 
unreacted residues or the release of monomers and small polymers during enzymatic 
degradation (Gough et al. 2002; Ju et al. 2010).  Therefore, several alternative cross-
linking agents have been used, such as carbodiimides and polyepoxy compounds 
(Tang & Yue 1995; Li et al. 2013).  Alternatively, a naturally occurring cross-linking 
reagent, genipin, has received an increasing interest in biomedical applications due 
to its low cytotoxicity (Mi et al. 2002; Liang et al. 2003; Li et al. 2014).  
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1.4.2.2.3 Collagen biodegradation 
Degradation of collagen in mammals is due to the existence of specific 
enzymes, namely, matrix metalloproteinases (MMPs) (Harrington 1996).  These 
enzymes are produced by fibroblasts, which can be stimulated to synthesize new 
enzyme for release outside of the cell (Wilhelm et al. 1986).  Under several 
inflammatory conditions, such as rheumatoid synovitis or inflammatory arthritis, 
modulation of MMP production is mediated by interactions with surrounding 
inflammatory cells, which trigger an increase in collagenase synthesis, and therefore, 
progressive cartilage degradation can occur (Moore et al. 2000; Vincenti & 
Brinckerhoff 2002).  MMPs have a differential rates of collagen hydrolysis, with 
different MMPS hydrolysing specific types of collagen (Fields 2013).   
These enzymes are also synthesized by some bacteria, such as Clostridium 
histolyticum (MacLennan et al. 1953).  Bacterial collagenase (an example of an MMP) 
has several applications in biotechnology and medicine and it has been widely used 
in laboratories to dissociate tissues and isolate cells (Suggs et al. 1992; Kurup & 
Bhonde 2002; Szot et al. 2009; Numpaisal et al. 2016).  Also, C. histolyticum 
collagenase is used for in vitro degradation of collagen-based scaffolds (Sang et al. 
2011; Perez et al. 2014). 
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1.4.2.3 Collagen applications in biomedical science 
Collagen’s ability to form fibres with enhanced strength and stability through 
its self-aggregation and cross-linking makes it a good candidate to be utilised as 
scaffold in biomedical applications.  Type I collagen has been extensively used as a 
hydrogel in tissue engineering, due to its abundance and tendency to self-assembly 
(Cen et al. 2008).   
Collagen can be loaded with drugs by hydrogen or covalent bonding, or simple 
entrapment in controlled drug release and wound healing applications (Marks et al. 
1991; Lazovic et al. 2005).  Drug-laden collagen films have been used as drug delivery 
systems in the treatment of a range of illnesses and infections, such as corneal 
infection (Bloomfield et al. 1978) and cancer (Sato et al. 1996).  Collagen inserts 
allowed for the delivery of high doses of active molecules at the site of implantation 
in a non-traumatic manner and demonstrated a long-term maintenance of the drug 
at the target site.   
Collagen’s ability to promote cell proliferation and differentiation has also 
been exploited for the construction of 3D scaffolds in tissue engineering (Glowacki 
and Mizuno 2008).  However, collagen has poor mechanical properties and it is 
usually combined with other biomaterials for long-term biomedical applications.  
Calcium phosphate is a common substrate used along with collagen for bone 
regeneration, because it provides the scaffold with the sufficient mechanical strength 
(Al-Munajjed et al. 2008).  Collagen’s porous structure also allows for the 
encapsulation of therapeutic cells and their use as controlled delivery systems to 
induce histogenesis in vivo (Nillesen et al. 2007; Lee et al. 2009). 
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Collagen is also an excellent substrate for cell immobilization and culture due 
to its ability to promote cell attachment.  Hence, collagen has been used for the 
production of scaffolds for 3D cell culture, allowing for more realistic in vitro studies, 
since such 3D scaffolds provide the cells with a similar structure to that found in vivo.  
Unlike standard 2D culture, cells seeded within collagen scaffolds can maintain their 
in vivo morphology and three-dimensional structure, thereby improving their 
function, as shown by in vitro studies (Mei et al. 2014).   
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1.5 Microfluidics 
Microfluidics can be defined as the science or technology that manipulates 
very small volumes of fluids, in the range of micro- to picolitres, flowing in networks 
of channels with micrometric dimensions (Stone et al. 2004).  The drastic reduction 
in length scale involves changes in the physical properties of fluids, giving rise to new 
phenomena that are not observed in the macroscale (Brody et al. 1996).  
Microfluidics aims to understand this behaviour for further application in science and 
technology.  
 
1.5.1 Physics in Microfluidics 
The behaviour of fluids can be described through a dimensionless magnitude 
known as the Reynolds number (Reynolds 1883).  This magnitude defines the flow 
pattern of a fluid under specific conditions by the correlation of inertial forces to 
viscous forces.  The Reynolds number (Re) is defined as follows: 
Re= 
Inertial forces
Viscous forces
 =
𝜌𝜐𝐿
µ
       (Equation 1.1) 
Where ρ is the density of the fluid, υ is the velocity of the fluid with respect to the 
object through which is flowing, L is the cross section area of the object, and μ is the 
dynamic viscosity of the fluid.  Depending on the Re value, the flow pattern of a fluid 
can be defined as turbulent or laminar (Figure 1.6).  In the macroscale, where 
interfacial forces are dominant, Re are high and the fluid flows in a turbulent regime.  
Turbulent regimes are characterized by irregular fluctuations or mixing, and the 
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speed of the fluid at a point is continuously undergoing changes in both magnitude 
and direction.  In contrast, low Re are typical for microsystems, where channel 
dimensions are reduced and viscous forces are predominant.  This leads to fluids 
flowing in a laminar regime, in which the fluid moves in smooth paths or layers, with 
minimal disruption between them.  The transition between the two regimes depends 
on the channel geometry.  In a straight channel it typically occurs at Re = 2300 (Ong 
et al. 2008).  In laminar flow regimes, two or more miscible fluid streams in contact 
with each other, flow side by-side, with mixing occurring via interfacial diffusion 
(Ismagilov et al. 2000).  The velocity of flow varies from zero at the walls to a 
maximum along the cross-sectional centre of the channel, which can permit the 
separation of particles depending on their size and velocities (Weigl & Yager 1999). 
 
 
Figure 1.6.  Graphical representation of turbulent and laminar flow regimes.  Flow regime can 
be predicted through the Re.  The transition between the two regimes depends on the 
channel geometry.  In a straight channel it typically occurs at Re = 2000.  Turbulent flow is 
characterized by irregular fluctuations or mixing.  In laminar flow, fluid flows in parallel layers, 
with no disruption between layers.   
Turbulent flow
Laminar flow
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The reduction in length scales also affects the diffusion rate of the molecules.  
Diffusion is the process by which molecules move from a region of high concentration 
to a region of low concentration.  The diffusion coefficient of a particle is defined by 
the following equation: 
D=
d2
2t
  (Equation 1.2) 
Where D is the diffusion rate and d is the distance a particle moves in a time t.  Since 
distance varies to the square power, diffusion rates are very high on the microscale.  
This reduction in diffusion times can be utilized in order to accelerate 
experimentation times of chemical reactions in microchannels (DeMello 2006).  
Another characteristic of microscale systems is the high surface area to volume ratio 
(SAV), which can lead to unconventional dominant forces.  Thus, large SAVs typically 
make surface forces dominant, while greatly reducing the influence of inertial forces. 
Because interfacial phenomena become dominant in microfluidic systems, 
surface tension forces are also significant when compared to the macroscale.  Surface 
tension is the result of cohesion forces between liquid molecules at the liquid/gas 
interface.  When surface tension forces are dominant, the fluid acquires the minimum 
surface area possible, that is, the total area that the surface of the object occupies.  
Surface tension forces play an important role in droplet-based microfluidics, which 
will be discussed in the next section. 
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1.5.2  Droplet-based microfluidics 
Microfluidic systems can operate within a continuous-flow regime or 
droplet/segmented-flow regime.  In continuous systems, liquid streams flow through 
microchannels with no interruption.  This method is usually acquired for large-scale 
applications, such as chemicals separation (Pamme 2007).  However, issues related 
with fluid interaction with channel walls, cross-contamination and long channel 
lengths, hinders its application in those situations where a high precision of fluid 
manipulation is required (Lignos et al. 2012).  Droplet-based microfluidics overcomes 
the problems mention above.  In this approach, the manipulation of droplets, instead 
of microflows, reduces the volume of sample liquid, providing an additional 
miniaturization step.  In biomedical research, droplets have the potential to become 
important tools for drug delivery and biosensing.  In order for them to function 
properly, correct dosing and manufacturing must be ensured.  Droplet microfluidics 
has been shown to generate highly monodisperse droplets with size variations 
smaller than 1% (Nisisako et al. 2006).  Hence, the precise generation and 
repeatability of droplets, makes droplet-based microfluidics a potent high-
throughput platform for biomedical research.  
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1.5.2.1 Physics involved in droplet formation 
Droplet-based microfluidics consists on the formation and manipulation of 
discrete droplets within an immiscible continuous phase.  Typically, the two phases 
involved are liquid, although the formation of droplets in a liquid/gas system is also 
possible (Jiang et al. 2015).  In liquid-liquid systems, droplets of one phase (dispersed 
phase) are produced as a result of the shear force generated by the continuous phase 
and the surface tension at the fluid-fluid interface (Teh et al. 2008).  Hence, the 
surface tension is a critical parameter that affects the evolution of the interface 
between two phases during the droplet formation.  Surface tension can be defined 
as an energy per unit area, which acts to minimise the total surface area, so as to 
reduce the free energy of the interface.  The minimum area for a given volume is a 
sphere, which is the shape taken by a droplet.  But also, viscous forces are important 
in the droplet formation.  As outlined in the previous section, fluids flowing in 
micrometric dimensions typically have low Re, which means that viscous forces 
become dominant over inertial forces.  In the mechanisms underlying droplet 
formation, surface tension and viscosity compete with each other, since both tend to 
become important at small scales (Baroud et al. 2010).  The relative strength of these 
two forces is expressed by the following equation:  
Ca=
µV
σ
  (Equation 1. 3) 
where Ca is the Capillary number, µ is the viscosity of the continuous phase, V is the 
velocity of the continuous phase, and σ is the surface tension at the interface 
between the two phases.  Above a certain critical capillary number, droplet break off 
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occurs.  However, this number depends on the system (Nisisako et al. 2005; Song et 
al. 2006; Anna & Mayer 2006).   
Droplet formation is also significantly affected by the wetting properties of the 
channel walls.  Wetting can be defined as the ability of a liquid to cover a solid surface, 
and depends on the physico-chemical properties of the surface.  It can be quantified 
through the contact angle (θ), which is the angle, conventionally measured through 
the liquid, where a liquid–vapour interface meets a solid surface (Figure 1.7).  
Controlling the wetting of the channel walls by the dispersed phase is important in 
order to prevent its adhesion to the walls and produce highly spherical droplets.  In 
the case where hydrophilic droplets are generated within a continuous hydrophobic 
phase, namely water in oil (W/O) emulsions, channel walls should be hydrophobic, in 
order to maximize the contact angle between the droplet and the wall surface.  For 
such applications, polydimethylsiloxane (PDMS) devices are frequently used to 
fabricate the microfluidic channels (Friend & Yeo 2010).  However, PDMS undergoes 
swelling and deformation in the presence of strong organic solvents and uncontrolled 
adsorption of substances is a major problem (Uchida et al. 2003).  Hence, other 
materials such as glass (Utada et al. 2005) silicon (Pollack et al. 2002) and 
polytetrafluoroethylene (PTFE), commonly known as Teflon (Walsh et al. 2016), are 
used instead.  
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Figure 1.7.  Contact angle.  High contact angles occur when a hydrophilic droplet gets in 
contact with a hydrophobic surface.  The repulsion forces between the two substrates 
provokes high surface tension at the interface, thereby producing highly spherical droplets. 
 
1.5.2.2 Microfluidic formats for droplet generation 
1.5.2.2.1 Co-flowing 
In co-flowing devices, one fluid flows inside the inner capillary while the other 
fluid flows through the outer capillary in the same direction, resulting in a coaxial flow 
of the two fluids (Cramer et al. 2004) (Figure 1.8).  The breakup of the liquid stream 
into droplets occurs under two different regimes: dripping and jetting.  When the 
fluids flow at low flow rates, monodisperse droplets are formed at the tip of the 
capillary orifice, in a dripping mode.  If the flow rate of either fluid is increased beyond 
a certain critical limit, the result is a jet, a long stream of the inner fluid with drops 
forming downstream.  The transition from dripping to jetting occurs when the 
continuous phase velocity increases above a critical value (Utada et al. 2007).  This 
value decreases as the flow rate of the dispersed phase increases.  It also depends on 
the viscosities of the inner and outer phases, as well as on the interfacial tension. 
θ
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Figure 1.8.  Droplet formation in a co-flowing system.  a) Dispersed phase flows through the 
inner capillary while the continuous phase flows through the outer capillary in the same 
direction, resulting in a coaxial flow of the two fluids.  b) Dripping mode: when the fluids flow 
at low rates, monodisperse droplets are formed at the tip of the capillary orifice c) Jetting 
mode: if the flow rate of either fluid is increased beyond a certain critical limit, the result is a 
jet, a long stream of the inner fluid with drops forming downstream.  Scale bar = 50µm.  
Adapted from Utada et al. 2007.   
 
1.5.2.2.2 T-junction 
In the T-junction format, the two phases flow through two perpendicular 
channels until they meet at the junction (Sivasamy et al. 2011) (Figure 1.9).  There 
are three regimes in this format, which are dripping, squeezing and parallel flowing 
(Garstecki et al. 2006).  At high Ca, droplet formation occurs through dripping mode.  
The disperse phase stream does not enter the continuous phase, and droplet 
formation occurs before the junction due to the action of the shear stress.  
Alternatively, if the capillary number is low, surface tension is dominant and the 
formed droplets obstruct the channel, constricting the continuous phase.  As a 
consequence, there is a dramatic increase in the hydrodynamic pressure upstream of 
(a)
(b)
(c)
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the droplet, which in turn induces the droplet pinch-off.  When the dispersed phase 
flow rate is higher than the continuous flow rate, the squeezing regime develops into 
the formation of parallel flowing streams (Guillot & Colin 2005).  The transition from 
dripping to squeezing modes depends on the balance of the forces involved, including 
dynamic pressure, surface tension, viscous and inertial forces (De menech et al. 
2008). 
 
 
Figure 1.9.  Droplet formation in a T-junction.  a) The two phases flow through two 
perpendicular channels until they meet at the junction.  b) Dripping: the disperse phase 
stream does not enter the continuous phase, and droplet formation occurs before the 
junction due to the action of the shear stress.  c) Squeezing: the formed droplets obstruct the 
channel constricting the continuous phase.  As a consequence, there is a dramatic increase 
in the hydrodynamic pressure upstream of the droplet, which in turn induces the droplet 
pinch-off.  d) Parallel flowing: when the dispersed phase flow rate is higher than the 
continuous flow rate, the squeezing regime develops into the formation of parallel flowing 
streams.  Scale bar = 100µm.  Adapted from De menech et al. 2008.   
 
(a)
(b) (c)
(d)
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1.5.2.2.3 Flow focusing 
In the flow-focusing format, the dispersed and continuous phases are forced 
through a narrow nozzle in the microfluidic device (Dreyfus et al. 2003; Anna et al. 
2003) (Figure 1.10).  This system integrates a symmetric design that provides a 
shearing stress on the dispersed phase by two counter-flowing streams of the 
continuous phase, which enables more controlled and stable generation of droplets.  
Like the previous formats, the droplet formation process depends on the balance of 
the forces involved.  Four different droplet breakup regimes have been identified in 
flow focusing devices: squeezing, dripping, jetting and thread formation.  In 
squeezing mode, the dispersed phase flows through the nozzle and grows until the 
droplet breaks off, which is entirely provoked by the shear force of the continuous 
phase.  Droplets formed in this mode are similar in size to the channel dimensions 
and are highly monodisperse.  In the dripping mode the droplet formation is 
controlled by both the shear force generated by the continuous phase and the 
surface tension at the interface, leading to smaller droplets (Eggers 1993).  In the 
jetting mode, the dispersed stream extends considerably further downstream on the 
channel and droplet generation takes place due to Rayleigh-Plateau instabilities 
(Plateau 1849; Rayleigh 1879).  When the flow rate of the dispersed phase is higher 
than the continuous phase, the shear force is not high enough to produce the stream 
pinch-off and the dispersed phase flows downstream the channel within the 
continuous phase forming a long thread. 
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Figure 1.10.  Droplet generation in a flow focusing device.  a) The dispersed and continuous 
phases are forced through a narrow nozzle.  This system integrates a symmetric design that 
provides a shearing stress on the dispersed phase by two counter-flowing streams of the 
continuous phase.  b) Squeezing: the dispersed phase flows through the nozzle and grows 
until the droplet breaks off due to the shear force of the continuous phase.  c) Dripping: 
droplet formation is controlled by the shear force generated by the continuous phase and 
the surface tension at the interface.  d) Jetting: the dispersed stream extends considerably 
further downstream on the channel and droplet generation takes place due to Rayleigh-
Plateau instability.  e) Threading: when the flow rate of the dispersed phase is higher than 
the continuous phase, the shear force is not high enough to produce the stream pinch-off 
and the dispersed phase flows downstream the channel within the continuous phase forming 
a long thread.  Scale bar = 100µm.  Adapted from Sullivan & Stone 2008.  
  
a
b c
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1.5.3 Microfluidics and Biomedical Research 
The miniaturization process leads to the observation of new phenomena, 
thereby allowing the performance of techniques and experiments not possible on the 
macroscale.  This enables new functionality and experimental paradigms to emerge 
(Beebe et al. 2002).  Microfluidic devices offer the possibility of working with smaller 
reagent volumes and shorter reaction times, thereby reducing experimentation 
costs.  Micrometric dimensions permit a better control of physical and chemical 
properties, which in turn allows the creation of more uniform reaction conditions to 
obtain products with higher grade (Streets & Huang 2013).  The reduction in 
dimensions’ scale permits the integration of an entire laboratory onto a single chip, 
or multichip module (i.e., lab-on- a-chip devices) (Guber et al. 2004) allowing the 
automatization of complex multistep processes.   
Microfluidics based approach allows the high-throughput of small sample 
volumes and ease of automation, thereby reducing experimental costs and times.  
This permits the expansion of point-of-care testing, which is defined as diagnostic 
testing at, or near, the site of patient care, to make the test convenient and 
immediate.  Patients can receive testing results within minutes, by utilizing 
miniaturized and portable devices (e.g., blood glucose meter).  Such devices can be 
used in hospitals, or simply by patients by themselves at home, without any 
professional knowledge or particular skill (Sia & Kricka 2008).  The low volumes of 
sample required by these devices permits sample collection in a minimally invasive 
manner.   
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1.5.3.1 Cell manipulation 
Cell differentiation in vitro is typically achieved by the exposure of cells to 
suitable differentiation cocktails, containing biochemical factors that lead to 
signalling cascades within the cell and determine their phenotype (Ntambi & Kim 
2000; Gao et al. 2014).  However, cell differentiation in living organisms is also 
affected by other external factors, such as mechanical stress induced by surrounding 
extracellular matrix (ECM) (Janmey & Miller 2011).  Microfluidic devices are capable 
of generating highly controlled shear stress gradients in physiological conditions, 
providing a tool for the in vitro differentiation of cells in a more realistic manner (Kim 
et al. 2017).   
Microfluidics has also been used to develop micromolds for cell patterning 
(Tan & Desai 2003; Kuribayashi-Shigetomi et al. 2010).  Such micromolds allows the 
patterning of several hundreds of different cell types and biomaterials, providing a 
simple and fast technique to produce complex tissue constructs or even whole organs 
(organ-on-a-chip) (Bhatia & Ingber 2014).  Cell patterning provides a method for 
studying the functional significance of tissue architecture at the resolution of 
individual cells, and the molecular interactions between cell types underlying 
processes such as embryonic morphogenesis (Suri et al. 2013), the formation of the 
blood–brain barrier (Van der Helm et al. 2016), and tumour angiogenesis (Stroock & 
Fischbach 2010). 
In vitro fertilization (IVF) is another field that takes advantage of microfluidic 
technology.  Conventional IVF technique involves manual manipulation and pipetting, 
therefore requiring the need for highly experienced professionals to achieve 
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satisfactory results.  The use of microfluidic systems for IVF, permits the integration 
of oocyte trapping, fertilization and subsequent embryo culture in a single device, 
thereby simplifying the whole process (Suh et al. 2006; Han et al. 2010). 
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2.1 Introduction 
Microfluidics has been broadly applied over recent years to the production of 
monodispersed, microscopic droplets, specifically for the production of polymer 
microspheres  (Choi et al. 2007; Liu et al. 2013).  However, few authors have 
employed the used of microfluidic devices along with internal gelation for the on-site 
production of such microdroplets (Liu et al. 2013).  Whereas external gelation 
involves two steps for the production and gelation of droplets, internal gelation 
permits the formation and on chip cross-linking of polymer beads, thereby potentially 
enabling the automatization of the entire process (Maeda et al. 2012).  Furthermore, 
the monodispersity of beads is greater, due to the more consistent gelation process 
conditions (Chan et al. 2002). 
Several strategies exist for polymer emulsification in microfluidic devices 
based on the network layout of microfluidic channels (Section 1.5.2.2).  The simplest 
method involves two immiscible fluids co-flowing in the same capillary, giving rise to 
droplet formation due to the shear force generated by the outer phase (Cramer et al. 
2004).  In a different approach, droplets can also be generated within T-junction 
devices, where dispersed and continuous phases meet at an angle of 90 degrees 
(Sivasamy et al. 2011).  Finally, flow focusing devices provides a method in which both 
phases flow in perpendicular directions and are then forced through the same 
channel (Dreyfus et al. 2003).  The large number of geometrical aspect ratios 
characterizing flow-focusing devices permits a better and more accurate control of 
droplet formation.  Hence, this strategy was used to produce alginate microcapsules 
in this thesis. 
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Alginate microcapsules should maintain their integrity for extended periods of 
time, allowing for a long-term protection of the encapsulated cells.  At the same time, 
the porosity of the microcapsules should be high, to guarantee an effective mass 
transfer, thereby providing higher cell survival rates (Smidsrød & Skjåk-Braek 1990).  
Alginates possessing a high guluronic acid content (medium viscosity alginates) 
develop stiffer, more porous gels.  Conversely, alginates rich in mannuronic acid 
residues (low viscosity alginates) produce softer, less porous microcapsules, which 
tend to disintegrate easier after long culture periods (Lee & Mooney 2012).  The 
viscosity of the matrix affects cell survival in that pre-polymer solutions with high 
viscosities need great shear forces to produce droplets, which can damage cell 
membrane (Gray 1997).  
 
2.2 Aims and Objectives 
The aims of this chapter were for the microfluidic production of alginate 
droplets and on chip gelation with a target, average diameter of ~500µm.  To this 
end, a PTFE microfluidic device was fabricated using milling machinery.  Optimization 
of the microfluidic parameters was investigated: namely with respect to droplet 
generation strategy, channel geometry and fluid flow rates.  
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2.3 Materials and Methods 
2.3.1 Microfluidic reagents 
- Medium viscosity alginic acid sodium salt from brown algae, mineral oil 
and glacial acetic acid were purchased from Sigma-Aldrich, UK.   
- Oil Blue N and Oil Red O were used to stain the mineral oil and purchased 
from Sigma-Aldrich, UK.   
- Nanocrystalline precipitated calcium carbonate (average particle size 
70nm) was purchased from Specialty Minerals, Birmingham, UK. 
- Red food dye (Silver Spoon) was used to stain the alginate solution.  
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2.3.2 Preparation of microfluidic reagents  
Nanocrystalline precipitated CaCO3 was dispersed in distilled water.  Sigma 
Medium Viscosity sodium alginate was added to the CaCO3 suspension.  The blend 
was stirred for 2 hours at 37°C.  Concentrations of CaCO3 and alginate are specified 
in Section 2.4.2.  Glacial acetic acid was dissolved in mineral oil at a final 
concentration of 0.3% (v/v). 
 
2.3.3 Chip design and manufacturing 
Microchannels were machined into PTFE discs using a Computer Numerical 
Controlled milling machine (LPKF C30) after being designed using SolidWorks 
software and then exported to CircuitCAM 5.0 (LPKF, Germany) as .DXF files.  The 
software allowed milling procedures to be assigned to cut the appropriate regions of 
the chip.  The file was then exported to BoardMaster (LPKF, Germany) where tools 
were assigned to the milling procedures.  The BoardMaster software controlled the 
micromachining tool.  BoardMaster software controls the tool movement in the X 
and Y planes, whereas the Z plane is controlled by manual adjustment to the desired 
depth.  To ensure a good surface finish within the channels, and to minimise the 
stress placed on the tool, multiple machine passes were used; typically, only 
increasing the depth by a quarter of the tool diameter for each pass.  Milling was 
carried out with a milling drill spin speed of 30,000 rpm.  Inlet and outlet holes were 
drilled at 3.25mm from the edge of the PTFE chip.  These positions lined up with holes 
in a prefabricated metallic manifold.  The chips were polished before and after milling 
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to obtain a smooth and flat surface.  Polishing was performed by hand by rubbing the 
PTFE chip over a series of sandpapers of increasing fineness with a cotton polish as 
the final stage (240-2500 grade SiC grinding paper for metallography, BUEHLER). 
 
2.3.4 Microfluidic device setup 
The microfluidic device used in all experiments consisted of a metallic 
manifold into which HPLC fluid connectors (Sigma-Aldrich, UK) were introduced 
perpendicularly through holes sealed with nitrile rubber O-rings (Sealmasters, 
Cardiff, UK), allowing fluid to flow in the channels of previously machined PTFE disc 
(50mm diameter x 6mm thickness, Good Fellow, Huntingdon, UK) located within the 
manifold.  A fluorinated ethylene propylene (FEP) film (5cm diameter, 0.1mm 
thickness; Good Fellow, Huntingdon, UK) was placed in between the PTFE chip and a 
borosilicate glass disc cover (5cm diameter x 10mm thickness; PI-KEM Ltd, 
Staffordshire, UK).  A metallic clamping piece was screwed to the manifold, allowing 
the entire assembly to be compression sealed.  Fluids were introduced into the 
microfluidic channels through sterile 1/16-inch outer diameter PTFE tubing (Sigma-
Aldrich, UK) using syringe pumps (KD Scientific – Linton Instrumentation, Norfolk, 
UK). 
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2.3.5 Imaging 
Droplet formation movies were recorded with a high-speed camera 
(Megaspeed MS40K) attached to an optical microscope (Nikon MM-800).  
Megaspeed AVI player software permitted the images acquisition of microfluidic 
channels.  Images of alginate microcapsules were acquired with an Eclipse TS100 
inverted phase contrast light microscope (Nikon, Japan) with a camera attachment 
(Canon, Japan). 
  
2.3.6 Statistics 
Data are represented as mean ± SEM.  Statistical significance was determined 
by Student’s t test.  P < 0.05 was considered statistically significant. 
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Figure 2.1.  Microfluidic device.  A) Picture of the whole set up used for the microfluidic 
experiments.  The microfluidic device was connected through HPLC tubing to syringes 
containing the fluids.  Flow rates were controlled by syringe pumps.  B) Detailed diagram 
showing each component of the microfluidic device.  
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2.4 Results 
2.4.1 Development of a customized microfluidic chip to produce 
alginate microcapsules 
PTFE was chosen as the material to fabricate the microfluidic device.  Due to 
its physical properties, PTFE is a hydrophobic material with excellent wetting features 
(Walsh et al. 2016).  Its high contact angle is stable along the surface as a 
consequence of its non-reactivity.  Therefore, it is possible to produce highly stable 
water in oil emulsions without the use of surfactants, hence minimizing cell damage 
and the number of washing steps.  The high melting point of PTFE allowed for its 
heated sterilization prior to any experiment carried out with live mammalian cells.  
Since the ultimate goal of this thesis was the encapsulation of stem cells, flow 
focusing was selected as the strategy to produce polymer micro beads.  In this 
method the dispersed phase is barely stressed and therefore is suitable for the 
encapsulation of cells, with no decrease in their viability (Martín-Banderas et al. 
2005).  In flow focusing devices, the dispersed and continuous phases are forced 
through a narrow nozzle in the microfluidic device.  The shear force generated by the 
continuous flow provokes the dispersed phase to break off into droplets.  This 
method enabled the production of alginate droplets and gelation in one unique step.  
Flow focusing allows for the production of droplets with greater dynamic size range 
from a given device compared with other strategies, e.g. T-junction (Baroud et al. 
2010). 
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To prevent prompt alginate cross-linking (the initial ECM molecule under 
investigation) CaCO3 was utilised as calcium ions source.  This salt has a low solubility 
at neutral pH in aqueous solutions, which allowed for its dispersion into the alginate 
solution (dispersed phase).  A solution of acetic acid in mineral oil (continuous phase) 
was used in order to trigger the release of Ca2+ according to the following chemical 
equation: 
CaCO3 + 2H+  Ca2++ H2O + CO2 (Equation 2. 1) 
 
Preliminary experiments using the chip layout in Figure 2.2 demonstrated that 
almost instantaneous (~<1s) alginate gelation occurred, at location ‘A’, causing the 
formation of a solidified alginate membrane, which eventually (in a matter of 
seconds) blocked the alginate inlet port, leading to a stalling of the syringe pump. 
 
Figure 2.2.  Chip design for the production of alginate microcapsules.  Alginate gelation 
occurred at the junction, provoking the blockage of the channels and therefore the disruption 
of alginate emulsification.  Scale bar = 500µm. 
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In order to prevent an immediate gelation at the site of droplet formation, an 
additional phase containing mineral oil was incorporated in the design (Figure 2.3).  
This new phase worked as a “shielding flow” preventing alginate solidification at the 
junction (Workman et al. 2007).  As mentioned in Section 1.5.1, fluid properties 
dramatically change when they are infused through networks of channels of 
micrometric dimensions.  Under these conditions, fluids flow in a laminar regime, 
where parallel layers of liquid flow with minimal disruption between them and run 
parallel to the channel walls.  However, particles move through different layers by 
diffusion.  This phenomenon allowed the acetic acid present in the continuous phase 
to diffuse through the shielding flow and reach the alginate droplets, provoking their 
controlled gelation.   
 
 
Figure 2.3.  Shielding flow. Alginate gelation on chip can be delayed by adding a “shielding 
phase”.  Due to the laminar flow, the two miscible phases (shielding and proton source) flow 
in parallel layers through the same channel with no disruption between layers.  Protons 
diffuse trough the different layers to finally reach the alginate, provoking its gelation.  Scale 
bar = 800µm. 
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The thickness of each phase could be easily controlled by the modification of 
their flow rates, thereby modifying alginate gelation kineticsl.  At low shielding phase 
flow rates (red) and high acetic acid flow rates (white), the shielding stream was 
narrow and the diffusion of protons towards alginate droplets was faster, allowing 
for quicker gelation times (Figure 2.4 A).  In contrast, when the flow rate of the 
shielding phase was increased, the flow stream was wider and the diffusion of 
protons through the channel was delayed, allowing for slower gelation times (Figure 
2.4 B).  A flow rates ratio of 1:1 was selected for subsequent experiments, in order to 
produce alginate droplets with slow cross-linking rates.  This avoided the blockage of 
microfluidic channels and ensured a uniform gelation through the entire droplet. 
Through the addition of the shielding flow, the premature gelation of alginate 
was prevented and continuous droplet formation was then achieved.  Since alginate 
cross-linking was delayed, chip channels were designed in order to increase the path 
length so that alginate gelation took place before leaving the microfluidic device.  
Towards this end, the main channel was fabricated in a meander-like format (Figure 
2.5 A).  However, an inconsistent droplet flow was observed due to the adhesion of 
alginate on the walls as a consequence of changes in directions.  Therefore, a 
modification on this initial design was required.  To this end, it was considered that a 
straight channel would overcome the issues previously mentioned (Figure 2.5 B).  A 
longer outlet HPLC tubing was used in order to compensate the channel shortening.  
Alginate beads were collected in distilled water, with no further processes needed 
(Figure 2.6).  
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Figure 2.4.  Laminar flow.  Two miscible phases (red corresponding to mineral oil, and 
horizontal white to acetic acid in mineral oil) flowing in parallel layers through the same 
channel.  The thickness of each phase could be modified by the alteration of their flow rates.  
A) Flow ratio 1:10. B) Flow ratio 1:1.  Scale bar = 500µm. 
 
 
Figure 2.5.  Geometry of microfluidic chips.  Both chips were formed by 5 inlets: alginate was 
introduced into the chip through inlet 1; the shielding phase (mineral oil) flowed through 
inlets 2 protecting a prompt alginate gelation.  Acetic acid in mineral oil (protons source 
phase) was injected through inlets 3, flowing in parallel layers with mineral oil.  Cross-linked 
alginate droplets left the device through the outlet (4).  A) Chip design 1: the main channel 
was designed in a meander-like shape to increase the path length of the microfluidic device.  
B) Chip design 2: the main channel was replaced by a straight line, avoiding changes in 
direction and therefore, allowing a consistent flow of alginate beads.  Channels dimensions: 
inlets 1, 2 and 3 were 500µm x 400µm; main channel was 800µm x 700µm.  
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Figure 2.6.  Collection of alginate microcapsules.  Alginate droplets underwent on chip cross-
linking by coordination of Ca2+ with the guluronic blocks of alginate chains.  Beads were 
collected in distilled water.  
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2.4.2 Optimization of the reagents concentration  
Three different alginate concentrations were tested: 1% (w/v) (low 
concentrated), 2% (w/v) (medium concentrated) and 4 % (w/v) (high concentrated).  
Low concentrated alginate gave rise to microspheres with low mechanical stability.  
Alginate droplets were easily deformed by mechanical pressure, thereby providing 
microcapsules with poor consistence.  High concentrated alginate solution had a high 
viscosity, which hindered its manipulation and injection through microchannels due 
to the high hydrodynamic pressure generated by alginate flowing inside the channels.  
Medium concentrated alginate viscosity permitted an easy manipulation and allowed 
for the production of microcapsules with good mechanical stability.  Hence, 2% (w/v) 
alginate was selected as the suitable concentration for further experiments.  Once 
the concentration of alginate was established at 2% (w/v), the appropriate 
concentration of CaCO3 was investigated (Figure 2.7).  Based on the reports of others 
(Workman et al. 2007), the concentration of CaCO3 was generally utilised as 5 mg/ml.  
In order to investigate the effect of a modification of CaCO3 concentration on the 
production of alginate microcapsules, 2% (w/v) alginate solution with 2,5 mg/ml, 
5 mg/ml, and 7,5 mg/ml suspended CaCO3 were tested.  2,5 mg/ml solutions brought 
about partially gelled alginate microbeads, with random shapes and sizes.  On the 
other hand, 7,5 mg/ml solutions produced stable alginate microspheres with 
rounded shapes and even diameters.  However, small deposits of CaCO3 were 
observed within the beads, suggesting that some CaCO3 was not dissociated.  
Microcapsules produced with 5 mg/ml CaCO3 demonstrated spherical shapes of high 
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consistency, as seen by a defined membrane and no CaCO3 deposits.  Therefore, a 
concentration of 5 mg/ml CaCO3 was established for further experiments.  
Based on the reports of others groups (Workman et al. 2007) 0.3% (v/v) acetic 
acid has been used for gelation of 2% (w/v) alginate hydrogels.  In order to minimize 
the potential harmful effect on cells in further applications (Chapter 3), lower 
concentrations of acetic acid were tested, namely 0.1% (v/v) and 0.2% (v/v).  
However, none of these concentrations achieved gelation of alginate microcapsules.  
Hence, for all the subsequent experiments carried out, the following concentrations 
were used: 2% (w/v) alginate solution in distilled water containing 5 mg/ml CaCO3 
and 0.3% (v/v) glacial acetic acid in mineral oil. 
 
 
Figure 2.7.  Optimization of CaCO3 concentration.  The utilization of alginates with 2,5 mg/ml 
CaCO3 gave rise to incomplete gelled beads, as seen by some beads merging with each other.  
When CaCO3 was resuspended in an alginate solution at a concentration of 5 mg/ml, 
microcapsules showed highly spherical shapes.  However, when the concentration of CaCO3 
was increased (7,5 mg/ml), some deposits were visible inside the microcapsules.  Scale 
bar = 100µm. 
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2.4.3 Optimization of flow rates 
One of the main benefits from the use of microfluidics for the production of 
micrometre-sized droplets is that the diameter of such droplets can be easily 
modified by variations in flow rates.  Depending on the flow rate ratios, emulsification 
happens through different modes.  Dripping mode occurs when the continuous phase 
and disperse phase flow rate ratio is high, and therefore, the shear force generated 
by the continuous phase is dominant over the hydrostatic pressure in the dispersed 
phase (Utada et al. 2007).  In this case, the droplet “pinch off” takes place at the 
vicinity of the junction.  On the contrary, when the dispersed phase flow rate is 
greater, and therefore the ratio between both flow rates is lower, the inertial forces 
become dominant over surface tension.  As a result, the dispersed fluid forms a jet 
which breaks into droplets further downstream due to Rayleigh-Plateau instability 
(Plateau 1849; Rayleigh 1879).  In the jetting mode, polydispersity of droplet 
diameters is greater, with higher coefficients of variance.  Since the main purpose of 
this project is the microencapsulation of stem cells, a high monodispersity is a 
fundamental requirement to achieve.  Hence, the droplet formation approach 
utilized in this study was flow focusing in dripping mode.  
Alginate beads of different sizes were produced by modification of the flow 
rates.  To ensure reproducibility of bead formation, each condition was performed 
on three different occasions.  Ten beads per condition, per day (total number of 
beads, n = 30) were utilised for the measurement of their diameters, using 
microscopy and calibrated ImageJ software tools.  In order to calculate bead 
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sphericity, the diameter of each bead was measured twice, lengthwise (d1), and 
transversely (d2). 
Sphericity=
d1
d2
  (Equation 1.4) 
 
The coefficient of variation (CV) was calculated as follows:  
CV %= 
Standard Deviation (SD)
Mean Diameter
 x 100 (Equation 1.5) 
 
Firstly, alginate flow rate (fd) was increased from 0.1 ml/h up to 2 ml/h, and a constant 
value of 10 ml/h was established for the continuous phase (combination of the co-
flow shielding phase and proton source phase).  According to the results in Figure 
2.8A, the diameter of the beads increased when the alginate flow rate was 
augmented.  In all cases, coefficients of variance were <2.5%, and the sphericity 
achieved was close to 1,0 (Figure 2.9 A-E). 
For stem cell encapsulation purposes, small bead diameters are preferred in 
order to enhance the diffusion of nutrients and oxygen inside the microcapsule 
(Ogbonna et al. 1991).  Therefore, with the chip design described in Figure 2.2B and 
the conditions tested above, an alginate flow rate of 0.1 ml/h should be used to 
produce the smallest beads.  However, the frequency of bead formation with this 
flow rate was too low, requiring long experimentation times to produce a significant 
amount of alginate beads (e.g. 10 hours to produce 1ml of alginate beads).  Hence, in 
order to produce small beads at a higher frequency, a second set of experiments were 
carried out.  In this case, alginate flow rate was maintained at a constant value of 
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1 ml/h, and the continuous phase flow rate (fc) was modified from 5 ml/h up to 
30 ml/h.  Results in Figure 2.8B show that the size of the beads decreased when the 
continuous phase flow rate was increased.  At 30 ml/h, beads with the smallest 
diameters were produced (440 ± 3 µm) at a greater frequency than in the previous 
experiment.  Photographs of alginate beads at each condition previously described 
were taken (Figure 2.9 F-J).  Hence, the flow rates selected for subsequent 
experiments were 1 ml/h for dispersed phase, and 30 ml/h for continuous phase, in 
order to produce the smallest beads in the shortest experimentation time.  
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Figure 2.8.  Variation of bead diameters with flow rates.  A) The size of the beads increased 
when the alginate flow rate was augmented.  B) the size of the beads decreased when the 
continuous phase flow rate increased.  Data shown as mean ± SEM, are representative of at 
least three independent experiments made in triplicate.  **, P < 0.01; ***, P < 0.001, 
Student’s t test. 
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Figure 2.9.  Alginate microcapsules of different sizes were produced by a combination of 
different flow rates.  In the first experiment, carrier phase flow rate was maintained at 10 
ml/h and alginate flow rate was modified as follows: 0.1 ml/h, 0.2 ml/h, 0.5 ml/h, 1 ml/h and 
2 ml/h (A, B, C, D and E, respectively).  In the second experiment, alginate flow rate was 
maintained at 1 ml/h and carrier phase flow rate was modified: 5 ml/h, 10 ml/h, 15 ml/h, 20 
ml/h and 30 ml/h (F, G, H, I and J, respectively).  Scale bar = 500µm. 
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2.5 Discussion 
A customized microfluidic PTFE device was fabricated for the production and 
on-chip cross-linking of alginate beads by an internal gelation approach.  The 
diameter of the microspheres was selectively modified by the manipulation of the 
flow rates.  
Since interest in the production of droplets arose, polydispersity has been a 
major problem in conventional emulsification methods.  The use of turbine reactors, 
colloid mills and homogenizers, imparts high mechanical forces and do not offer 
sufficient control over the size of the generated droplets (Mollet & Grubenmann 
2001).  The first attempt of internal gelation was made by Poncelet et al. (1992).  An 
alginate solution containing dispersed CaCO3was mixed with canola oil in a turbine 
reactor and emulsified by stirring during 15 minutes.  Polymer gelation was achieved 
by adding acetic acid to the emulsion in a second step.  Alginate beads were then 
filtered through a strainer for their collection and further characterized.  The resulting 
beads demonstrated a size distribution containing several peaks, demonstrating the 
polydispersity of the generated droplets.  The use of microfluidics allows for the 
production of droplets in a physically gentler manner than the conventional methods 
mentioned above, thereby offering a high degree of control over their size and shape 
(Ushikubo et al. 2014).  Indeed, the coefficient of variance obtained in the results of 
this chapter highlights a high monodispersity in the production of alginate 
microcapsules. 
Since the dispersed phase used in this project was hydrophilic (alginate 
aqueous solution) a hydrophobic surface was required for droplet generation in order 
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to produce high spherical droplets (Section 1.5.2.1).  Hence, PTFE was chosen as the 
material for the chip manufacturing.  Channel fabrication strategies on this substrate, 
commonly soft lithography or photolithography, are time-consuming and require 
several steps (Cuchiara et al. 2010).  The majority of the microfluidic devices 
fabricated with PDMS involve inner channels permanently sealed.  For example, 
Shintaku et al. (2007) fabricated a PDMS chip for the encapsulation of cells in alginate 
microcapsules.  The method involved the use of an epoxy-based negative photoresist 
as a mask for PDMS channels manufacturing, requiring 4 hours curing process.  The 
resulting PDMS substrate was then bonded to a previously PDMS coated glass by 
curing for other 4 hours.  In the study presented in this thesis, microchannels were 
effortless fabricated on PTFE discs by a milling process requiring short periods of time, 
generally less than 30 minutes.  The chip was then mounted in a compressed-sealed 
metallic manifold which allowed the assembly and disassembly of the entire 
mounting in an effortless and quick manner.  The use of a compressed-sealed PTFE 
device allowed the formation of alginate droplets and their in situ gelation in one 
step, allowing the automatization of the whole process, thereby reducing 
experimentation times.   
An alginate cross-linking approach is crucial to achieve highly monodisperse 
microcapsules.  Using external gelation, unsolidified alginate droplets are collected in 
a reservoir of divalent cations, acquiring random uncontrolled shapes (Capretto et al. 
2008).  Divalent cations cross-link the surface of the alginate droplet, hindering the 
diffusion of cations through the core of the droplet.  On the contrary, the internal 
gelation strategy used in this thesis permitted the production of highly monodisperse 
alginate microbeads (CV < 3%), by adding an insoluble calcium salt, CaCO3, in the 
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alginate solution.  Droplets were then formed in the microfluidic device and divalent 
cation release was triggered by the action of acetic acid.  This caused cross-linking of 
the alginate droplets in an evenly and controlled manner, giving rise to microcapsules 
with a homogeneous matrix structure.  The gelling times required for alginate cross-
linking using internal gelation are commonly shorter than those needed for external 
gelation, involving brief experimentation times (a few seconds compared to 15-20 
minutes in external gelation).  In fact, the drastic reduction of dimensions from 
macro-scale to micro-scale increases the diffusion rate of the molecules, giving rise 
to faster kinetics of the processes involved, thereby reducing experimentation times 
(DeMello 2006).  
In this chapter, two different strategies for the on chip alginate internal 
gelation were attempted, using a flow-focusing device.  It was hypothesized that the 
use of a proton source in the continuous phase would provoke alginate emulsification 
and gelation in one single step.  The alginate solution containing disperse CaCO3 was 
segmented by an immiscible solution of acetic acid dissolved in mineral oil.  The 
protons in the continuous phase rapidly diffused through the alginate membrane, 
triggering the release of calcium ions, thereby cross-linking the polymer chains.  
Continuous droplet formation and solidification was observed over a short period of 
time, but undesired and prompt solidification of alginate took place at the junction 
after several minutes, blocking the channel and inhibiting a continuous alginate 
emulsification.  Based on the work reported by Workman et al. (2007), the 
microfluidic device was modified to include a new inlet in the continuous phase, 
acting as a “shielding” flow, thereby preventing alginate gelation immediately after 
bead formation.  Due to the laminar flow regime, protons diffused through the 
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shielding phase, inducing the slow release of calcium ions from CaCO3, then leading 
to the alginate cross-linking in a controlled and uniform manner along the path length 
of the channel.  Alginate cross-linking on chip has been attempted through different 
methods.  For example, Zhang et al. (2006) used a Y-shaped microfluidic planar device 
for the production of alginate droplets.  Alginate emulsification was produced by the 
shear force imposed by a parallel stream formed by undecanol.  Polymer gelation was 
achieved by the solubilisation of CaCI2 into the undecanol phase.  However, the 
extrapolation of this strategy for the encapsulation of stem cells would compromise 
their viability due to the effect of undecanol.  In a different approach, Kalyanaraman 
et al. (2009) incorporated an independent channel to introduce the cross-linking 
agent, CaCl2.  This was mixed with the alginate solution on chip prior to emulsification.  
However, the droplets produced were different in shape as a consequence of the 
prompt gelation triggered by the quick dissociation of CaCl2.  In the method 
developed in this thesis, beads were highly monodispersed. 
Upon optimization of emulsification and cross-linking method, two different 
chip designs were tested.  As a first approach, a meander-like network was designed 
in order to increase the path-length of the microfluidic device.  However, an 
inconsistent droplet flow was observed due to the adhesion of alginate on the corner 
walls as a consequence of changes in direction.  The unsteady velocity of the droplets 
could be explained by the changes in flow direction through the meanders.  This 
alginate film led to further undesired interactions between the channel walls and 
passing droplets, occasionally causing their fragmentation.  This led to smaller 
droplets, which flowed at higher velocity than bigger droplets, giving rise to inter-
droplet collisions.  As gelation was delayed by the shielding flow, alginate beads were 
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not completely solidified in the channel and collisions provoked the droplets to 
merge.  Merging beads brought about larger droplets, leading to the production of 
alginate microcapsules with different shapes and sizes, and the blockage of the outlet 
due to the formation of large beads.  This was resolved by modification of the design 
of the main channel.  The meander-like channel was substituted by a straight line 
channel, thereby avoiding directional changes, and hence, minimizing alginate 
adherence on channel walls.   
The concentration of the dispersed phase was another parameter optimized 
in this chapter.  Alginate solution viscosity plays a key role in the mechanism of 
droplet formation.  As explained in Section 1.5.2.2, droplet generation mode 
depends upon the balance between the forces taking place, including surface 
tension, viscosity, hydrodynamic pressure and inertial forces.  Dispersed phases with 
high viscosities give rise to high Capillary numbers (Ca).  As a consequence, the shear 
force required for the generation of the droplet is higher, due to the resistance of the 
dispersed phase to deformations (Nie et al. 2008).  On the other hand, low viscosities 
produce droplets with poor mechanical properties, thereby hindering their further 
application for cell encapsulation purposes.  Thus, three different concentrations of 
alginate were tested, 1%, 2% and 4% (w/v).  Indeed, 1% alginates gave rise to 
inconsistent microcapsules with low mechanical stability.  In contrast, 4% alginates 
produced highly spherical and stable beads but its manipulation due to its high 
viscosity was difficult, requiring higher continuous phase flow rates in order to 
produce alginate emulsification.  Finally, 2% alginates provided highly monodispersed 
beads with good mechanical properties and its manipulation and emulsification was 
simpler than that of 4% alginate.  The suitable concentration of CaCO3 was also 
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investigated.  High concentration (7,5 mg/ml) produced deposits of CaCO3 in the 
produced droplets, which could have a harmful effect for further cell encapsulation 
experiments.  Low concentration (2,5 mg/ml) did not provide enough calcium ions to 
achieve an even and complete alginate cross-linking, as observed by the formation of 
inconsistent and merged beads.  A medium concentration of CaCO3 (5 mg/ml) 
allowed for an adequate alginate cross-linking with no deposits observed within the 
droplets.  Hence, 2% (w/v) alginate solution and 5 mg/ml CaCO3 were selected for 
further experiments. 
Finally, the influence of flow rates on the size and sphericity of droplets was 
investigated.  Dispersed and continuous flow rates were independently modified and 
the diameter of the beads produced at each condition were measured.  When 
alginate flow rate was increased from 0.1 ml/h up to 2 ml/h an increase in the 
diameter of the beads was observed.  On the contrary, when continuous phase flow 
rate was increased from 5 ml/h up to 30 ml/h, a decrease in the size was noticed.  
Changes in diameter of the beads were not linear-dependent on flow rates.  This can 
be explained by the fact that droplet size cannot be entirely attributed to the 
influence of flow velocities, but also to channel geometries, fluid viscosities and 
surface tension (Baroud et al. 2010).  This behaviour has been observed in other 
studies analysing droplet size in flow focusing devices (Ward et al. 2005; Lapierre et 
al. 2011). 
In summary, the production of alginate microdroplets has been achieved by 
numerous groups, using a wide range of different techniques.  However, since the 
main purpose of the research reported here was the encapsulation of stem cells for 
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healthcare therapies, only cell-friendly reagents and techniques were investigated.  
The microfluidic device developed in this chapter provides a simple platform for the 
selective production of alginate droplets of defined diameters depending on the flow 
rates of dispersed and continuous phases. 
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3.1 Introduction 
Cell transplantation is a promising technique in regenerative medicine and 
wound healing.  However, the viability of transplanted cells is often compromised 
due to the harsh environment within damaged tissues and potential immune 
rejection after grafting (Orive et al. 2015).  The result is that the majority of the 
transplanted cells die and their therapeutic effect is then hindered.  To overcome 
these issues, the administration of immunosuppressants is widely utilised alongside 
transplantation therapies.  However, the use of these drugs should be limited due to 
their negative side effects, such as immunodeficiency, hypertension and liver/kidney 
problems (Halloran 2004).  
Cell encapsulation techniques have been applied in clinical trials to overcome 
the problems mentioned above for the treatment of several illnesses including type I 
diabetes (Calafiore et al. 2006) and Huntington´s disease (Bachoud-Lévi et al. 2000).  
Encapsulation of cells in a protective environment helps increase the number of 
viable cells after transplantation, protecting against the negative effects of immune 
cells and antibodies, and avoiding the need of immunosuppressives (Krishnan et al. 
2013).  Furthermore, whereas the control of cell fate within an organism is often 
difficult to achieve/control, the immobilization of cells in a confined environment 
permits a better control of cell-based parameters, such as proliferation, migration 
and differentiation (Barthes et al. 2014).  
It has been well reported that cells can be immobilized within polymers of 
differing formats, e.g. macroscopic hydrogels (Michalopoulos et al. 2012) or fibres 
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(Xu et al. 2017).  However, the microcapsule approach has received much recent 
attention due to the high surface area to volume ratio, which enhances mass transfer 
through the polymer membrane (Liu et al. 2014).  The polymers used for cell 
encapsulation need to be biocompatible and biodegradable.  This is of key 
importance in order to avoid immunoreactivity and toxic effects within the organism.  
Alginate is one of the biopolymers most frequently used for encapsulation due to its 
relatively mild gelling conditions which are compatible with cell viability (Sun & Tan 
2013).  At the same time, alginate cross-linking can be easily reversed in a cell-friendly 
manner, allowing for the controlled release of the encapsulated cells.  Importantly, 
alginate hydrogels provide a porous structure which allows the bidirectional diffusion 
of nutrients and oxygen inside the capsule and the output of therapeutic agents and 
waste products emanating from cell metabolism (Andersen et al. 2015). 
In order to maintain a healthy population of cells within the microcapsules, 
such 3D structures require an appropriate size, so that nutrients/gases can diffuse 
through the polymer membrane and reach every cell at the centre of the capsule.  
Many efforts have been made over the last few decades to obtain micrometre-sized 
beads fit for such a purpose.  It has been subsequently demonstrated that 
microfluidics is one of the most suitable and reproducible techniques to produce 
monodisperse cell-laden polymer microcapsules in a sealed environment, thereby 
avoiding any potential contamination (Pennathur et al. 2008; Velasco et al. 2012).  
Polymer microcapsules produced by microfluidic devices have smaller diameter and 
a narrower distribution size compared to the conventional methods, such as droplet 
extrusion and emulsification (Dulieu et al. 1999; Chan. et al. 2002).  These methods 
typically produce polydisperse droplets with diameters > 500 µm, hindering nutrient 
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diffusion to the centre of the microspheres (Koch et al. 2003).  The difficult 
standardization of cell number per microcapsule, as well as the inability to produce 
large-scale volumes of cell-containing microspheres with conventional methods, 
have delayed the clinical application of encapsulated cells.  In response to this, 
microfluidics offers a powerful method to rapidly produce large-scale volumes of 
monodisperse polymer microdroplets with diameters of up to a few hundred 
micrometres (Tan & Takeuchi 2007; Capretto et al. 2008; Workman et al. 2008; 
Martinez et al. 2012).  Smaller diameters enhance the diffusion of oxygen and 
nutrients, improving cell viability over extended periods of time (Drury & Mooney 
2003; Sugiura et al. 2005) and facilitates bead injection for cell transplantation 
therapies (Yu et al. 2010). 
 
3.2  Aims & Objectives 
The aims of this chapter are: 
 To optimize the parameters for the encapsulation of murine NSCs and DPSCs 
within ECM-based microcapsules. 
 To study the viability and proliferation of the encapsulated cells. 
 To study the ability of cells to retain their multipotency after long-term 
maintenance within the microcapsules. 
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3.3  Materials & Methods 
3.3.1 Cell culture 
To maintain sterility, all tissue culture procedures were performed in a 
Microflow Peroxide Class II advanced biological safety cabinet (Bioquell, UK).  
 
3.3.1.1 Dental pulp stem cell culture 
Murine GFP DPSCs were isolated by others in the group of Prof. Ketan Patel, 
within the School of Biological Sciences (University of Reading).  Cells were cultured 
in α-modification Minimum Essential Medium containing 2 mM glutamine, 
ribonucleosides and deoxyribonucleosides (Life Technologies, UK).  The medium was 
supplemented with 1% (v/v) penicillin/streptomycin, 20% (v/v) heat-inactivated 
foetal bovine serum (FBS) (Life Technologies, UK) and 100µM l-ascorbic acid 
2-phosphate (Sigma-Aldrich, UK).  Medium was changed every 2-3 days until cells 
reached 80-90% confluence. 
 
3.3.1.2 Passaging DPSC Cultures 
Upon reaching confluence, culture medium was removed by aspiration and 
the cells washed with phosphate buffered saline (PBS) (Sigma-Aldrich, UK).  Cells 
were dissociated by adding 0.25% trypsin-EDTA (Sigma-Aldrich, UK) and returning 
them to the incubator for 3 - 5 minutes until they became rounded and detached. 
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Culture medium was then added to neutralise the trypsin.  The resultant solution of 
medium plus cells was transferred to 15ml falcon tubes and centrifuged at 400x g for 
5 minutes.  After discarding the supernatant, pellets were resuspended in medium 
and cell counts performed using a haemocytometer with trypan blue to assess cell 
viability (Section 3.3.2.1).  Cells were reseeded on new culture plastics at a density of 
4000 viable cells/cm2 for continuous culture, or as per experimental requirements. 
 
3.3.1.3 Cryopreservation and re-establishment of DPSCs 
DPSCs were cryopreserved at regular intervals during culture.  Following 
passaging, a minimum of 1x106 cells were resuspended at 1x106 cells/ml in heat-
inactivated FBS + 20% (w/v) dimethyl sulphoxide (DMSO) (Fisher Scientific, UK) and 
transferred to 2ml cryovials (Greiner Bio-one, Germany).  Cryovials were slowly 
cooled to -80°C in a propan-2-ol filled Mr Frosty (Nalgene, USA).  After being stored 
for 24 hours at -80°C, cryopreserved cells were transferred to liquid nitrogen storage. 
As required, DPSCs were re-established from frozen stock by thawing in a 37°C 
water bath.  Thawed cell suspensions were transferred to 15ml conical tubes 
containing culture medium and centrifuged at 400x g for 5 minutes.  Following 
centrifugation, traces of DMSO were removed by discarding the supernatant and 
resuspending the cell pellets in culture medium and then a further 5-minute 
centrifugation.  Cell counts with trypan blue (Section 3.3.2.1) where undertaken and 
cells reseeded in culture plastics at a density of 4000 cells/cm2. 
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3.3.1.4 Embryonic neural stem cell culture 
GFP NSCs isolated from the cortex of E14.5 C57Bl/6 mice by others in the 
group of Prof. Ketan Patel, within the School of Biological Sciences (University of 
Reading) were maintained in Dulbecco’s Modified Eagle Medium (DMEM)/Ham’s F12 
(1:1) containing 2.5 mM of L-glutamine and 15mM HEPES buffer (Life Technologies, 
UK).  This was supplemented with 1% (v/v) penicillin/streptomycin, 2% (v/v) B27 
supplement (Life Technologies), 10 μg/mL insulin-transferrin-sodium selenite 
supplement (ITSS) (Roche Life Science, UK), 20 ng/ml bFGF and 20 ng/ml EGF (both 
Peprotech). 
 
3.3.1.5 Subculturing NSC cultures 
NSCs were cultured as floating neurospheres at 37°C with 5% CO2 and half 
medium changes performed every 2 days.  As neurospheres expanded and increased 
in size, the centre of the spheres began to turn dark as cells became deprived of 
nutrients.  Before reaching this stage, spheres were subcultured.  The media and 
floating spheres were aspirated and centrifuged at 100x g for 5 minutes.  1ml of 
accutase was used to dissociate the pellet and left to incubate in the water bath at 
37°C for 5 minutes, dissociating spheres to a single cell suspension.  The action of 
accutase was then stopped by the addition of PBS.  Following a further centrifugation 
at 100x g for 5 minutes, the supernatant was discarded and the cells resuspended in 
medium.  Cells were passed through a 40µm cell strainer (Falcon™) to remove any 
clumps of cells.  Cell counts were performed and the cells resuspended at a density 
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of 100,000 cells/ml for continuous culture, or, seeded on 50 µg/ml poly-D-lysine (PDL) 
and 20 µg/ml laminin coated plates for experiments. 
3.3.2 Viability and proliferation assays 
3.3.2.1 Trypan Blue Exclusion Assay 
Trypan blue is a dye that selectively stains non-viable tissues/cells blue.  Live 
cells with intact membranes do not allow the absorption of this stain.  However, 
trypan blue penetrates the compromised membrane of dead cells.   
To determine the percentage of viable cells, an aliquot of cell suspension was 
mixed with an appropriate volume of trypan blue.  The mix was then placed in the 
haemocytometer chamber and cell counting was performed under phase contrast 
microscopy.  The percentage of viable cells was calculated according to the following 
equation: 
Percentage of cells viability=
Number of unstained cells counted
Total number of cells counted
x100 (Equation 3. 1) 
Cell viability was assessed using the trypan blue exclusion assay prior to 
encapsulation and on days 1, 3, 7, 10, 14 and 21 after encapsulation.  The method 
was slightly modified to be applied on encapsulated cells.  200µl of bead suspension 
were taken and beads left to settle at the bottom of the tube.  Culture medium was 
removed carefully so as not to remove any of the beads.  Beads were dissolved and 
cells released as described in Section 3.3.4.  Cells were centrifuged (100x g for NSCs 
and 400x g for DPSCs), supernatant removed, and the pellet resuspended in 10µl of 
culture medium.  Since NSCs grew in aggregates within the microcapsules, cells were 
accutase treated prior to suspension in culture medium in order to obtain a single 
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cell suspension.  10µl of trypan blue were added, mixed and the cell suspension was 
placed in a haemocytometer for cell counting. 
3.3.2.2 MTT Assay 
MTT assay was used to study cell viability/proliferation based on the cell’s 
metabolic activity.  MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) is reduced to its precipitated formazan product by the action of NAD(P)H-
dependent cellular oxidoreductase enzymes.  As MTT reduction depends on 
NAD(P)H-dependent oxidoreductase enzymes, this reaction is related to the cellular 
metabolic activity due to NAD(P)H flux.  Since rapidly dividing cells exhibit high 
metabolic activity, therefore giving high rates of MTT reduction, this analytical 
method is suitable to study relative cell proliferation. 
MTT (Sigma-Aldrich, UK) aliquots were prepared fresh by dissolving the 
powder in PBS at a concentration of 5 mg/ml, and were then filter sterilized.  Bead 
suspension was mixed to give a dispersed, homogenous distribution.  Cells or beads 
containing cells were seeded in 96-well plates in 200µL of medium.  20µL of MTT 
solution was added to each well, including controls, and incubated for 4 hours at 
37°C/5% CO2.  Culture medium was then removed and 150µL of DMSO was added to 
each well to dissolve any formed formazan crystals.  Plates were incubated for an 
additional 30 minutes to allow the precipitate to dissolve completely.  Absorbance 
was subsequently measured at a wavelength of 540nm (FLUOstar Omega microplate 
reader, BMG Labtech). 
In order to test the potential absorbance due to alginate or alginate-collagen 
microcapsules, empty microcapsules were plated on surfaces in 96-well plates.  MTT 
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reagent was added, incubated and then absorbance measured at 540nm.  
Measurement values were, in both cases, close to the medium only control.  
Therefore, a control including empty microcapsules was not required, and only blanks 
containing culture medium were performed.  
 
3.3.2.3 Live/Dead ® Viability/Cytotoxicity Assay 
The cell-impermeant viability indicator ethidium homodimer-1 (EthD-1) is a 
high-affinity nucleic acid stain that is weakly fluorescent until bound to DNA.  When 
used with GFP cells (488nm excitation max and 509nm emission max), it allows the 
simultaneous determination of live and dead cells.  Co-expression of green and red 
fluorescence permits identification of dead/dying cells.  Dead or damaged-
membrane cells are permeable to EthD-1, which undergoes an increase of 
fluorescence upon binding to nucleic acids, and producing red fluorescence in dead 
cells (528nm excitation max and 617nm emission max).   
Encapsulated cells were rinsed with PBS three times and then stained with a 
PBS solution containing EthD-1 at a final concentration of 2µM.  Cells were incubated 
for 30 minutes at room temperature and then the dye solution was removed and cells 
washed three times with PBS before imaging.  Laser scanning confocal microscope 
imaging of encapsulated cells was performed using a Leica SP5 Confocal Microscope 
and LAS AF imaging software.  An argon 488nm laser was used for excitation of GFP 
and emission light between 505 and 530nm was detected. A HeNe 543nm laser was 
used for excitation of EthD-1 and emission light over 650nm detected (Figure 3.1).  
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Images of encapsulated cells were acquired from confocal Z scans over a depth of 
400μm. 
 
 
Figure 3.1.  Absorption and fluorescence emission spectra of GFP and EthD-1.  Blue lines show 
absorption and fluorescence emission spectra of GFP (488 nm/509 nm).  Orange lines show 
absorption and fluorescence emission spectra of EthD-1 bound to DNA (528nm/617 nm). 
 
3.3.2.4 CellTrace™ Far Red staining for proliferation analysis by Flow 
Cytometry  
A CellTrace™ Far Red Cell Proliferation Kit was used for labelling cells to track 
proliferation by flow cytometry.  The kit contains a cell-permeant, non-fluorescent 
ester of an amine-reactive fluorescent molecule, which enters cells by diffusion 
through the plasma membrane.  Upon entry into the cell, the non-fluorescent 
molecule is converted to a fluorescent derivative by cellular esterases.  The active 
succinimidyl ester covalently binds to amine groups in proteins, resulting in long-term 
dye retention within the cell.  Through subsequent cell divisions, daughter cells 
GFP
EthD-1
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receive approximately half of the fluorescent label of their parent cells, allowing for 
the analysis of the fluorescence intensities of labelled cells.  Analysis of the level of 
fluorescence in the cell populations by flow cytometry permits the determination of 
the number of generations through which a cell has progressed since the label was 
applied. 
Cells were stained with CellTrace™ Far Red Cell Proliferation Kit according to 
manufacturer’s instructions (Life Technologies, UK).  Briefly, cells were dissociated 
with 0.25% trypsin-EDTA.  Culture medium was then added to neutralise the trypsin 
and cells were centrifuged at 400x g for 5 minutes.  After discarding the supernatant, 
pellets were resuspended in PBS at a concentration of 1x106 cells/ml.  A stock solution 
of staining reagent was prepared by dissolving CellTrace™ Far Red in DMSO at a final 
concentration of 1mM.  The appropriate volume of CellTrace stock solution was 
added to cell suspension to give a concentration of 1µM.  Cells were incubated for 20 
minutes at 37 °C protected from light.  Five times the original staining volume of 
culture medium containing at least 20% FBS was added to the cells and incubated for 
5 minutes in order to remove any free dye remaining in the solution.  Cells were then 
centrifuged and resuspended in fresh pre-warmed complete culture medium.  Cells 
were then seeded on flasks or encapsulated for further analysis. 
Cell samples were analysed using a FACSCanto flow cytometer (BD 
Biosciences).  Output data from the flow cytometer was analysed using FACS Diva 
Version 6.1.3 software, which presents data as dot plots and histograms, and permits 
calculation of the mean fluorescent intensity of the cells.  To analyse the stained cells, 
10,000 events were captured for each sample.  Two different lasers were used for 
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excitation: an argon 488nm laser and a HeNe 633nm laser.  Green fluorescence 
emission for GFP expressing cells (530/30 nm bandpass filter) and red fluorescence 
emission for CellTrace™ Far Red (660/20 nm long pass filter) were measured.  The 
data was then analysed with FlowJo Version 10.2 software. 
 
3.3.2.5 Inhibition of cell proliferation with Mitomycin C 
Mitomycin C is an alkylating agent that inhibits DNA synthesis by covalently 
reacting with DNA, forming crosslinks between complementary strands of DNA.  This 
interaction prevents separation of complementary DNA strands, inhibiting DNA 
replication and therefore, cell proliferation. 
DPSCs were treated with mitomycin C according to manufacturer’s 
instructions.  Briefly, mitomycin C (Fisher Scientific, UK) was reconstituted at 
0.5 mg/mL in water.  The appropriate volume of mitomycin C solution was added to 
flasks containing 80‐90% confluent DPSCs and culture medium to achieve a 10 µg/ml 
final concentration.  Cells were then incubated for 3 hours at 37°C in humidified 
incubator with 5% CO2.  Culture medium containing mitomycin C was removed and 
cells were washed twice with PBS.  Cells were then trypsinized and seeded in flasks 
(Section 3.3.1.2).  
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3.3.3 Encapsulation of stem cells 
3.3.3.1 Preparation of encapsulation matrix solutions 
3.3.3.1.1 Alginate matrix 
Nanocrystalline precipitated CaCO3 was dispersed in PBS at a final 
concentration of 5 mg/ml.  Medium Viscosity sodium alginate was added to the 
CaCO3 suspension at a final concentration of 2% (w/v).  The blend was stirred for 2 
hours at 50°C and then autoclaved for sterilization.  
 
3.3.3.1.2 Alginate-collagen matrix 
Alginate scaffold was modified with type I collagen in Section 3.4.3.  Hence, 
an alginate solution of 4% (w/v) in PBS containing 100mM nanocrystalline 
precipitated CaCO3 was prepared as mentioned above.  Ice cold rat tail type I collagen 
(5 mg/ml; First Link, UK) was neutralized with 0.25M NaOH and mixed with the 
4% (w/v) alginate solution, giving rise final concentrations of 2 mg/mL collagen and 
2% (w/v) alginate.  
 
3.3.3.2 Production of cell-laden microspheres 
Each component of the microfluidic device (Figure 2.1) along with PTFE tubing 
and nitrile o-rings were sterilized by autoclaving prior to any encapsulation 
experiment being carried out.  The entire assembly was then assembled within a 
Microflow Peroxide Class II advanced biological safety cabinet (Bioquell, UK) to 
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maintain sterility.  Syringes were loaded with mineral oil and pumped through HPLC 
fluid connectors and microfluidic chip, in order to lubricate the walls and avoid 
alginate adhesion and blockages.   
Cells were trypsinized (DPSCs) or accutase treated (NSCs) and resuspended in 
culture medium for cell counting (Section 3.3.2.1).  The appropriate number of cells 
was taken and centrifuged at 400x g (DPSCs) or 100x g (NSCs) for 5 minutes.  After 
the supernatant was removed, the cells were resuspended in the encapsulating 
matrix solution.  Cell suspension, mineral oil, and 0.3% (v/v) acetic acid in mineral oil 
were introduced in the chip through HPLC tubes (Section 2.3.4).  Their flow rates 
were established at 1 ml/h, 15 ml/ h and 15 ml/h, respectively, and controlled by 
syringe pumps.  Polymer microcapsules containing cells were collected in pre-
warmed culture medium.  Residual mineral oil was removed and microcapsules were 
then washed with PBS before replacement with fresh culture medium.  Encapsulated 
cells were maintained in the incubator under standard conditions (37°C, 5% CO2) until 
further experiments were undertaken. 
 
3.3.4 Cell release from microspheres 
Encapsulated cells were released from microcapsules following a 5 min 
incubation with 55mM sodium citrate (Sigma Aldrich, UK) at 37°C.  Cells were then 
centrifuged (100x g for NSCs and 400x g for DPSCs), supernatant removed and 
resuspended in culture medium.  For alginate-collagen encapsulated cells, an 
additional incubation step with 1% (w/v) type I collagenase (Sigma Aldrich, UK) was 
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performed for 5 minutes at 37°C, following incubation with sodium citrate.  Cells were 
then centrifuged, supernatant removed and resuspended in culture medium. 
 
3.3.5 Estimation of number of cells per bead 
Specific number of beads were taken for each concentration. Cells were 
released from microcapsules as previously mentioned and resuspended in specific 
volumes of culture medium. Cells were counted and the result (total number of cells 
in the specific volume) was divided by the number of beads taken.  
 
3.3.6 Neuronal differentiation 
NSCs isolated from the cortex of E14 C57Bl/6 mice, and DPSCs isolated from 
21-28 day old C57/Bl6 mice, by colleagues in Prof. Bing Song´s laboratory (School of 
Dentistry, Cardiff University) were used in Section 3.4.5.  A nestin expressing 
clonogenic population of DPSCs previously expanded by colleagues in Song´s lab was 
selected to carry out the experiments in this section.  Since DPSCs represents a highly 
heterogeneous population of cells (Section 1.2.2.1), a specific clone with neuronal 
differentiation potential was selected to carry out the neuronal differentiation 
experiments, in order to increase the yield of differentiated cells.  
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3.3.6.1 NSCs neuronal differentiation 
Culture plates were coated with 50 µg/ml PDL (Sigma-Aldrich, UK) and 
incubated overnight at 37°C.  This was removed the day after and the surfaces rinsed 
with PBS.  Laminin (Sigma-Aldrich, UK), diluted to 20 μg/ml in PBS, was then used to 
coat the culture plates at 37°C for 30 minutes.  Laminin solution was removed and 
washed with PBS.  The surfaces were then ready for seeding with cells. 
Encapsulated NSCs were released from beads 21 days after encapsulation and 
seeded at a density of 10,000 cells/cm2 on poly-d-lysine/laminin-coated plates in 
DMEM/F12 (1:1) containing L-glutamine and HEPES buffer, 1% (v/v) 
penicillin/streptomycin, 2% (v/v) B27 supplement, 20 ng/ml bFGF, 20 ng/ml EGF and 
10 μg/mL ITSS.  When cells reached 80-90% confluence, growth factors were 
gradually removed by half media changes every other day for up to 10 days with 
growth factors-free culture medium. 
 
3.3.6.2 DPSCs neuronal differentiation 
Culture plates were coated with 10 µg/ml PLL (Sigma-Aldrich, UK) for 5 
minutes at 37°C. This was removed and rinsed with PBS. Laminin (Sigma-Aldrich, UK), 
diluted to 20 μg/ml in PBS, was then used to coat the culture plates at 37 ºC.  Laminin 
solution was removed the day after and washed with PBS. The surfaces were then 
ready for seeding with cells. 
Encapsulated DPSCs were released from beads 21 days after encapsulation 
and seeded at a density of 10,000 cells/cm2 on PLL/laminin-coated plates in 
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DMEM/F12 (1:1) containing L-glutamine and HEPES buffer, 1% (v/v) 
penicillin/streptomycin, 2% (v/v) B27 supplement, 20 ng/ml bFGF, 20 ng/ml EGF and 
10 μg/mL ITSS.  After 5 days in culture, cells were washed with PBS and medium 
replaced with Neurobasal medium supplemented with 1% (v/v) 
penicillin/streptomycin, 2 mM L-glutamine, 1 x NEAA (Sigma-Aldrich, UK), 10 ng/ml 
nerve growth factor (NGF), 10 ng/ml BDNF and 10 ng/ml NT-3 (all Peprotech).   
 
3.3.7 Immunocytochemistry staining 
After the differentiation protocol and following removal of medium, cells were 
washed with PBS for 3 minutes before being fixed with 4% (w/v) paraformaldehyde 
(PFA) for 30 minutes at room temperature.  Three further washes with PBS were 
performed and the cells were then permeabilized with 0.1% (v/v in PBS) Triton X-100 
for 30 minutes at room temperature.  After three washes, 5% (w/v) bovine serum 
albumin fraction V (BSA; Fisher Scientific, UK) in PBS was applied for one hour in order 
to block non-specific binding groups.  This was removed and replaced with antibodies 
against Nestin, Sox2, Oct4, β-III tubulin and Map2 (Table 1) and the isotype control 
(Table 2) diluted in 5% (w/v) BSA at a concentration of 5 µg/ml and incubated 
overnight in a dark humid chamber at 4°C.  The following day, three PBS washes were 
performed.  Slides were then incubated with complementary fluorophore-
conjugated secondary antibodies (Table 3) diluted in 5% (w/v) BSA at a concentration 
of 4 µg/ml in the dark at room temperature for 1 hour.  Three further washes with 
PBS were performed before the cells were mounted onto glass cover slips using 
mounting medium supplemented with DAPI stain (VectorLabs, UK). bSlides were 
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stored at 4°C in the dark to prevent bleaching, until required for imaging (Section 
3.3.8.2). 
 
3.3.8 Cellular Imaging 
3.3.8.1 Phase contrast imaging 
Phase contrast images of microspheres and cells in culture were captured 
using an Eclipse TS100 inverted phase contrast light microscope (Nikon, Japan) 
equipped with a digital camera (Canon, Japan). 
 
3.3.8.2 Fluorescent imaging 
GFP expressing cells and fixed and fluorescent antibody-stained cells were 
viewed and images acquired using an ultra violet (UV) microscope (Olympus AX70 
with a Digital Eclipse DXM1200 digital camera attachment, Tokyo, Japan).  The images 
were captured using the Automatic Camera Tamer (ACT-1) control software (Nikon 
Digital, Tokyo, Japan). 
 
3.3.8.3 Confocal laser scanning microscopy 
A Leica SP5 Confocal laser scanning microscope and LAS AF imaging software 
were used for all confocal microscopy experiments (Leica Microsystems, Germany).  
An argon 488nm laser was used for excitation of GFP and emission light between 505 
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and 530nm was detected.  A HeNe 543nm laser was used for excitation of EtDh-1 and 
emission light over 650nm detected. 
 
3.3.8.4 Image processing 
Acquired images were processed and overlapping images merged using freely 
available ImageJ version 1.47i software. 
 
3.3.9 Statistics 
Data are represented as mean ± SEM, unless otherwise indicated.  Statistical 
significance was determined by Student’s t test.  P < 0.05 was considered statistically 
significant. 
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3.4  Results 
3.4.1 Study of the cytotoxicity of the reagents used on stem cells 
The production of alginate microcapsules with a diameter of 440 ± 3 µm was 
achieved utilising a customized PTFE microfluidic device developed in Chapter 2.  
Since the main purpose of this project was the encapsulation and maintenance of 
stem cells within alginate micro beads, a study of the potential toxicity on cells of the 
reagents used was undertaken. 
The technique developed in the previous chapter was based on an internal 
gelation method for the continuous and reproducible production of alginate 
microspheres.  The alginate stream was “broken-off” by the shear force generated by 
the immiscible phase mineral oil.  The mineral oil used for alginate emulsification in 
this project was classified as suitable for cell culture, and, therefore, it was assumed 
that it would not have any toxic effect on cells.  However, as an internal gelation 
approach was used, a source of protons was required to trigger the release of calcium 
ions to cross-link alginate chains.  To this end, acetic acid was dissolved in mineral oil 
at a final concentration of 0.3% (v/v) and hence the effects of an acidic environment 
and its potential detrimental effect on cells was investigated.  
In the microfluidic system developed in this project, alginate droplets were 
collected in pre-warmed culture medium, alongside the continuous phase (mineral 
oil plus acetic acid).  Since mineral oil has a lower density than culture medium, it was 
easily removed with a pipette.  However, the acetic acid present in the mineral oil 
diffused through the interphase between both liquids, which was indicated by a 
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pH/colour change of the culture medium.  Therefore, the effect on cells of the 
addition of acetic acid into the culture medium was also investigated.   
Three similar samples of each cell type suspension were centrifuged and 
supernatant discarded.  Sample 1 was resuspended in mineral oil, sample 2 was 
resuspended in 0.3% (v/v) acetic acid in mineral oil, and sample 3 was resuspended 
in 0.3% (v/v) acetic acid in culture medium.  Cell suspension in culture medium was 
used as a control.  Since mineral oil is immiscible with aqueous solutions, 10µl of 
culture medium were added to samples 1 and 2 and the mixture was pipetted up and 
down in order to force the diffusion of the cells into the aqueous phase (culture 
medium).  10µl of each sample were taken and viability was estimated using trypan 
blue exclusion assay (Section 3.3.2.1). 
The duration between the beginning of the droplet formation and its 
collection in culture medium was approximately 30 seconds.  To ensure this was not 
detrimental, the viability of the samples 1 and 2 were determined one minute after 
resuspension.  As demonstrated in Figure 3.2, cell viability decreased slightly when 
either DPSCs or NSCs were resuspended in mineral oil or in 0.3 % (v/v) acetic acid in 
mineral oil, suggesting a minimal effect on cell viability but not whole scale cell death 
on exposure to the microfluidic reagents (P < 0.05). 
Viability of sample 3 was estimated 1, 10 and 20 minutes after resuspension.  
These time points were chosen as the experimentation times for cell encapsulation 
were fixed at 1 hour, with the collection medium changed every 10-20 minutes.  It 
was clear that the addition of 0.3% (v/v) of acetic acid into the culture medium had 
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no toxic effect on cells over the test period, since no significant difference was 
observed in cell viability throughout the period tested (Figure 3.3; P > 0.05). 
Alginate has been demonstrated to be one of the biocompatible polymers 
most used for cell encapsulation (Lee & Mooney 2012).  However, it was 
hypothesised that the suspension of crystalline CaCO3 nanoparticles may have a 
harmful effect on any cells present within the micro-beads.  It is well stablished that 
variations in cytosolic Ca2+ concentration can affect cellular functions, from the 
secretion to hormones to the regulation of cell death (Pinton et al. 2008).  Hence, the 
study of cell survival within alginate-CaCO3 matrix solution was also required.  The 
viability of the cells resuspended in the encapsulation matrix (2% (w/v) alginate 
solution plus 5 mg/ml precipitated CaCO3) was studied over a period of 5 hours prior 
to any encapsulation procedure being carried out.  As demonstrated in Figure 3.4 the 
viability of the cells over the time course of the experiment was not significantly 
different compared to control (P > 0.05). 
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Figure 3.2.  Viability of DPSCs (green) and NSCs (blue) resuspended in mineral oil or in 0.3 % 
(v/v) acetic acid in mineral oil.  Cell viability was estimated one minute after resuspension.  
Data are shown as mean ± SEM, and are representative of at least three independent 
experiments made in triplicate. *, P < 0.05; ** P < 0.01; ***, P < 0.001, Student’s t test.  
 
Figure 3.3.  Viability of DPSCs (green) and NSCs (blue) resuspended in 0.3% (v/v) acetic acid 
in culture medium (Acid in CM).  Cell viability was determined 1, 10 and 20 minutes after 
resuspension.  Data are shown as mean ± SEM, and are representative of at least three 
independent experiments made in triplicate. 
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Figure 3.4. Viability of DPSCs (green) and NSCs (blue) resuspended in 2% (w/v) alginate 
solution containing 5 mg/ml CaCO3.  Cell viability was investigated over a period of 5 hours 
at intervals of 45 minutes.  Data are shown as mean ± SEM, and are representative of at least 
three independent experiments made in triplicate.  
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3.4.2  Optimization of microcapsule initial cell seeding density 
Since the ultimate goal of this thesis was the transplantation of encapsulated 
cells within an animal model of SCI, a study of the microcapsule seeding density was 
required.  It was ultimately hypothesized that a high population of viable cells would 
have a greater therapeutic effect.  Furthermore, it has been reported that cell density 
plays a crucial role in the cells’ functionality, i.e. their proliferation and differentiation 
(Issa et al. 2011).  Hence, an investigation of the appropriate initial cell seeding 
density was undertaken of whether such stem cells within a confined environment 
would maintain optimal survival. 
Preliminary encapsulation experiments with both cell types demonstrated 
different behaviours (Figure 3.5).  Whereas NSCs exhibited proliferation within the 
microcapsules in form of neurospheres, this was not observed with DPSCs.  
Therefore, it was hypothesized that high NSCs seeding densities would lead to the 
formation of large cell aggregates in a short period of time, potentially provoking 
apoptosis in the centre of the neurospheres since the cells could become deprived of 
nutrients.  Hence, two different cell concentrations were tested, namely 1x105 
cells/ml and 1x106 cells/ml.  In the case of DPSCs, since no signs of cell proliferation 
were observed, greater cell seeding densities were investigated: 1x106 cells/ml, 2x106 
cells/ml, 5x106 cells/ml, and 1x107 cells/ml.  Both cell types and all the concentrations 
mentioned above were encapsulated under the same conditions (Section 3.3.3.2).   
In Figure 3.6, images A, C, E, G, I, K correspond to laser scanning confocal 
microscope images of the encapsulated cells.  The green dots, representing GFP cells, 
were randomly distributed within the alginate microcapsules.  At low concentrations 
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(1x105 cells/ml – 2x106 cells/ml) the majority of the space within the capsules was 
unoccupied, whereas at high concentrations (5x106 cells/ml – 1x107 cells/ml) cells 
filled most of the cavities in the microspheres.  Images B, D, F, H, J, L are bright field 
images. 
 
 
Figure 3.5.  Encapsulated NSCs and DPSCs within alginate microcapsules.  A-B) Encapsulated 
NSCs 0 and 5 days after encapsulation, respectively.  Single NSCs were visible on day 0 (red 
arrows), whereas some cell aggregates (white arrows) were observed 5 days after 
encapsulation.  C-D) Encapsulated DPSCs 0 and 5 days after encapsulation, respectively.  No 
cell number increase nor aggregates were observed within microcapsules, suggesting that 
cells did not proliferate within the beads.  Scale bar = 100µm. 
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Figure 3.6. Encapsulated cells in alginate microcapsules.  Images were taken 1 day after 
encapsulation.  Laser scanning confocal images of encapsulated cells were performed using 
a Leica SP5 Confocal Microscope.  Images of encapsulated cells were acquired from a 
confocal Z scan over a depth of 400μm.  Optical images were taken with an Eclipse TS100 
inverted phase contrast light microscope (Nikon, Japan).  Scale bar = 200µm.   
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In terms of cell transplantation, an accurate estimation of the number of 
transplanted cells is important in respect of eventual clinical application.  Therefore, 
both theoretical and experimental estimation of number of cells per bead were 
carried out for each cell type and condition investigated.  In general, (Table 3.1) there 
was good correlation between the different estimated numbers of cells within each 
bead (P > 0.05). 
 
 
Table 3.1.  Theoretical calculation and experimental estimation of the number of cells per 
bead.  For concentrations greater than 1x106 cells/ml there was good correlation between 
the different estimated numbers of cells within each bead.  Value = mean ± SD (n=9). 
 
3.4.2.1 Study of cell survival within alginate microcapsules using the Trypan 
Blue Exclusion Assay 
The viability of encapsulated cells at each concentration and each cell type 
was studied over a period of 21 days after encapsulation.  Before each measurement, 
cells were released from the capsules (Section 3.3.4) and then viability estimated by 
Trypan Blue exclusion assay (Section 3.3.2.1). 
NSCs
Initial seeding density
(cells / ml)
Cells/bead
(theoretical calculation)
Cells/bead
(experimental estimation)
SD
1,00E+05 5 3 3,4
1,00E+06 45 38 8,6
DPSCs
Initial seeding density
(cells/ml)
Cells/bead
(theoretical calculation)
Cells/bead
(experimenta estimation)
SD
1,00E+06 45 43 11,2
2,00E+06 89 86 13,8
5,00E+06 223 230 30,5
1,00E+07 446 416 42,1
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Results in Figure 3.7 A demonstrated that NSCs viability remained consistent at 
a low seeding density (1x105 cells/ml) over the period tested, with little sign of cell 
proliferation.  On the contrary, an increase in viability was observed when the 
microcapsules were laden with a concentration of 1x106 cells/ml (P < 0.001).  
For the DPSCs (Figure 3.7 B), cell viability remained high and consistent over 
the first three days for all the conditions investigated.  Seven days after 
encapsulation, the number of viable cells reduced to around 70 – 80 %, followed by 
a progressive decrease up to 21 days, regardless the initial cell concentration 
(P < 0.001).  No significant differences were observed between concentrations at the 
same time point (P > 0.05). 
As mentioned above, a high concentration of cells per microcapsule could have 
a greater therapeutic effect when transplanted into the site of injury.  However, this 
concentration should permit the optimal survival of the cells within the confined 
microenvironment.  According to the results obtained above, the seeding densities 
investigated demonstrated little effect on cell survival.  Therefore, the highest 
densities, 1x106 cells/ml for NSCs and 1x107 cells/ml for DPSCs, where used in 
subsequent experiments, unless otherwise stated.  
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Figure 3.7.  Graph showing the influence of initial cell density on cells viability.  Pre-
encapsulation viability was represented as time point 0.  A) Viability of NSCs encapsulated at 
two different seeding densities within alginate microcapsules.  NSCs encapsulated at 
1x106 cells/ml demonstrated proliferation over the period tested.  However, no cell growth 
was observed when cells were encapsulated at a density of 1x105 cells/ml.  B) Viability of 
DPSCs encapsulated at four different seeding densities within alginate microcapsules.  For all 
the concentrations investigated, the viability of encapsulated DPSCs decreased to ~70%.  
Data are shown as mean ± SEM, and are representative of at least three independent 
experiments made in triplicate. ***, P < 0.001, Student’s t test versus first point. 
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3.4.2.2 Live/Dead® Viability Assay and confocal imaging of encapsulated 
cells 
Encapsulated NSCs and DPSCs were stained 1 and 21 days after encapsulation 
with EthD-1 stain as described in Section 3.3.2.3.  Confocal images of the cells were 
taken using a Leica SP5 Confocal Microscope from confocal Z scan over a depth of 
400μm. 
As observed in Figure 3.8, the behaviour of the two cell types within alginate 
microcapsules was different.  NSCs grew within the microspheres in the form of 
aggregates, with these aggregates increasing in size (and hence cell density) over the 
21 days period.  This behaviour was similar to that found when culturing NSCs in the 
form of neurospheres.  However, little sign of proliferation was observed for DPSCs, 
whose viability was slightly compromised over the period tested, as demonstrated by 
an increased in the number of dead cells (red) 3 weeks after encapsulation.  
According to the rounded shape of the cells, neither NSCs nor DPSCs appeared to 
adhere to the alginate scaffold within the beads. 
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Figure 3.8.  Confocal images of encapsulated stem cells within alginate microspheres stained 
with EthD-1.  Green fluorescence was emitted from GFP cells, whereas red fluorescence was 
emitted from EthD-1 binding the nuclei of dead cells.  Encapsulated NSCs 1 and 21 days after 
encapsulation (A-B, respectively) - NSCs grew in aggregates within the microspheres.  
Encapsulated DPSCs 1 day and 21 days after encapsulation (D-E, respectively) – little 
proliferation was observed for DPSCs, with the viability of the cells decreasing over the period 
tested.  Scale bar (A, B, D and E) = 100µm.  Scale bar (C and F) = 10µm. 
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3.4.2.3 Cell proliferation studies within alginate microcapsules 
In order to further investigate cell proliferation within the microspheres, MTT 
assay were performed for each cell type 1, 3, 7 and 10 days after encapsulation. 
MTT solution was added to encapsulated cells and blanks as described in 
Section 3.3.2.2.  Formazan was dissolved with DMSO and absorbance measured at 
540nm.  Results in Figure 3.9 revealed that NSC proliferated significantly within the 
microcapsules between days 1 and 10 (P < 0.001).  However, readings obtained from 
encapsulated DPSCs demonstrated a slight decreased in overall cell numbers over the 
time course (P < 0.01). 
 
Figure 3.9.  Graph of MTT assay on days 1, 3, 7 and 10 after encapsulation.  Mean ± SEM, and 
are representative of at least three independent experiments made in triplicate. **, P < 0.01; 
***, P < 0.001, Student’s t test versus first time point. 
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Images of the cells after formazan formation were taken at each time point 
for each cell type (Figure 3.10).  It was observed that formazan formation increased 
in encapsulated NSCs.  Furthermore, NSCs grew forming a branched network over 
the alginate microcapsules.  However, for the DPSCs, it was noted that some cells 
actually escaped from the capsules around day 3, adhered onto the tissue culture 
plastic surface and proliferated.  Therefore, the use of the MTT assay to measure 
relative cell number was deemed to be compromised and not truly reflective of cell 
number within the beads.  
 
 
Figure 3.10.  Bright field images of encapsulated cells after formazan formation in MTT assay.  
(A-D) Encapsulated NSCs 1, 3, 7 and 10 days after encapsulation, respectively.  The number 
of NSC increased over the period tested, as it could be observed by an increase in the 
precipitate formed.  (E-H) Encapsulated DPSCs 1, 3, 7 and 10 days after encapsulation, 
respectively.  Images show cells escaping from microcapsules and proliferating 3 days after 
encapsulation.  Scale bar = 200µm. 
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3.4.3 Modification of the encapsulation matrix 
The main purposes of cell encapsulation process are the protection of the cells 
from the immune response after grafting and the control of cell fate within the 
organism.  The encapsulation matrix should, at the same time, allow for the 
controlled migration/egress of the encapsulated cells at the appropriate time in order 
to integrate within the host organ, replacing lost/damaged tissue, and ultimately lead 
to recovery of normal tissue function.  Therefore, the composition of the scaffold 
needs to ‘entrap’ the cells but also allow their controlled migration in due course. 
Since cell escape from the alginate microcapsules was observed for DPSCs 
3 days after encapsulation, a modification of the encapsulation material was then 
required in order to delay any such migration.  Type I collagen was selected to modify 
the alginate scaffold, since it is the main component of the extracellular matrix and 
promotes cell attachment and cell proliferation (Kleinman et al. 1981).  It was 
postulated that this collagen would retain the cells within the capsules by providing 
cell adhesion sites.   
Both NSCs and DPSCs were encapsulated in alginate-collagen microcapsules 
as described in Section 3.3.3.2.  Viability and proliferation of the cells within the new 
scaffold was investigated and compared with the results obtained in the previous 
section, where only alginate was utilised as the encapsulation matrix.  
 
Chapter 3: Optimization of stem cell encapsulation in ECM-based microcapsules 
154 
3.4.3.1 Cell viability and proliferation: comparison between alginate and 
alginate-collagen microcapsules 
3.4.3.1.1  Trypan Blue exclusion assay 
The viability of the encapsulated cells within alginate-collagen microcapsules 
was studied by Trypan Blue exclusion assay 1, 3, 7, 10, 14 and 21 days after 
encapsulation.  Alginate-collagen beads were dissolved and cells released as 
described in Section 3.3.4.  Cells were then counted and viability estimated (Section 
3.3.2.1). 
Figure 3.11 demonstrates that the addition of type I collagen had little effect 
on cell viability compared to alginate alone (P > 0.05).  As for NSCs encapsulated in 
alginate beads, their viability within the alginate-collagen microcapsules significantly 
increased up to 21 days (P < 0.001).  Similarly, the behaviour of DPSCs within alginate-
collagen beads did not demonstrate any significant alteration when compared with 
alginate-encapsulated DPSCs (P > 0.05).  However, in both scaffolds, the number of 
viable DPSCs slightly decreased over the period tested (P < 0.001).  
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Figure 3.11.  Graph showing the influence of the encapsulation matrix on cell viability.  Pre-
encapsulation viability was represented as time point 0.  Data are shown as mean ± SEM, and 
are representative of at least three independent experiments made in triplicate. 
***, P < 0.001, Student’s t test versus first point. 
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3.4.3.1.2 Live/Dead ® Viability Assay and confocal imaging 
Samples from both cell types at day 1 and 21 after encapsulation were stained 
with EthD-1 dye as described in Section 3.3.2.3.  As observed in Figure 3.12, NSCs 
maintained in alginate-collagen exhibited a similar behaviour to that in alginate 
microcapsules alone, with cells growing in aggregates within the microspheres.  As in 
alginate alone, DPSCs within alginate-collagen microcapsules did not demonstrate 
any sign of cell adhesion and the viability decreased over the period tested, as 
evidenced by an increase in the number of non-viable cells (red).   
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Figure 3.12.  Confocal images of encapsulated stem cells within alginate-collagen 
microspheres stained with EthD-1.  Green fluorescence is emitted from GFP cells, whereas 
red fluorescence is emitted from EthD-1 binding the nuclei of dead cells. Encapsulated NSCs 
1 day and 21 days after encapsulation (A-B, respectively).  Encapsulated DPSCs 1 day and 21 
days after encapsulation (D-E, respectively).  Scale bar (A, B, D and E) = 100µm.  Scale bar (C 
and F) = 10µm. 
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3.4.3.1.3 MTT proliferation assay 
MTT assay was also performed on encapsulated cells within alginate-collagen 
microspheres.  For the same cell type, results at the same time point could not be 
compared, since the quantity of sample seeded for each condition was different 
(alginate or alginate-collagen microcapsules).  Therefore, an analysis of the trend was 
undertaken.  Results in Figure 3.13 show that over the time course, NSCs proliferated 
in alginate-collagen in a similar manner to how they did in alginate microcapsules 
(P < 0.001).  On the other hand, DPSCs in alginate-collagen demonstrated an overall 
decrease in absorbance 10 days after encapsulation (P < 0.01).  This trend was similar 
to that observed in DPSCs within alginate beads.   
In order to investigate whether cell egress was delayed with the modified 
encapsulation scaffold, pictures of cells after MTT formation were taken at each time 
point, and compared with those taken of alginate microcapsules (Figure 3.14).  NSCs 
grew in aggregates within the microcapsules, regardless of the encapsulation matrix.  
The formation of cell networks on microcapsules was observed on day 10 in both 
scaffolds.  In the case of DPSCs, a different behaviour was observed when compared 
with cells encapsulated in alginate beads.  Cells escaped from alginate microcapsules 
approximately 3 days after encapsulation.  This migration was not noticed until day 
10 in alginate-collagen microspheres.  Therefore, the modification of the 
encapsulation matrix allowed for a delay in cell egress.   
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Figure 3.13.  Graph of MTT assay on days 1, 3, 7 and 10 after encapsulation within alginate 
and alginate-collagen microcapsules.  A) MTT values of NSCs.  B) MTT values of DPSCs.  Data 
are shown as mean ± SEM, and are representative of at least three independent experiments 
made in triplicate. **, P < 0.01; ***, P < 0.001, Student’s t test. 
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Figure 3.14.  Bright field images of encapsulated cells after formazan formation. (A-H) 
Encapsulated NSCs within alginate or alginate-collagen microcapsules after formazan 
formation 1, 3, 7 and 10 days after encapsulation.  (I-P) Encapsulated DPSCs within alginate 
or alginate-collagen microcapsules after formazan formation 1, 3, 7 and 10 days after 
encapsulation.  Images show that DPSCs migration outside the microcapsules is delayed 
within the alginate-collagen scaffold.  Scale bar = 200µm.   
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3.4.4 Study of cell turnover within alginate-collagen 
microcapsules using CellTrace™ staining and flow cytometry 
Based on the results provided by the Trypan Blue exclusion assay, Live/Dead® 
staining and MTT assay, it was demonstrated that NSCs proliferated within the 
microcapsules.  However, since no increase in the total number of cells was observed, 
nor an increase in absorbance after formazan formation by DPSCs, the proliferative 
behaviour of these cells remained unknown.  Whilst the MTT assay is a useful assay 
to give an overall idea of relative cell number within the microcapsules, it does not 
inform on actual cell turnover – i.e. are cells dying and being replaced by new cells, 
or, is the cell number actually relatively static?  To investigate this, DPSCs were 
stained with CellTrace™ Far Red Cell Proliferation Kit and analysed with flow 
cytometry as described in Section 3.3.2.4.  Prior to labelling, one group of cells was 
treated with mitomycin C to inhibit cell proliferation (Section 3.3.2.5) and then 
stained with the CellTrace™ kit (+MC; negative control).  A second group of cells was 
not treated with mitomycin C but labelled with the CellTrace™ kit (-MC; positive 
control).  The third group of cells was stained and encapsulated within alginate-
collagen microcapsules (sample).  Both controls and encapsulated cells were cultured 
at standard conditions for up to 7 days.  Samples were taken at 1, 3, 5 and 7 days 
after labelling and cells were analysed by flow cytometry (Figure 3.15).  Encapsulated 
cells were released from microcapsules prior to analysis.  Untreated monolayer 
cultures of cells (-MC; positive control) demonstrated clear cellular proliferation as 
evidenced by a shift and fall off of the fluorescent signal as the cells divided over a 
period of 7 days, and hence ‘shared’ their fluorescent marker.  Treated monolayer 
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cultures of cells (+MC; negative control) failed to divide, as demonstrated by a 
consistent fluorescent signal.  Pre-stained, encapsulated cells were released from the 
microcapsules (sample) after set periods of time in culture and analysed.  No drop or 
shift in the fluorescence peak indicated that the DPSCs did not proliferate within the 
microcapsules. 
 
 
Figure 3.15.  Study of DPSCs proliferation within alginate-collagen microcapsules.  Both 
controls and samples were stained with CellTrace™ Far Red Cell Proliferation Kit and analysed 
by flow cytometry over a period of 7 days.  Mitomycin C treated cells (+MC) failed to divide, 
since no decrease in fluorescent signal was observed.  No mitomycin C treated cells (-MC) 
demonstrated cellular proliferation as evidenced by a shift and fall off of the fluorescent 
signal over a period of 7 days.  No drop or shift in the fluorescence peak of encapsulated cells 
indicated that the DPSCs did not proliferate within the microcapsules. 
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3.4.5 Cell functionality studies upon release from alginate-
collagen microspheres 
The appropriate encapsulation technology should not affect cell functionality.  
The results described above indicated that cells were successfully encapsulated 
within alginate-collagen microspheres, showing high viability over extended periods 
of time.  However, further investigation of cellular function was required in order to 
study the potential of encapsulated cells for cell replacement therapy.  Stem cells are 
characterized by high proliferation rates in vitro, but also the expression of 
pluripotency markers such as Nanog, Oct-4, Sox2 & SSEA4 (Zhao et al. 2012).  Hence, 
growth rates and expression of stem cells and neuronal markers by NSCs and DPSCs 
were investigated before and after neuronal differentiation, upon release from 
alginate-collagen microcapsules.  
 
3.4.5.1 Cell proliferation potential 
NSCs and DPSCs were released from microcapsules 21 days after 
encapsulation and seeded on 96-well plates at a density of 1,000 cells/well along with 
appropriate controls (no encapsulated NSCs and DPSCs).  Surfaces were pre-coated 
with 50 µg/ml of PDL and 20 µg/ ml of laminin before NSCs seeding to allow cells to 
grow in monolayer.   
MTT proliferation assay was carried out on days 1, 3, 5 and 7 after seeding as 
described in Section 3.3.2.2.  Results in Figure 3.16 demonstrate that released cells 
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preserved high growth rates (day 7 significantly different to day 1; P <0.001), similar 
to those observed for the control cultures (never encapsulated).  
 
Figure 3.16.  NSCs and DPSCs proliferation upon release from alginate-collagen 
microcapsules.  NSCs and DPSCs were released from microcapsules 21 days after 
encapsulation and seeded on 96-well plates.  MTT proliferation assay was carried out on days 
1, 3, 5 and 7 and absorbance measured at 540nm.  Both cell types showed similar growth 
rates to the non-encapsulated controls, suggesting that proliferation of cells was not 
compromised upon release from alginate-collagen microcapsules.  Data are shown as mean 
± SEM, and are representative of at least three independent experiments made in triplicate.  
**, P < 0.01; ***, P < 0.001, Student’s t test. 
Time (days)
0 1 2 3 4 5 6 7 8
0,0
0,2
0,4
0,6
0,8
1,0
1,2
Released DPSCs
Control
***
***
**
***
***
***
Time (days)
0 1 2 3 4 5 6 7 8
A
b
so
rb
an
ce
(5
40
 n
m
)
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
Released NSCs
Control
***
***
***
***
***
A
B
A
b
so
rb
an
ce
(5
40
 n
m
)
Chapter 3: Optimization of stem cell encapsulation in ECM-based microcapsules 
165 
3.4.5.2 Stemness and neuronal differentiation potential  
Neuronal differentiation of DPSCs based on NSCs culture protocols has been 
previously reported in our group (Young et al. 2016).  In this study, the aim was to 
demonstrate that encapsulation of NSCs and DPSCs did not affect their capacity for 
differentiation into neuronal-like cells in vitro after release from microcapsules.   
Nestin is one of the markers used to identify cells with potential for neuronal 
differentiation (Messam et al. 1999).  Hence, expression of this protein along with 
the stem cell pluripotency markers Sox2, Oct4, and the neuronal markers β-III tubulin 
and Map2 (associated with more mature phenotypes), were investigated.  
Both NSCs and DPSCs were released from microcapsules 21 days after 
encapsulation and seeded on pre-coated plates at a density of 10,000 cells/cm2 in 
NSC growth medium (Section 3.3.6).  Undifferentiated NSCs in growth medium 
demonstrated bipolar morphology (Figure 3.17A).  When NSCs reached over 80% 
confluence, growth factors were gradually removed from medium and half-medium 
changes were performed every other day for up to 15 days.  An increased in cell death 
was observed as growth factors were gradually removed.  After 15 days in culture 
with growth factor-free medium, surviving cells developed more projections and 
created connections with adjacent cells (Figure 3.17B).   
Undifferentiated DPSCs were typically bi-/tri-polar, showing fibroblast-like 
shapes (Figure 3.17C).  DPSCs were cultured in NSC growth medium for 5 days to 
stimulate neuralisation and then medium was changed for neurotrophin containing 
medium to promote neurogenic maturation.  This was replaced every 3 - 4 days for a 
10 further days.  Cells cultured in NSCs growth medium adopted neuronal-like 
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phenotypes.  Maturation in neurotrophin containing medium led to cells developing 
rounded bodies with multiple long processes sprouting out and forming neuronal-
like connections (Figure 3.17D).  
Both NSCs and DPSCs were fixed after the differentiation protocol and stained 
with antibodies against Nestin, Sox2, Oct4, β-III tubulin and Map2, along with the 
isotype control (APPENDIX IIAPPENDIX II).  Figure 3.18 shows that NSCs stained 
positively for all markers tested in both undifferentiated and differentiated states, 
suggesting that full neuronal differentiation had not taken place (as they retained 
some pluripotency markers).  However, significant changes in cell morphology were 
observed as the cells developed long axons after the differentiation protocol.  DPSCs 
demonstrated production of Nestin before and after differentiation (Figure 3.19).  
Cells stained positively for Sox2 and Oct4 before differentiation, demonstrating 
retained stem cell properties upon release from the microcapsules, but this was lost 
after differentiation.  DPSCs expressed the mature neuronal markers β-III tubulin and 
Map2 after 15 days in neurotrophin-containing medium and demonstrated a 
neuronal-like morphology.  
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Figure 3.17.  Morphology changes during neuronal differentiation of NSCs and DPSCs.  A) 
Undifferentiated NSCs in growth medium showing bipolar morphology with rounded bodies.  
B) Differentiated NSCs developed cell projections emerging from cell body, creating 
connections with adjacent cells.  C) DPSCs in DPSCs medium, before differentiation.  Cells 
were typically bi-/tri-polar and fibroblast-like.  D)  After the differentiation protocol, DPSCs 
cell bodies adopted rounded morphology with multiple long processes sprouting out forming 
neuronal-like connections.  Scale bars = 100 μm. 
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Figure 3.18.  Immunocytochemical staining of NSCs before and after neuronal differentiation.  
NSCs were stained with antibodies against Nestin, Sox2, Oct4, β-III tubulin and Map2 before 
(A – E) and after differentiation (F – J).  Scale bar = 50µm. 
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Figure 3.19.  Immunocytochemical staining of DPSCs before and after neuronal 
differentiation.  NSCs were stained with antibodies against Nestin, Sox2, Oct4, β-III tubulin 
and Map2 before (A – E) and after differentiation (F – J).  Scale bar = 100µm. 
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3.5 Discussion 
This chapter was concerned with the optimization of the parameters for the 
encapsulation of two types of stem cells, NSCs and DPSCs.  The behaviour within 
microcapsules of the two cell types was compared and their stem cell and neuronal 
differentiation properties were investigated upon release from hydrogel beads. 
 
3.5.1 Cytotoxicity of reagents used on stem cells 
The preliminary study of the potential toxic effect of microfluidic reagents on 
cell viability was required in order to assess the biocompatibility of the method 
developed in Chapter 2.  Whereas some authors have developed successful 
microfluidic techniques for droplet generation, some of these methods might not be 
suitable for the immobilization of living systems due to the use of organic solvents 
(Nie et al. 2008; Liu et al. 2013).  Choi et al. (2007) used hexadecane as continuous 
phase for the microfluidic production of alginate microcapsules containing GFP yeast 
cells.  Although cell fluorescence could be observed after encapsulation, this is not an 
appropriate indicator of cell survival, since GFP can be observed after cell death.  
Hence, the use of organic solvents was avoided in the method developed in this thesis 
in order to prevent detrimental effects on cell viability.   
The cellular cytotoxicity of the reagents used for encapsulation was tested.  
DPSC viability was mildly decreased when resuspended in mineral oil.  The mineral 
oil used was that utilized to prevent dehydration in embryonic cell culture and 
therefore, it was expected to be cell compatible.  It is possible that the slight decrease 
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in viability was actually due to the mechanical stress that the cells were subjected to 
when they were forced to diffuse from the organic phase to the aqueous phase as 
part of the cell counting methodology (i.e. it could damage cell membranes).  When 
cells were resuspended in the reactive phase (0.3% (v/v) acetic acid in mineral oil), 
the decrease in viability was slightly higher.  In this case, not only the mechanical 
stress but also the alteration in pH, could have been factors in this decline in viability.  
It should be noted, however, that during the encapsulation procedure cells were also 
resuspended in alginate solution, and hence a direct/sole contact with either the 
mineral oil or acetic acid was highly unlikely.  Thus, the detrimental effect that these 
reagents were demonstrated to have on the cells when they were directly 
resuspended was a ‘worst case’ scenario.  The potential deleterious effect of 
acidification of culture medium was also investigated.  Results demonstrated that cell 
survival was unaffected when cells were resuspended in a solution of 0.3% (v/v) 
acetic acid in culture medium.  This result is not surprising, as culture medium 
contains buffers to regulate low changes in pH.  Finally, biocompatibility of the 
encapsulation matrix was demonstrated when cells were resuspended in a 2% (w/v) 
alginate solution containing 5 mg/ml resuspended CaCO3.  Although alginate 
biocompatibility was not an issue, potentially the precipitated CaCO3 could have a 
detrimental effect on cell survival.  This hypothesis was unfounded when it was 
observed that the viability of the cells resuspended in the polymer solution was 
practically unaffected over an extended period of 5 hours.  
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3.5.2 Viability and proliferation of encapsulated cells 
Several methods have been used for cell encapsulation.  For example, Aijaz et 
al. 2015 produced encapsulated insulin-producing RIN-m cells by vortexing a cell pre-
polymer suspension with mineral oil, although the size of the capsules obtained was 
highly polydisperse.  Other authors have used interfacial polymerization for the 
encapsulation of mammalian cells (Cruise et al. 1999).  Polymer capsules produced 
by this technique present high strength and mechanical stability, allowing the 
formation of microcapsules ranging from 1 – 30 µm to several mm in diameter 
(Salaön 2013).  However, the method involves several complex steps in which the 
slow kinetics of the reactions involved is a limiting step.  Also, the use of organic 
solvents constitutes a major problem in terms of potential cell viability 
(Khademhosseini et al. 2005).  As an attempt to increase cell survival avoiding the use 
of organic solvents, complex coacervation arose as an alternative method for 
encapsulation (Baracat et al. 2012).  Nonetheless, the polydispersity of the capsules 
produced is a major problem when using this method (Knezevic et al. 2002).  Among 
the numerous methods that have been applied for cell encapsulation, droplet 
extrusion generation is the most widely used (Duvivier-Kali et al. 2001; Murua et al. 
2007; Wikström et al. 2008; Bhujbal et al. 2014).  Cells are resuspended in the 
polymer solution and the suspension is extruded through a needle.  The resulting 
droplets are collected in a stirred CaCl2 solution where they are maintained in 
agitation for about 10 min for complete ionic gelation.   
In this chapter, it was demonstrated that microfluidics represents a highly 
suitable technique for the continuous and consistent production of cell-laden 
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microcapsules in a sealed environment, avoiding any cross-contamination.  The 
formation of highly monodisperse droplets allowed for an accurate theoretical 
estimation of the number of cells per bead, as demonstrated by comparison of these 
results with the corresponding experimental calculations.  This is of a great utility in 
cell transplantation techniques where the monodispersity of droplets allows an 
accurate determination of the number of transplanted cells and hence clinical 
delivery dose (Tan & Takeuchi 2007).  However, these estimations were only accurate 
for seeding densities above 1x106 cells/ml.  Lower cell concentrations gave rise to 
microcapsules containing variable numbers of cells or even, empty capsules.  
Unlike all the conventional methods mentioned above, the microfluidic 
method developed in this thesis permitted the production of stem cell microcapsules 
that were gelled in situ in a matter of seconds.  This is of a great importance in terms 
of cell viability, since it permitted the quick transfer of the encapsulated cells to 
culture medium, minimizing the risk of cell viability loss due to unfavourable 
conditions, such as contact with gelling baths, polymerizing solvents, etc.  Indeed, 
estimation of the number of viable cells after encapsulation showed that the 
microfluidic method was compatible with cell survival, since no significant decrease 
in cell viability was observed for the two cell types studied, regardless the initial 
seeding density.  
Further investigations into the effect on cell viability of initial seeding density 
was carried out over a period of 3 weeks.  In order to establish the highest viable 
initial cell seeding density, different concentrations of cells were encapsulated in 
alginate beads.  Potentially, a high concentration of cells could be detrimental to 
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overall cell survival, as a greater number of cells within the capsules could hinder 
diffusion of nutrients and oxygen throughout the microsphere.  Preliminary studies 
demonstrated that NSCs grew within microcapsules, whereas no increase in total cell 
number was observed for DPSCs.  It was then hypothesized that high NSCs seeding 
densities would give rise to an overgrowth of cells within the capsules, provoking 
apoptosis of cells in the centre of the aggregates.  Hence, only the seeding densities 
1x105 cells/ml and 1x106 cells/ml were investigated for NSCs.  In the case of DPSCs, 
higher cell concentrations were studied, using 1x106 cells/ml, 2x106 cells/ml, 5x106 
cells/ml and 1x107.  Differences were found in the two seeding densities in NSCs.  
Although low seeding density showed a consistent high viability over the period 
tested, high density led to proliferation of cells within the capsules, increasing both 
the total number of cells and the number of viable cells.  This increase in cell viability 
was then confirmed by MTT assay, where the absorbance of the encapsulated cells 
increased over a period of 10 days.  Also, laser scanning confocal microscopy showed 
an increase in the size of NSCs aggregates, supporting the previous observations.  The 
size of the cell aggregates after three weeks in culture was still appropriate to permit 
the diffusion of oxygen and nutrients, since no dead cells were observed in the centre 
of the aggregates when samples were stained with EthD-1 and analysed by confocal 
microscopy.  Neurosphere growth in standard culture conditions occurs at a higher 
rate than that observed in encapsulated NSCs.  Hence, it was assumed that 
encapsulation did not prevent proliferation of NSCs, but it provoked a delay in cell 
growth.  This observation was similar to that found by Wilson et al. 2014.  The 
proliferation rate of non-encapsulated and encapsulated embryonic stem cells were 
compared and results revealed that unencapsulated cells had the highest net growth 
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rate.  Other investigations on the influence of alginate matrix on the proliferation of 
encapsulated NSCs demonstrated that the growth rate of NSCs decreased with an 
increase in the hydrogel stiffness (Banerjee et al. 2009).  Thus, proliferation of cells 
could be directly related to the mechanical resistance of the surrounding 
environment.  
The initial seeding densities investigated for the DPSCs did not show any 
significant difference in cell viability at similar time points.  Unlike NSCs, DPSCs did 
not exhibit any sign of cell proliferation, and actually, a decrease in the number of 
viable cells was observed.  However, cell viability at the different seeding 
concentrations tested was still encouragingly high (more than 60% of viable cells) up 
to 21 days after encapsulation.  Interestingly, both bright field and confocal 
microscopy images of encapsulated cells showed little evidence of adhered cells as 
they remained rounded within the alginate microspheres.  Other studies on DPSCs 
immobilized within alginate hydrogels reported similar results (Umemura et al. 2011; 
Kanafi et al. 2014).  Kanafi et al. 2014 highlighted the different morphology of DPSCs 
depending on the culture conditions.  When these cells were cultured in standard 2D 
culture they acquired fibroblast-like shapes, whereas when the cells were 
encapsulated within alginate microspheres they adopted rounded morphologies.  
The same behaviour has been observed in olfactory ensheathing cells, Schwann cells 
and BMSCs cultured on alginate hydrogels, where the cells acquired atypical spherical 
shapes and their metabolic activities were inhibited (Novikova et al. 2006).  However, 
despite the prolonged period of time that these cells remained rounded within the 
hydrogels, they were still viable. 
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MTT studies of encapsulated DPSCs revealed that cell egress was occurring as 
early as 3 days after encapsulation.  The escaped cells attached on tissue culture 
plates surfaces and proliferated.  Hence, whilst the MTT assay in this situation was 
not a suitable assay (as cells both inside and outside the beads were being measured) 
it did reveal that cells could escape from the beads over the time course of the 
investigation.  
Early cell egress is a non-desirable event in transplantation therapies, since 
one purpose of cell encapsulation is their protection and isolation from the immune 
system to prevent cell death (Lee & Bae 2000; Emerich & Winn 2001; Hao et al. 2005).  
To overcome this, it was hypothesized that type I collagen would prevent cell escape 
by promoting cell attachment and at the same time that would improve cell viability, 
as has been reported by others (Hunt & Grover 2010).  Unlike collagen, alginate does 
not interact with mammalian cells, and therefore, does not promote cell adhesion 
(Rowley et al. 1999).  Hence, the alginate matrix was modified with type I collagen.  
As a result, migration of DPSCs from the beads was delayed with no cells observed to 
escape until day 10 after encapsulation.  However, little cell attachment was again 
observed.  Viability and proliferation were again studied for the two cell types in the 
new encapsulation matrix.  Importantly, no differences were observed compared to 
the results found with alginate alone, with the maintenance of NSCs and DPSCs high 
viabilities over the 3 weeks period and NSCs proliferating within the alginate-collagen 
microcapsules.   
An alternative method was designed in order to elucidate the proliferation 
behaviour of DPSCs within microcapsules.  This consisted on cell labelling prior to 
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encapsulation with a stain whose fluorescence intensity decreases as the cells transit 
through the cell cycle and divide.  This clearly demonstrated that the DPSCs did not 
proliferate within alginate nor alginate-collagen microcapsules.  This finding is 
opposed to that reported by Kanafi et al. (2014), where an increase in cell absorbance 
was observed over a period of 10 days in respect of DPSCs encapsulated within 
alginate beads.  This can be explained by the fact that, in the method developed by 
Kanafi et al. (2014), the MTT reagent was directly added on plates where 
encapsulated cells were cultured.  Some of these cells might have escaped, having 
attached on the surface of the plates and proliferated.  Hence, the MTT absorbance 
measured was the overall value of encapsulated and escaped cells.  However, the 
CellTrace method developed in this thesis overcame the issue related with cell 
escape, and demonstrated that DPSCs did not proliferate within alginate-collagen 
microcapsules.  Studies on human MSCs have also reported that cell proliferation was 
impeded when cells were encapsulated in both alginate and alginate-GRGDY 
hydrogels, although a retained viability of > 80% was observed 15 days after 
encapsulation (Markusen et al. 2006).  These authors postulated that growth 
inhibition might be due to hindered nutrient access in the alginate hydrogel.  
However, the random distribution (some in central area and some in more peripheral 
areas) of dead cells (red) for both cell types observed in this thesis (Figure 3.8 and 
Figure 3.12) suggests that microsphere nutrients and oxygen diffusion inside the 
microcapsules was not an issue.  The accumulation of dead cells in the centre of the 
capsules would be a sign of nutrient deprival due to an ineffective diffusion through 
the entire sphere.  Since this effect was not observed, it can therefore be concluded 
that the size of the microcapsules was such that it enabled bidirectional diffusion of 
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nutrients inside the capsules and the efflux of waste products from cell metabolism 
outside the beads.   
Furthermore, the composition of alginate hydrogel could also influence cell 
behaviour.  It has been reported that an increase in molecular weight and 
concentration of high guluronic acid alginates prolongs the hindrance of glucose 
metabolism, insulin secretion and cell growth of murine insulinoma βTC3 cells 
encapsulated in alginate/PLL/alginate (APA) beads (Stabler et al. 2001).  It is 
documented in the literature that alginates with a high guluronic acid content form a 
more compact network due to the coordination of Ca2+ ions and contiguous guluronic 
acid residues from different alginate chains, strengthening the resultant network 
(Grant et al. 1973; Sikorski et al. 2007) .  Thus, the stronger the network the more 
difficult it is to displace it.  Consequently, cell growth might be inhibited within stiffer 
hydrogels (Stabler et al. 2001). 
As part of preliminary studies, cells were encapsulated in low viscosity alginate 
(high content in mannuronic acid residues).  These microcapsules exhibited low 
mechanical stability, as an inconsistent spherical shape was observed.  Also, the 
efficacy of encapsulation was poor since a great number of cells were observed 
outside the capsules after the encapsulation experiment.  Hence, low viscosity 
alginates were not considered in this thesis.   
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3.5.3 Cell functionality upon release from microcapsules  
One of the initial purposes of this chapter was to test the neuronal 
differentiation potential of stem cells maintained for prolonged periods of time 
within microcapsules.  The majority of the methods developed for in vitro neuronal 
differentiation require pre-coating of surface plates with substrates that promotes 
cell attachment, such as poly-lysine, laminin, ornithine, etc. (Reynolds & Weiss 1992; 
Wang et al. 2006).  However, little cell attachment was observed for both NSCs and 
DPSCs in alginate and alginate-collagen microcapsules.  Since cell attachment is one 
pre-requisite for neuronal differentiation, these scaffolds offer a synthetic 
microenvironment which is able to prevent spontaneous differentiation.  Hence, 
these matrices are good candidates in order to protect the cells from the adverse 
environment after injury and preventing their auto-differentiation before the acute 
phase following SCI has ceased.  
It should be noted that an objective of this thesis was to use ECM hydrogels 
as vehicles to protect transplanted cells from an adverse environment after injury 
and to direct cell location at the site of implantation.  Therefore, ECM hydrogels 
should degrade as the cellular system replaces the ‘artificial’ matrix after 
transplantation.  To this end, it was observed that cells were able to migrate out from 
the capsules and proliferate on plates 10 days after encapsulation.  Therefore, the 
studies moved towards the investigation of the cellular functionality upon release 
from microcapsules 21 days after encapsulation.   
It was observed that proliferation of cells within the microcapsules was slowed 
down in NSCs and inhibited in DPSCs.  However, when cells were released from beads 
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and seeded on plates, they showed growth rates similar to those exhibited by non-
encapsulated cells.  As mentioned in the previous section, NSCs proliferation might 
be hindered within microcapsules due to the mechanical stiffness of the hydrogels.  
On the other hand, DPSCs proliferation only occurred after the release from capsules 
and seeding on plates.  I hypothesized that alginate-collagen microcapsules provide 
an artificial stem cell niche, where DPSCs reside in a quiescent state.  This is like DPSCs 
residing within the dental pulp of living organisms, usually remaining quiescent when 
they are within the dental pulps, but responding quickly after injury (Potdar & 
Jethmalani 2015).  Although similar behaviour has been observed in DPSCs and MSCs 
in several publications (Markusen et al. 2006; Novikova et al. 2006; Umemura et al. 
2011; Kanafi et al. 2014) none of these studies report on the mechanisms underlying 
cell survival despite their lack of attachment and proliferation.  However, research on 
how to extend lifespan in yeast gives a hint of the potential mechanisms involved in 
the behaviour of adherent stem cells encapsulated in low adherence hydrogels.  
Nagarajan et al. 2014 showed that encapsulated yeast cells within calcium alginate 
beads and fed ad libitum ceased to divide but they maintained >95% viability over 
the course of 17 days.  Analysis of gene expression of immobilized yeast cells 
demonstrated decreasing transcription of genes that regulate the cell cycle.  A similar 
mechanism might take place in non-attached DPSCs within alginate-collagen 
microcapsules, where cells go into cell cycle arrest but continue to be metabolically 
active.  Since cell aging is related to how many times a cell divides, controlled 
inhibition of cell division would allow for the temporal extension of stem cell lifespan.  
It has been observed in this chapter that the behaviour of NSCs and DPSCs was 
altered under encapsulation conditions.  However, upon release from the capsules, 
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cells retained stem cell properties, as demonstrated by high growth rates and the 
expression of both stem cell and neuronal markers.  When cells were liberated from 
hydrogels and seeded on coated plates, both NSCs and DPSCs developed neuronal-
like morphologies after application of a neuronal differentiation protocol previously 
developed in our group (Young et al. 2016).   
Analysis of protein production showed that NSCs expressed the neuronal 
markers Nestin, β-III tubulin and Map2 and the stem cell markers Sox2 and Oct4 
before and after differentiation.  Nestin is a marker commonly used to identify early 
stage neural cells (Dahlstrand et al. 1995; Messam et al. 1999).  Nestin expression is 
downregulated when CNS stem/progenitor cells differentiate into neurons or glial 
cells (Frederiksen & McKay 1988; Dahlstrand et al. 1995).  After NSCs differentiate, 
nestin expression is typically replaced by the expression of neuronal or glial specific 
markers, such as NF-I and GFAP (Hendrickson et al. 2011).  Expression of nestin after 
the differentiation protocol suggests that neuronal differentiation was not complete.  
This presumption was supported by the production of the stem cell marker proteins 
Sox2 and Oct4 after 15 days in differentiation medium.  NSCs also expressed the early 
stage neuronal markers β-III tubulin and Map2 at both undifferentiated and 
differentiated state.  Co-expression of Nestin and β-III tubulin has been suggested to 
be involved in the formation of cell processes during the differentiation of NSCs (Liu 
et al. 2013).  Although no variations in proteins production was reported by NSCs, it 
was observed that cells developed long axons and neurites emerging from cell body, 
creating connections with adjacent cells and adopting neuronal morphology. 
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Expression of nestin by DPSCs was also observed both before and after 
differentiation.  However, their behaviour differed from that shown by NSCs in that 
DPSCs produced the stem cell markers Sox2 and Oct4 in the undifferentiated state 
but not after the differentiation protocol.  On the other hand, early stage neuronal 
markers β-III tubulin and Map2 were only visible in the differentiated state.  DPSCs 
exhibited a change in their phenotype towards a neuronal-like morphology.  Cells 
were typically bi-/tri-polar and fibroblast-like before differentiation.  After the 
differentiation protocol, DPSC cell bodies adopted a rounded morphology with 
multiple long processes sprouting out forming neuronal-like connections.  Although 
several protocols for DPSCs neuronal differentiation have been developed (Karaöz et 
al. 2011; Ellis et al. 2014; Gervois et al. 2015), this is the first time that it has been 
demonstrated that DPSCs maintain their stem cell and neuronal properties after 
encapsulation within alginate-collagen microcapsules.   
 
The results presented in this chapter demonstrate that the microfluidic 
technique developed in this thesis allowed for the encapsulation of different types of 
stem cells.  Encapsulation of NSCs and DPSCs within alginate and alginate-collagen 
microcapsules permitted their culture in 3D scaffolds for up to 21 days.  Viability and 
proliferation assays demonstrated that the cells were viable for this 3-week period.  
However, proliferation of NSCs was delayed and inhibited in the case of DPSCs.  This 
effect might permit the use of such scaffolds to ‘extend’ the cell lifespan by 
positioning them within an appropriate niche which supports cell quiescence.  When 
stem cells were released from the microcapsules, both NSCs and DPSCs clearly 
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retained stem cell and neuronal-like differentiation properties, as demonstrated by 
high proliferation rates and the expression of stem cell pluripotency markers and 
neuronal markers.  
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4.1 Introduction 
One of the limitations of in vitro experiments is that they fail to replicate the 
precise cellular conditions of an organism (Staton et al. 2009).  Because of this, in 
vitro studies often lead to results that do not fully correspond to the events occurring 
within a living organism.  For example, intact functional organs or tissues in vivo 
exhibit complex interactions with many different cell types.  These mechanisms are 
difficult to replicate in most in vitro cell culture models (Whitehead et al. 2012).  
Therefore, when extrapolation of in vitro data to the in vivo situation is required, the 
model must try to reflect the complexity of the studied system.  Thus, ex vivo systems 
offer a valuable tool before progressing onto in vivo investigations.  Ex vivo 
experiments include procedures with living tissues or organs isolated from an 
organism and cultivated outside that organism in an artificial environment under 
highly controlled conditions.  As such, an ex vivo model system in which the full 
complexity of the host-associated environment can be eliminated, provides an ideal 
experimental arena in which the underlying cellular and molecular mechanisms 
between the host and grafted cells can be studied. 
Spinal cord explant culture systems preserve partial histological architecture 
of a surgically removed piece of organ, allowing the study of in vivo processes under 
controlled ex vivo conditions (Sypecka et al. 2015).  Different SCI ex vivo models have 
been established for the study of several aspects of neuroscience investigations.  
Okada et al. (2014) developed a laser-induced SCI model to assess the mechanisms 
of axonal degeneration in real time.  The similarity of the model with clinically 
relevant contusion/compression-induced axonal pathologies permitted the 
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differentiation between the primary insult that directly injures axons and secondary 
injury mechanisms.  Ex vivo models have also been utilised to study repair strategies 
after SCI.  These include peripheral nerve graft implants into cultured spinal cords 
(Zhang et al. 2010) and cell transplantation (Kim et al. 2009; Park et al. 2010).   
The promising results obtained with ex vivo models have encouraged 
researchers to apply these findings into in vivo systems.  Indeed, the potential of both 
NSCs and DPSCs for neuronal repair after SCI have been reported (Ogawa et al. 2002; 
Sakai et al. 2012).  Most of the times, neuron survival and regrowth after injury is 
mediated by neurotrophins and growth factors released by the grafted cells rather 
than by direct cell incorporation/replacement (Corti et al. 2010; Rossi et al. 2010; De 
Almeida et al. 2011).  Current therapies that apply cell replacement to promote 
neuronal survival and/or growth have had modest success in allowing injured 
neurons to regrow through the area of the lesion (Pfeifer et al. 2004; Parr et al. 2007).  
This is because of the lack of three-dimensional organization in cellular 
transplantation, resulting in random directions of axonal growth in the lesion site and 
poor bridging beyond the injury (Pires & Pêgo 2015).  Hence, strategies for successful 
regeneration will require an engineering approach that guide regenerating axons in 
the proper direction to create a bridge across the injured area (Geller & Fawcett 
2002).  In fact, when BMSCs were seeded in alginate-based scaffolds with an 
anisotropic capillary structure, enhanced axonal growth oriented parallel to the 
hydrogel channel walls was demonstrated (Günther et al. 2015).  Hence, in this 
investigation, an ex vivo model of SCI and transplantation was utilised to investigate 
the potential of the grafting of stem cells encapsulated within alginate-collagen 
microbeads.   
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4.2 Aims & Objectives 
The objectives of this chapter were to: 
 Develop a method for the transplantation of encapsulated stem cells into 
an ex vivo model of SCI. 
 Study of the behaviour of the transplanted stem cells within the tissue, 
including cell survival and neuronal differentiation. 
 
4.3  Materials & Methods 
4.3.1 Animals  
21-28 day old C57/Bl6 mice were used for tissue harvest and obtained from 
Charles River Laboratories, UK, and maintained at the Joint Biological Services Unit 
(JBIOS) at Cardiff University, Cardiff, Wales.  Mice were sacrificed by CO2 asphyxiation 
in accordance with Schedule 1 of the Animals (Scientific Procedures) Act 1986. 
 
4.3.2 Dissection and preparation of murine spinal cord explants 
Spinal cord slice cultures were prepared as previously described (Meng et al. 
2012).  Briefly, 21-28 day old C57BL/6 mice were sacrificed by CO2 asphyxiation and 
complete spinal cords were dissected on ice.  Meninges were carefully removed, so 
as not to damage the cord, under a dissecting microscope.  Cords were then washed 
twice in PBS supplemented with 1% (v/v) penicillin/streptomycin.  Cords were cut 
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with surgical blades on ice into approximately 1cm long sections.  These were 
transferred to the centres of 35mm tissue culture dishes with the dorsal area facing 
upwards.  An injury was induced on the centre of each section by removing part of 
the tissue with a scalpel.  
 
4.3.3 Transplantation of encapsulated cells 
To allow for easy identification of transplanted cells, a mixed population of 
NSCs and fibronectin-adherent DPSCs were isolated from transgenic mice expressing 
GFP (Section 3.3.1). 
Cells in culture were trypsinized (DPSCs) or accutase-digested (NSCs) and 
encapsulated in alginate-collagen microcapsules as described in Section 3.3.3.2.  
Neuronal-like pre-differentiated DPSCs were cultured in NSC growth medium for 5 
days (Section 3.3.6.2) and also encapsulated.  Microcapsules were then transplanted 
with forceps into the spinal cord sections so as to fill the gap generated after injury 
(2.5mm long and 0.5cm wide, approximately).  Six microcapsules were transplanted 
for each experimental condition and sealed in position with 30μl of Matrigel® (BD 
Biosciences, UK) to avoid the beads becoming released from the tissue.  The plates 
were then transferred to the tissue culture incubator for 1 hour to allow the 
Matrigel® to polymerise.  Pre-warmed DMEM/F-12 medium containing 25mM HEPES 
buffer supplemented with 1% (v/v) penicillin/streptomycin and 20% heat-inactivated 
FBS (all Life Technologies, UK) was then added such that the surface of the spinal cord 
sections was completely covered with culture medium.  Samples were then returned 
to the incubator and culture medium replaced every other day for up to 10 days.  
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4.3.4 Cryosectioning of spinal cord tissue samples  
Spinal cord tissues were removed from culture and fixed overnight at 4°C with 
4% PFA either immediately after transplantation (0 days) or 10 days after 
transplantation.  The following day, samples were washed for 3x 20 minutes in PBS 
and then washed in 30% (w/v) sucrose (Sigma-Aldrich, UK) solution overnight to 
provide cryoprotection.  Spinal cord tissue was then mounted in OCT embedding 
compound (Thermoscientific, UK). 20μm-thick longitudinal sections were cut using a 
Leica CM3050 S cryostat (Leica Microsystems, Germany) and mounted onto glass 
microscope slides (VWR International, UK).  Glass slides were stored at -80°C until 
required for further analysis. 
 
4.3.5 Apoptosis Tunel Assay 
Slides were removed from the -80°C freezer and air dried at room temperature 
for 20 minutes.  Spinal cord slices were permeabilized with 1X Proteinase K solution 
in PBS for 15 minutes.  Samples were washed with PBS twice for 5 min and then post-
fixed with 4% (v/v) paraformaldehyde for 5 min at 37°C.  Slices were immersed in PBS 
twice for 5 minutes and after rinsing with deionized water samples were ready for 
staining.   
To induce DNA strand breaks (positive control, APPENDIX III), tissues were 
fixed and permeabilized with 1 unit of DNase I diluted into 1X DNase I Reaction Buffer 
(20mM Tris-HCl, pH 8.4, 2mM MgCl2, 50mM KCl) for 30 minutes at room temperature 
(both LifeTechnologies, UK).  Positive control and samples were then stained with 
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Click-iT® Plus TUNEL Assay (Life Technologies, UK) according to the manufacturer’s 
instructions.  Briefly, samples were incubated with TdT reaction buffer for 10 minutes 
at 37°C.  Buffer was removed and TdT reaction mixture containing 94% (v/v) TdT 
reaction buffer, 2% (v/v) EdUTP and 4% (v/v) TdT enzyme was then added to tissues 
and incubated for 60 minutes at 37°C.  The reaction mixture was removed and slides 
rinsed with deionized water.  Slides were then washed with 3% BSA and 0.1% Triton® 
X-100 in PBS for 5 minutes before rinsing in PBS.  The reaction cocktail was prepared 
by addition of 87% (v/v) reaction buffer, 2% (v/v) copper protectant, 0.2% (v/v) Alexa 
Fluor® picolyl azide and 10% (v/v) reaction buffer additive.  The mixture was then 
added to samples and incubated for 30 minutes at 37°C, protected from light.  The 
reaction cocktail was removed and slices washed with 3% BSA before washing in PBS 
for 5 minutes.  Samples were mounted onto glass cover slips using mounting media 
supplemented with DAPI stain (VectorLabs, UK).  Fluorescent images were then 
acquired of the stained spinal cord tissues. (Section 3.3.8.2). 
 
4.3.6 Immunohistochemical staining of spinal slice cultures 
Slices were removed from the -80°C freezer and air dried at room temperature 
for 20 minutes.  A ring was created around each slice using a hydrophobic pap pen 
(Sigma-Aldrich, UK) in order to minimise antibody wastage.  Samples were 
permeabilized with 0.1% (v/v in PBS) Triton X-100 for one hour at room temperature.  
After three washes with PBS, 5% (w/v) BSA (Fisher Scientific, UK) in PBS was applied 
for one hour in order to block non-specific binding.  This was removed, washed with 
PBS and replaced with primary antibodies against Nestin, Map2 and GFAP (Table 1) 
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diluted in 5% (w/v) BSA along with the isotype control (Table 2) and incubated 
overnight in a dark humid chamber at 4°C.  The following day, three PBS washes were 
performed before incubation with complementary fluorophore-conjugated 
secondary antibody diluted in 5% (w/v) BSA (Table 3), in the dark at room 
temperature for 2 hours.  Three further washes with PBS were performed before the 
samples were mounted onto glass cover slips using mounting medium supplemented 
with DAPI stain (VectorLabs, UK).  Slides were stored at 4°C in the dark, to prevent 
bleaching, until required for imaging (Section 3.3.8.2). 
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4.4 Results 
4.4.1 Development of a method for the transplantation of 
encapsulated stem cells into an organotypic model of spinal cord 
injury 
Most of the methods developed for transplantation of microcapsules use 
needles to inject the encapsulated cells into the injury site (Sah & Chien 1996; Toso 
et al. 2003; Zhao et al. 2016).  However, the size of the beads produced in this thesis 
was too large to use needle injection.  The narrow internal diameters of the needles 
provoked their blockage and injection was impeded.  The reduction of microcapsules 
diameter would have involved the re-optimization of the encapsulation parameters.  
Hence, a method for implantation of the microcapsules with diameters ~400µm was 
developed in this section.   
The transplantation technique should be reproducible in order to compare the 
behaviour of the transplanted cells.  Also, the technique must permit a precise control 
of graft implantation, which directly affects cell arrangement within the tissue.  
Whilst conventional cell grafting can promote growth of injured axons, they rarely 
extend across the lesion site due to the lack of a proper guidance.  Hence, a precise 
control of cell orientation is of a key importance in SCI in order to assess linear axonal 
regeneration through the injury site (Günther et al. 2015). 
Following CO2 asphyxiation, spinal cords from mice were dissected as 
described in Section 4.3.2.  After the injury was induced, encapsulated cells were 
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transplanted following the steps in Section 4.3.3.  Different strategies were 
considered in order to induce the injury.  Due to the anatomy of the cord (Figure 
4.1A) the injury could not be too deep since beads would escape underneath the 
tissue.  The first approach involved the removal of the tissue on the dorsal part of the 
cord in a “V” shape (Figure 4.1B).  Then beads were implanted to fill the gap 
completely.  However, the number of beads that could be implanted was limited and 
their arrangement difficult to control.  Therefore, a different approach was 
considered in order to maximize the number of transplanted beads per tissue section.  
This consisted of the removal of part of the tissue on the surface of the cord in order 
to induce the injury lengthwise.  This method allowed for the visualization of all the 
beads transplanted in the same section, increasing the number of visible cells (Figure 
4.1). 
 
 
Figure 4.1.  Approaches for injury induction into an ex vivo model of SCI.  A) Schematic 
representation of the anatomy of the spinal cord.  B) Injury induction in a “V” shape.  C) Injury 
induction lengthwise.  
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The main challenge to overcome was to fix the position of the microcapsules 
within the injury during the investigation period otherwise they would float free 
within the culture medium.  Therefore, a cell friendly “glue” was utilised to seal the 
capsules at the injury site.  Matrigel® is a biocompatible matrix rich in ECM proteins 
that mimics in vivo environments.  When added on the top of the beads and cultured 
for 1 hour at 37°C, it became solid, thereby entrapping the beads (Figure 4.2).  In this 
way, it was possible to improve cell engraftment by sealing the microcapsules at the 
transplantation site, avoiding the loss of beads during the culture period and 
preventing any potential spread of the injury.  After Matrigel® solidification, explants 
were fixed, dehydrated and cryosectioned in 20µm thick slices (Section 4.3.4).  
Tissues were then imaged with a fluorescence microscope as described in 
Section 3.3.8.2.  Figure 4.3 shows a longitudinal section of spinal cord tissue after 
transplantation (day 0).  Alginate-collagen capsules containing GFP DPSCs can be 
observed in the middle of the cord, demonstrating the efficacy of Matrigel® to retain 
the capsules at the site of implantation. 
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Figure 4.2.  SCI induction and transplantation of encapsulated cells.  A) Murine spinal cord 
was dissected after CO2 asphyxiation.  Meninges were then removed and an injury was 
induced on the dorsal part of the cord.  Encapsulated cells were transplanted at the site of 
injury and sealed with Matrigel®.  Scale bar = 500mm.  B) Picture of spinal cord after 
transplantation of encapsulated cells.  Scale bar = 500µm.  
B
A
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Figure 4.3.  Spinal cord longitudinal section after transplantation of encapsulated cells.  A) 
20µm thick frozen section of spinal cord.  Scale bar = 1mm.  B-C) Detailed images (bright field 
and fluorescence, respectively) showing encapsulated GFP DPSCs within the spinal cord.  
Scale bars = 200µm.   
 
In order to highlight the benefits of this cell encapsulation technique for 
transplantation purposes, a comparison between implantation of unencapsulated 
and encapsulated cells was carried out.  The same number of cells corresponding to 
the transplantation of 6 beads loaded with cells (~ 2700 cells) were pipetted at the 
site of injury resuspended in 2μl of culture medium.  Matrigel® was then added on 
the top to seal the injury and to retain the cells at the site of implantation.  Tissues 
were fixed, dehydrated and sliced into 20µm slices (Section 4.3.4).  
Figure 4.4 demonstrates that cells could be observed after both methods of 
delivery immediately after transplantation.  However, the longer-term localization of 
the cells differed dependent on the implantation method utilised.  After 10 days, no 
GFP-positive cells were found at the injury site when cells were implanted as cell 
suspension (non-encapsulated).  On the other hand, GFP positive encapsulated cells 
were observed within the capsules at the injury site 10 days after transplantation. 
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Figure 4.4.  Behaviour comparison of non-encapsulated and encapsulated cells transplanted 
in spinal cord slice cultures.  Coexpression of DAPI and GFP.  (A) Few unencapsulated cells 
could be observed within the tissue directly after implantation (white arrows).  (B) Ten days 
post-injection, the injury site remained devoid of any non-encapsulated cells.  (C) 
Encapsulated cells were transplanted and visible at the injury site.  (D) Encapsulated cells 
were still visible 10 days after transplantation.  Scale bar = 100µm.  
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Differentiation of transplanted cells in situ is heavily influenced by the 
surrounding tissue/environment (Kshitiz et al. 2012; Gattazzo et al. 2014; Griffin et 
al. 2015).  In this chapter, the behaviour of different cells types was investigated in 
order to study the influence of the host tissue on the fate of the transplanted cells.  
The three different conditions investigated were the following: (1) undifferentiated 
DPSCs, (2) DPSCs pre-differentiated into neuronal-like cells following the protocol 
described in Section 3.3.6.2 and (3) undifferentiated NSCs (Figure 4.5). 
Cells for the three conditions were encapsulated in alginate-collagen 
microcapsules at an initial density of 1x107 cells/ml.  Whilst the optimized 
concentration for encapsulation of NSCs was stablished at 1x106 cells/ml (Section 
3.4.2), preliminary experiments demonstrated that very few cells were visible after 
cryosectioning.  Hence, it was decided to increase the concentration of initial seeding 
density for NSCs from 1x106 cells/ml to 1x107 cells/ml for this set of experiments.  The 
viability and the neuronal differentiation potential of the encapsulated cells were the 
investigated 1 and 10 days after transplantation into the ex vivo SCI model.  
 
Figure 4.5.  Bright field images of cells at three different conditions before encapsulation and 
transplantation.  A) Condition 1: undifferentiated DPSCs.  B) Condition 2: pre-differentiated 
DPCSs into neuronal-like cells.  C) Condition 3: undifferentiated NSCs.  Scale bar = 100µm.  
A B C
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4.4.2 Analysis of cell survival after transplantation 
The survival of cells within the alginate-collagen microcapsules was described 
in the previous chapter.  Both DPSCs and NSCs demonstrated high viabilities after 3 
weeks in culture within tissue flasks (>65% and >85%, respectively).  In order to 
progress towards further applications in the repair of SCI, the suitability of the 
encapsulated cells should be investigated within an ex vivo model of SCI.  
The three different types of encapsulated cells were implanted into spinal cord 
tissues and cell viability was studied immediately and 10 days after transplantation.  
Cells were fixed, dehydrated and cryosectioned before staining with Apoptosis Tunel 
Assay (Section 4.3.5).  For the three cell types studied, microcapsules were easy to 
visualize immediately after transplantation, but no complete capsules were observed 
after the culture period.   
As observed in Figure 4.6, cells of all three types were viable at the time of 
implantation, since no co-expression of DAPI/GFP/AF 594 was observed.  Ten days 
after transplantation, a number of apoptotic nuclei were observed for cell types 1 
and 2, as observed by co-expression of DAPI/AF 594.  However, some encapsulated 
cells were still viable for the three cell types.  Furthermore, NSCs (cell type 3) 
proliferated within the tissue and started to form aggregates.  No signs of cell 
proliferation were observed for either DPSCs population.  This behaviour was similar 
to that observed in standard culture of encapsulated cells, where NSCs grew in the 
form of aggregates but DPSCs did not proliferate (Section 3.4.3.1.2)  
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Figure 4.6.  Apoptosis Tunel Assay of encapsulated cells transplanted into an ex vivo model of SCI.  Co-expression of DAPI-stained nuclei, GFP cells and apoptotic 
nuclei.  Encapsulated cells from the three conditions were transplanted and viability was studied using Apoptosis Tunel Assay 0 (A-C) and 10 (D-F) days after 
transplantation.  Condition 1: undifferentiated DPSCs (A, D); Condition 2: pre-differentiated DPSCs into neuronal-like cells (B, E); Condition 3: undifferentiated 
NSCs (C, F).  Scale bars = 50μm 
A B C
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4.4.3 Study of the neuronal marker levels within encapsulated 
stem cells transplanted into ex vivo spinal cord cultures 
All three cell types were encapsulated within alginate-collagen microcapsules, 
implanted into ex vivo spinal cord slices and cultured for 0 or 10 days.  Tissue sections 
were then fixed, dehydrated and stained with antibodies against nestin, map2 and 
GFAP as described in Section 4.3.6, along with the appropriate isotype control 
(APPENDIX IV).  An intense endogenous staining of GFAP was observed in the spinal 
cord cultures, regardless of the cell type or the time point.  However, no endogenous 
staining for nestin and map2 was observed (APPENDIX V).  
Undifferentiated DPSCs (cell type 1) expressed the neuronal marker nestin 
before and after culture within the section of spinal cord (Figure 4.7).  On the other 
hand, none of the neuronal markers associated with more mature neuronal 
phenotypes, map2 and GFAP, were observed immediately after transplantation.  
However, cells did stain positive for these neuronal markers after 10 days in culture. 
Unlike undifferentiated DPSCs, neuralised DPSCs (cell type 2) showed staining 
for both nestin and GFAP before culture, whilst the cells did not stain positive for 
map2 (Figure 4.8).  Ten days after culture, nestin and GFAP staining was evident as 
was positive staining for map2.   
Unlike undifferentiated and neuralised DPSCs, undifferentiated NSCs (cell type 
3) did not show GFAP expression before or after culture.  However, cells stained 
positively for nestin and map2 at both time points (Figure 4.9).   
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Figure 4.7.  Expression of neuronal markers by undifferentiated DPSCs (cell type 1).  Alginate-collagen microcapsules loaded with undifferentiated DPSCs were 
implanted in spinal cord slices and cultured for up to 10 days.  Explants were stained with antibodies against nestin, map2 and GFAP before (A - C) and after 
culture (D - F).  Transplanted cells (green) expressed the neuronal marker nestin before and after culture.  On the other hand, none of the neuronal markers 
associated with more mature phenotypes, map2 and GFAP were observed after transplantation.  However, cells stained positive for these proteins after 10 
days in culture.  Scale bars = 100µm. 
B
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Figure 4.8.  Expression of neuronal markers by neuralised DPSCs (cell type 2).  Alginate-collagen microcapsules loaded with neuralised DPSCs were implanted 
in spinal cord slices and cultured for up to 10 days.  Explants were stained with antibodies against nestin, map2 and GFAP before (A - C) and after culture 
(D - F).  Neuralised DPSCs (green) showed expression of both nestin and GFAP before culture, while cells did not stain positive for map2.  Ten days after culture, 
cells were positive for all three markers.  Scale bar = 100µm. 
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Figure 4.9.  Expression of neuronal markers by undifferentiated NSCs (cell type 3).  Alginate-collagen microcapsules loaded with undifferentiated NSCs were 
implanted in spinal cord slices and cultured for up to 10 days.  Explants were stained with antibodies against nestin, map2 and GFAP before (A - C) and after 
culture (D - F).  Undifferentiated NSCs (green) did not show GFAP expression before or after culture.  However, cells stained positively for nestin and map2 at 
both time points.  Scale bar = 100µm. 
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4.5 Discussion 
NSCs and DPSCs encapsulated in alginate-collagen microcapsules exhibited 
high viabilities after three weeks in culture and retained stem cell and neuronal 
differentiation potential upon release from microcapsules (Section 3.4.5).  As an 
attempt to apply this technique in a clinically relevant model, the behaviour of the 
encapsulated cells was studied in an ex vivo model of SCI developed in this thesis.  
Organotypic models permit a tight control of the artificial environment, which allows 
for the reliable comparison of the different conditions studied. 
The lack of ECM at the lesion site, that directs and organizes the wound healing 
cells, is one of the mechanisms that interferes with regenerative processes after SCI 
(Gaudet & Popovich 2014).  Thus, the use of biomaterials to replace ECM and support 
axonal growth has gained great attention over the last years as a promising strategy 
for neural tissue engineering.  In this thesis, it was demonstrated that encapsulation 
of cells and further transplantation helps retain the grafted cells at the wound site.  
Comparison between transplantation of non-encapsulated and encapsulated cells 
demonstrated that microcapsules aided retention of transplanted cells at the site of 
injury 10 days after implantation.  However, no cells were found after this period of 
time when cells were implanted as a free cell suspension.  This demonstrates the 
added benefits of using scaffolds as mean of transplantation in cellular therapies.  
These materials not only help to retain grafted cells at the injury site but also allow 
manipulation of the direction of cell transplantation in a three-dimensional manner, 
facilitating the integration of implanted cells within the host tissue (Yoshii et al. 2003; 
Tsai et al. 2006; Günther et al. 2015; Sugai et al. 2015; Fan et al. 2017).  
Chapter 4: Transplantation of encapsulated stem cells into an organotypic model of SCI 
  
208 
After cell transplantation, one of the main challenges is the loss of cellular 
material due to inflammatory responses (Wilson and Chaikof 2009).  Thus, 
immobilization of cells within polymer hydrogels has been useful to protect the 
enclosed cells from the host’s immune response (Zhong et al. 2010; Ye et al. 2011; 
Jun et al. 2013).  The survival of the encapsulated cells after transplantation in the ex 
vivo model of SCI was studied after 10 days in culture.  Encapsulated cells of three 
cell types survived throughout the culture period, as evidenced by limited apoptosis 
staining.  Ex vivo slice cultures are avascular and as such, reduced apoptosis as a result 
of a lack of inflammatory response was expected.  Co-culture of organotypic spinal 
cord slices along with a controlled concentration of pro-inflammatory molecules, 
such as IL-1β, IL-6, and TNF-α (Zhang & An 2007), would provide a more accurate ex 
vivo model to study grafted cell survival under the harsh conditions found in SCI.  For 
instance, the co-culture method has been adapted for the study of insulin-secreting 
cell survival whereby the cells have been encapsulated within anti-inflammatory 
peptide functionalized hydrogels and then cultured in the presence of diffusible pro-
inflammatory cytokines (Su et al. 2010). 
Although encapsulated cells survived within the spinal cord cultures, neither 
undifferentiated, nor neuralised DPSCs showed signs of proliferation, since no 
increased cellular density at the site of grafting could be observed.  This behaviour 
was similar to that observed in vitro, where cells did not proliferate but maintained a 
high percentage of viable cells after 3 weeks in culture.  On the other hand, NSCs 
showed some signs of cell proliferation, as indicated by the observation of small cell 
aggregates after the culture period.  In relation to this it has been demonstrated that 
immobilized neural progenitor cells within microfibers showed high proliferation 
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rates after transplantation into an in vivo mouse model of SCI (Sugai et al. 2015).  On 
the other hand, it has been reported that DPSCs do not proliferate after implantation 
into the mouse hippocampus but they stimulate proliferation of endogenous neural 
cells (Huang et al. 2008).  
Spinal cord slices were analysed in order to elucidate whether transplanted 
cells migrated out from the capsules and integrated within the host tissue.  Since cell 
escaping from alginate-collagen was observed after 10 days in vitro culture (Section 
3.4.3.1.3), migration of cells within the tissue was expected.  However, no cells were 
found outside the site of implantation in any of the sections analysed.  On the 
contrary, when DPSCs were transplanted in the spinal cord of traumatic injured rats, 
transplanted cells were observed in the spinal cord tissue reaching a distance of 
~1 mm from the lesion epicentre 42 days post-injury (Nicola et al. 2016).  Hence, cell 
migration through the host tissue might be a time-dependent factor.  It must be 
borne in mind that the culture periods in the ex vivo experiments carried out in this 
thesis were established at 10 days.  Cells might need longer culture times to migrate 
within this ex vivo system.  Also, the microcapsules composition might play a key role 
in cell migration.  The coating of culture plastics with laminin, a major constituent of 
CNS extracellular matrix, and poly-L-ornithine (PLO) increases the migratory capacity 
in vitro of DPSCs and NSCs, respectively (Howard et al. 2010; Ge et al. 2016).  Hence, 
the modification of microcapsule composition with these proteins could promote cell 
migration within the spinal cord cultures. 
Whilst it was easy to visualize the microcapsules immediately after 
transplantation, no complete capsules were observed after the culture period.  Also, 
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it was clear that the number of transplanted cells decreased after 10 days in culture.  
The first hypothesis would consider the possibility of alginate-collagen microcapsule 
degradation during the culture period.  Microcapsules showed good mechanical 
properties in that no changes in morphology nor signs of bead degradation were 
observed after three weeks in culture in vitro (Chapter 3).  However, spinal cord 
tissues might release sodium cations that promote alginate degradation by 
monovalent ions interchange.  Shahriari et al. (2016) demonstrated that calcium 
cross-linked alginate hydrogels did not maintain adequate mechanical integrity in 
vivo 14 days after transplantation in rat spinal cord.  Hence, the development of new 
approaches to decrease the degradation rate of alginate should be pursued to make 
it a viable scaffold material for nerve regeneration.  Also, collagen is a biodegradable 
material due to the existence of MMPs within the organism, which are responsible 
for collagen degradation (Harrington 1996).  Hence, the consistence of 
alginate-collagen microcapsules might have been compromised due to the existence 
of such enzymes within the host tissue.  After SCI, activated microglia release 
proteolytic and oxidative enzymes, which might affect the stability of the polymer 
microcapsules (Fleming et al., 2006).  Thus, collagen cross-linking should be 
considered to improve the mechanical stability of the microcapsules to guarantee the 
protection of the encapsulated cells against the inflammatory response.  Another 
possibility might be that microcapsules integrated within the spinal cord tissue, 
thereby reducing the damaged area.  In order to elucidate the fate of alginate-
collagen microcapsules within the spinal cord cultures, microcapsule labelling and 
further visualization under fluorescent microscope would be necessary.  Alginate can 
be fluorescently labelled by covalent binding of the amino groups of fluorescent 
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molecules to the carboxylic groups of the alginate.  A method for alginate labelling 
using fluoresceinamine has been described (Strand et al. 2003).  However, the 
excitation and emission wavelengths are similar to those to visualize GFP-labelled 
cells, which would hinder the detection of transplanted cells.  The last hypothesis 
considers the loss of microcapsules during the culture period, which also would 
explain the decrease in cell number.  Matrigel® would retain the capsules for a short 
period of time, but after several days and medium changes, some capsules might 
have been lost.  Culture medium was examined under the microscope in search of 
floating beads after every medium change but no microcapsules were discovered.  
Hence, the actual fate of alginate-collagen microcapsules within the spinal cord 
tissues after the culture period remains to be determined.   
The expression of neuronal markers by transplanted cells was also 
investigated.  It is well known that the fate of in vivo differentiation of stem cells 
depends on the niche into which they have been transplanted.  When NSCs are 
transplanted into a neurogenic region e.g. dentate gyrus, or subventricular zone, they 
will differentiate into neurons (Fricker et al. 1999; Shihabuddin et al. 2000).  However, 
transplantation into non-neurogenic regions, such as spinal cord, induce neural cells 
to differentiate towards glial lineage (Cao et al. 2001).  This demonstrates the 
importance of environmental cues in directing the differentiation of transplanted 
cells.  Cell differentiation towards undesirable lineages might hinder tissue 
regeneration.  Hence, pre-differentiation of stem cells prior to transplantation is a 
commonly adopted method used to induce a lineage restriction in CNS regeneration 
studies (Abeysinghe et al. 2015; Fortin et al. 2016).  In this thesis, the neuronal marker 
expression of encapsulated cells transplanted of three different types was compared: 
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undifferentiated DPSCs, neuralised DPSCs and undifferentiated NSCs.  At the time of 
implantation, undifferentiated and neuralised DPSCs showed distinct marker profiles.  
Whereas undifferentiated DPSCs only expressed nestin, neuralised cells expressed 
both nestin and GFAP.  None of the cells showed positive staining for Map2.  
However, after 10 days in culture, both cellular conditions stained positive for the 
three neuronal markers nestin, map2 and GFAP.  Expression of map2 and GFAP by 
undifferentiated cells and expression of map2 by neuralised cells after the culture 
period suggests that the local environment provides signals driving the fate of stem 
cells.  Human umbilical cord blood–derived NSCs (HUCB-NSCs) co-cultured with 
different rat brain–specific primary cultures differentiated towards different lineages 
depending on the cellular microenvironment (Markiewicz et al. 2011).  The presence 
of astrocytes and oligodendrocytes promoted neuronal differentiation of HUCB-
NSCs, whereas postmitotic neurons induced oligodendrogliogenesis of these cells.  
Hence, transplanted DPSCs could have received signals from the spinal cord culture 
microenvironment that stimulated their differentiation towards neuronal lineages in 
the absence of external growth factors in the culture medium.  On the other hand, 
the marker profile of NSCs did not change along the culture period.  Cells stained 
positive for nestin and map2, but not for GFAP, before or after culture.  As mentioned 
before, spinal cord cultures with transplanted NSCs showed the presence of cell 
aggregates after several days in culture, suggesting cell proliferation.  As cells 
differentiate, their rate of proliferation usually decreases.  Since NSCs were still 
proliferative within the tissue explants, the cells did not just completely commit to 
the differentiation process.  This highlights the different behaviour of different stem 
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cell types under the same conditions and the need for a cell-dependent methodology 
in order to direct differentiation. 
Nonetheless, the three cell types investigated in this thesis showed poor 
immunofluorescent labelling for the three markers studied.  Because the host tissue 
presented high endogenous fluorescence, it was difficult to elucidate whether the 
positive staining was produced by the transplanted cells or by the spinal cord 
cultures.  Analysis of tissue sections by laser scanning confocal microscopy might 
have provided more evidence about the fluorescence origin.  Also, retrieval of 
transplanted cells from the tissues and further gene analysis expression by 
polymerase chain reaction would provide unequivocal information about the 
neuronal behaviour of the grafted cells.  
Although the results reported in this thesis represent a promising method for 
further application in neuronal tissue restoration, there are still several issues to be 
addressed.  First of all, cells must be able to migrate and proliferate at the site of 
injury to completely bridge the gap and reconnect both sides of the lesion site.  
Although it has been demonstrated that alginate-collagen microcapsules are useful 
to retain cells at the site of injury, the number of transplanted cells might represent 
a limitation in this technique.  Due to the three-dimensional structure of alginate-
collagen microcapsules, the number of cells that can be implanted in the injury site 
is lower than that when cells are transplanted by simple cell injection.  Since it has 
been proven that transplanted DPSCs might direct endogenous repair by the release 
of tropic factors (Huang et al. 2008), the number of cells might influence the degree 
of therapeutic effect in terms of concentration of released growth factors.  Thus, a 
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greater therapeutic effect would be achieved with a higher release of growth factors 
that, in turn, would depend on the number of grafted cells.   
All in all, neuronal replacement after SCI represents a challenging procedure 
due to the harsh environment after damage, which is naturally inhibitive of axonal 
regrowth.  But also, the different cell types involved in the correct function of spinal 
cord makes necessary the implantation of simultaneous therapies to ensure a 
complete recovery.  Cell transplantation has been proven to be ineffective when no 
control of cell orientation can be achieved.  Hence, combination of cellular material 
with appropriate scaffolds that mimic the ECM in the central nervous system and 
directs axon regeneration is, so far, the most attractive approach.  
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The use of cell encapsulation technology has increased over the past decades 
due to the great number of fields in which it can be applied (Acarregui et al. 2013).  
Although it was first intended as a method for immunoisolation of cells in 
transplantation therapies (Freimark et al. 2010), the great variety of encapsulation 
techniques, matrices and cell types that can be combined has contributed to this 
versatility.  Pancreatic islet encapsulation is, by far, the most studied method (Buder 
et al. 2013).  The successful immobilization of islet cells encouraged researches to 
apply this technology in living organisms.  Indeed, promising results allowed the 
establishment of the first clinical trial involving cell encapsulation for the treatment 
of type I diabetes (Soon-Shiong et al. 1994).   
Encapsulation of different cell types, specifically stem cells, has permitted the 
expansion of the applicability of this technique.  Stem cells offer a renewable source 
of cells with the potential to transform into virtually any cell type within the organism.  
Stem cells have been isolated from both embryonic and adult tissues.  It has been 
demonstrated that ESCs can be expanded and differentiated in vitro into any cell type 
within the three germ layers (ectoderm, mesoderm and endoderm).  However, the 
therapeutic application of human ESCs is still debated due to ethical issues and 
problems of allogeneic rejection and uncontrolled development of malignancies 
(Hentze et al. 2007).  These obstacles have attracted the attention of the researches 
towards the study of ASCs.  Although it was first hypothesized that these cells had a 
lineage restricted differentiation potential, further studies have demonstrated that, 
under the appropriate reprogramming mechanisms, ASCs could be manipulated to 
differentiate towards cell lineages different from their tissue of origin in a process 
known as transdifferentiation (Filip et al. 2004).   
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ASCs have been typically isolated from bone marrow but this process involves 
painful and invasive procedures.  Hence, different sources of adult stem cells have 
been investigated, including adipose tissue (Lindroos et al. 2011), skin (Nowak & 
Fuchs 2009) and umbilical cord (Zhang et al. 2008) to name a few.  In 2000, Gronthos 
et al. isolated, for the first time, a stem cell population from the dental pulp.  A similar 
marker profile to that demonstrated for BMSCs was observed for DPSCs, thereby 
these cells were classified as MSCs (Kawashima 2012).  However, further studies 
revealed that DPSCs also expressed embryonic stem cell markers, such as Oct4 and 
Sox2 (Kerkis et al. 2007) and even markers associated with more mature phenotypes, 
including muscle (Patel et al. 2009) and neural cells (Karaöz et al. 2011).  These 
findings have attracted attention of researches towards the application of DPSCs for 
the treatment of CNS diseases and injuries.   
The main benefit of using DPSCs is their isolation procedure.  Cells can be 
easily isolated from the pulp of teeth extracted in routine orthodontic treatments or 
from deciduous teeth naturally shed in childhood (Tatullo et al. 2015).  In vitro 
expansion of these cells could provide a personalized stem cell bank readily available 
to be used in the cure of diverse conditions.  Specifically, the potential of DPSCs to 
differentiate down to neural lineages has been investigated by our group in Cardiff 
(Young et al. 2016).  Since DPSCs represent a highly heterogeneous population of 
stem cells, their marker expression and differentiation potential varies between 
clonogenic populations.  The work presented by Young et al. (2016) provides a 
potential method for the identification of DPSCs populations with neuronal 
differentiation potential, based on the levels of nestin expression.  Furthermore, 
several protocols have been developed for DPSCs neuronal differentiation 
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(Nosrat et al. 2004; Hisham et al. 2013; Young et al. 2016).  The success of these 
protocols along with the ability of these cells to release growth factors and 
neurotrophins involved in the maintenance and development of the CNS, have 
contributed to the application of DPSCs to the CNS in vivo (Huang et al. 2008; Leong 
et al. 2012; Sakai et al. 2012).  
The cellular and molecular mechanisms involved after SCI create an adverse 
environment which is extremely challenging with respect to the application of cell 
replacement therapies.  Although significant progress has been achieved over the last 
years, the application of single therapies does not provide fully recovery after spinal 
cord damage (Pfeifer et al. 2004; Parr et al. 2007).  Whilst cell transplantation 
provides trophic support for regenerating axons (Huang et al. 2008) the loss of ECM 
after injury and the lack of a three-dimensional organization of cellular grafts hinders 
complete recover after damage.  Hence, the combination of cellular replacement 
with appropriate scaffolds that provide support and mimic the ECM conditions, could 
provide an effective alternative for the regeneration of neuronal tissue after SCI. 
In this thesis, a method for the successful encapsulation of DPSCs and NSCs 
was developed.  In order to further apply encapsulated cells in clinical therapies, 
microcapsules should be highly monodisperse.  Microcapsules with narrow size 
distributions allows for an accurate estimation of the number of cells per bead, 
permitting the determination of the clinical dose before transplantation (Tan & 
Takeuchi 2007).  Also, in order to bring this technology towards clinical application, 
large batches of encapsulated cells need to be produced with high reproducibility.  
Most of the conventional methods for cell encapsulation do not provide reproducible 
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results, only producing small batches of encapsulated cells with wide polydispersity 
(Poncelet et al. 1992; Mollet & Grubenmann 2001).  Comparison of theoretical 
calculation and experimental estimation of number of cells per bead demonstrated 
that the microfluidic device developed in this thesis provides a reproducible method 
to produce polymer microcapsules. 
The use of microfluidics for the formation of polymer microcapsules, provides 
several benefits, including a better control of shape and size of the microcapsules and 
the use of small volumes of reagents, leading to a reduction in experimentation costs 
and expenses.  Several strategies have been developed for the formation of polymer 
droplets within microfluidic devices.  The simplest consists on the co-flow of two 
immiscible fluids through concentric capillaries (Cramer et al. 2004).  Different 
approaches utilize a T-junction format for the emulsification of the dispersed phase 
(Sivasamy et al. 2011) or droplets has been achieved utilising flow focusing devices 
(Dreyfus et al. 2003; Anna et al. 2003).  Flow focusing provides the most reproducible 
method, since the formation of droplets depend on several parameters including flow 
rates, channels geometry and fluids viscosities  (Baroud et al. 2010).  The 
manipulation of these parameters allows for a better control of the size of the 
droplets produced, giving rise to a greater dynamic size range from a given device 
compared with other strategies.   
In order to fabricate a flow focusing microfluidic device, PTFE was selected as 
the most suitable material.  PTFE offers several advantages over other materials used, 
such as PDMS.  Firstly, PTFE’s chemical properties means that it is predominantly non-
reactive and therefore has stable wetting properties.  In contrast, PDMS undergoes 
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swelling and deformation in the presence of strong organic solvents and uncontrolled 
adsorption of substances is a major issue (Uchida et al. 2003).  Secondly, PTFE’s high 
hydrophobicity allows for the formation of alginate droplets with high contact angles, 
thereby producing highly spherical microcapsules.  In the study presented in this 
thesis, microchannels were easily fabricated on PTFE discs by a milling process 
requiring short periods of time, generally less than 30 minutes.  They were then 
mounted in a compressed-sealed metallic manifold which allowed the 
assembly/disassembly of the entire mounting in an effortless and quick manner.  
Other methods utilized for the fabrication of microfluidic devices generate 
permanently sealed constructs (hindering their application in cases of blockages) 
which often involve multiple steps in their assembly and hence are time consuming 
to use (Shintaku et al. 2007).   
The flow focusing microfluidic device fabricated in this thesis allowed for the 
production and on-chip cross-linking of alginate-based microcapsules via internal 
gelation.  The design incorporated a continuous phase formed by a laminar flow of 
mineral oil (shielding flow) and acetic acid dissolved in mineral oil (protons source 
phase).  The controlled and smooth diffusion of protons through parallel layers within 
the continuous phase led to the release of calcium ions from CaCO3 dispersed in the 
alginate solution.  Unlike other methods utilized by other authors (Poncelet et al. 
1992; Capretto et al. 2008), the system applied in this investigation permitted the 
emulsification and cross-linking of alginate capsules in one single step, minimizing 
experimentation times.  This is of a key importance in cell encapsulation, where cell 
viability might be compromised due to the cells residing in unfavourable conditions 
for long periods of time.  In conventional external gelation approaches, encapsulated 
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cells are collected in a CaCl2 bath were they reside for 15-20 min in order to achieve 
proper gelation rates (Duvivier-Kali et al. 2001; Murua et al. 2007; Bhujbal et al. 
2014).  In contrast, the method developed in this thesis permitted gelation times 
< 1 min, as observed by the collection of solidified droplets from the outlet of the 
microfluidic chip.  External gelation of alginate microcapsules has been attempted 
within microfluidic devices (Choi et al. 2007).  In this approach, two separate inlets 
containing alginate phase and CaCl2 solution were continuously injected into a flow 
of water-immiscible hexadecane, where they spontaneously separated and broke up 
into stream droplets.  Once the alginate solution was in contact with the Ca2+ ions, it 
immediately transformed into a gel.  A similar approach was utilized by Shintaku et 
al. (2007),  where the incorporation of an additional channel containing CaCl2 solution 
after alginate emulsification permitted the hydrogel cross-linking.  However, the 
alginate microbeads showed random shapes and were highly polydisperse.  
Hence, although the experimentation times of external gelation can be 
reduced using microfluidic devices, poorly controlled gelation kinetics due to the high 
solubility of CaCl2 in aqueous solutions remains an issue.  Therefore, an internal 
gelation approach is the method preferred in order to produce highly monodisperse 
microcapsules.  For example, Liu et al. (2013) produced highly monodisperse alginate 
microcapsules via an internal gelation approach within a glass capillary microfluidic 
device.  However, in order to assess a proper emulsification, the use of surfactants 
was required.  The microfluidic device developed in this thesis allowed for the 
production of highly monodisperse microcapsules without the need of surfactants, 
minimizing the number of washing steps.   
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The encapsulation technology presented in this work permitted the 
immobilization of two different types of stem cells, DPSCs and NSCs.  It is noteworthy 
that the behaviour of these two cell types in vitro is different.  Whereas DPSCs adhere 
on plastic surfaces and grow in monolayers, NSCs proliferate in suspension as 
neurospheres.  However, the same encapsulation procedure and encapsulation 
matrix could be applied for the successful encapsulation of both cell types, 
highlighting the versatility of the method developed in this investigation.  Two 
different encapsulation matrices were tested.  First of all, alginate was selected as 
the encapsulation scaffold due to its biocompatibility, mild gelling conditions and 
good mechanical properties (Lee & Mooney 2012).  Cell viability and proliferation 
were studied and results revealed a different behaviour between DPSCs and NSCs.  
NSCs proliferated within the capsules and their viability increased up to 3 weeks in 
culture.  However, the proliferation rate was delayed when compared with standard 
culture conditions.  On the contrary, no signs of cell proliferation were observed in 
DPSCs, whose viability decreased to ~ 70% after the same culture period.  Cell viability 
and proliferation were studied with three different methods, including trypan blue 
exclusion assay, the MTT assay and Live/Dead staining.  The trypan blue exclusion 
assay provided the only quantitative method between those tested.  Live/Dead 
staining and confocal microscopy allowed for the observation of live and dead cells 
localization and shape within the microcapsules.  The random distribution of dead 
cells (red) suggested that the diameter of the microcapsules was appropriate for the 
survival of the encapsulated cells, since no dead cells accumulation at the centre of 
the capsules were observed, which would be the result of inefficient diffusion of 
oxygen and nutrients through the entire capsule.  However, the MTT assay did not 
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provide conclusive results about the proliferation behaviour of the cells as it was 
observed that DPSCs escaped from the microcapsules as early as 3 days after 
encapsulation.  Hence, the absorbance measured was not only that from the 
encapsulated cells but the overall of encapsulated and plastic bound ‘escaped’ cells.   
Therefore, the encapsulation matrix was modified in order to prevent/delay 
cell egress.  Thus, alginate microcapsules were modified by the addition of type I 
collagen.  Collagen is one of the most widely utilised biomaterials due to its inherent 
compatibility and its ability to induce cell attachment (Parenteau-Bareil et al. 2010).  
This modification delayed cell migration out of the microcapsules until about 10 days 
post-encapsulation.  However, like alginate microcapsules, cells did not attach on this 
scaffold, as observed by the formation of NSCs aggregates and rounded DPSCs.  
Similar behaviour in encapsulated adherent cells has been reported (Markusen et al. 
2006; Novikova et al. 2006; Umemura et al. 2011; Kanafi et al. 2014) but this 
behaviour has not been fully explained.  It was hypothesized in this thesis that 
alginate-based microcapsules provided the cells with an artificial niche in which cells 
reside in a metabolic quiescent state.   
Cell adhesion within alginate-collagen scaffolds has been demonstrated by 
other groups.  Sang et al. (2011) demonstrated that cells attached and proliferated 
within alginate-collagen fibrils.  They observed that the degree of cell proliferation 
was directly related with the concentration of collagen in the scaffolds.  Hence, in 
order to promote cell attachment, an increased concentration of collagen in the 
microcapsules would have been helpful.  However, due to its low mechanical stability 
(Shoulders & Raines 2010), microcapsules with high concentrations of collagen would 
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result in beads with poor mechanical properties.  In order to fabricate 
alginate-collagen hydrogels that promote cell attachment without the loss of 
mechanical stiffness, one approach would involve the formation of collagen-core 
microcapsules with an alginate shell.  Perez et al. (2014) utilized this technique to 
immobilize MSCs.  Cells were able to attach and proliferate within this scaffold, and 
underwent osteogenic differentiation under the appropriate stimuli, providing a 
promising tool in bone tissue regeneration.  Also, alginate has been modified with 
RGD sequences (Alsberg et al. 2001) or fibronectin (Mosaheb et al. 2003) to promote 
cell adherence, thereby improving cell viability and proliferation.  Viability of DPSCs 
immobilized within low adherence biomaterials could also be increased by the 
modification of the culture conditions.  DPSCs culture in NSC growth medium 
transforms these cells into neurospheres-like aggregates that grow in suspension 
culture (Gervois et al. 2015).  Thus, under these conditions, cell attachment is not a 
requisite to maintain high viability.   
The lack of cell adhesion on the alginate-collagen microcapsules produced in 
this thesis permitted the prevention of spontaneous differentiation of cells.  
However, upon release from microcapsules, NSCs and DPSCs exhibited retained stem 
cell and neuronal differentiation properties, as demonstrated by high proliferation 
rates and production of neuronal markers.  Cell phenotypes evolved from an 
undifferentiated state, where NSCs were bipolar and DPSCs were typically bi-/tri-
polar and fibroblast-like shaped, to a more mature phenotype.  NSCs developed 
neurites sprouting out from cell bodies and long axons.  DPSCs developed several 
processes from cell bodies, forming neuronal-like connexions.  Differentiation of 
stem cells into neuronal cells within hydrogel microcapsules have been achieved by 
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different groups.  Pan et al. (2009) showed that hydrogel composition plays a key role 
in directing cell differentiation.  Whereas hyaluronic acid (HA) combined with PLL 
hydrogels support cell viability, attachment and proliferation, modification of HA with 
Nogo receptor antibody (NgR-Ab) induced the differentiation of NSCs into neurons 
and glial cells.  In a different study, ESCs were differentiated towards neuronal 
lineages within alginate-based microcapsules.  The addition of fibronectin to the 
scaffold induced cell attachment and further addition of HA allowed ESCs neuronal 
differentiation under differentiation culture medium (Bozza et al. 2014).  The 
alginate-collagen microcapsules produced in this thesis provided the cells with a 
favourable environment for cell survival, working as an artificial stem cell “niche” 
capable of maintaining the cells in a quiescent state.  Analysis of gene expression of 
cells under encapsulation conditions would provide a better understanding of the 
metabolic state of the encapsulated cells.  Nagarajan et al. (2014) demonstrated that 
immobilized yeast cells within alginate beads exhibited a stable pattern of gene 
expression that differed markedly from growing cells, highly expressing genes in 
glycolysis, cell wall remodelling, and stress resistance, but decreasing transcription of 
genes that regulate the cell cycle.  Hence, investigation of the gene expression profile 
of encapsulated cells would provide a defined correlation of cell behaviour depending 
on the physico-chemical properties of the encapsulating biomaterial. 
In the last stage of the investigation carried out in this thesis, the potential of 
alginate-collagen microcapsules as cell transplantation systems was investigated in 
an ex vivo model of SCI.  The microcapsules were implanted into the dissected tissues 
after partial injury on the dorsal part of the cord.  The effectiveness of hydrogel 
microcapsules as a method to control integration of transplanted cells was 
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demonstrated.  Whereas cells transplanted as a free cell suspension were easily lost 
within the tissue and did not integrate within the large injury cavity, encapsulated 
cells stayed at the site of injury over the culture period.  Indeed, the difficult control 
of cell disposition and fate within an organism is a major challenge in cell 
transplantation therapies (Gaudet & Popovich 2014).  Due to the lack of ECM 
production after SCI, transplanted cells lack a three-dimensional structure with which 
to interact, which hinders their integration within the host.  The combination of 
hydrogel scaffolds to guide axon regeneration has been successfully applied by 
several groups (Yoshii et al. 2003; Tsai et al. 2006; Günther et al. 2015; Fan et al. 
2017)..  However, some of these scaffolds are typically macroscopic and their 
implantation involves surgical procedures.  Polymer microcapsules provide a less 
invasive method for cellular replacement assisted by an artificial ECM.  Nonetheless, 
the diameter of the microcapsules developed in this thesis (~400 µm), was too large 
to permit cell implantation by simple injection.  Hence, in order to further apply this 
technology in in vivo SCI models, the size of the microcapsules should be reduced.  
This might be easily achieved by reduction of dimensions in the microfluidic device, 
along with an increase in the continuous and dispersed flow rates ratio.  Also, the 
formation of injectable microfibers rather than microcapsules would allow for a 
better control of cell guidance parallel to axonal growth. 
The alginate-collagen microcapsules developed in this thesis allowed for the 
retention of the encapsulated cells at the site of injury.  The viability of encapsulated 
NSCs and DPSCs was studied after transplantation.  Results demonstrated that the 
cells remained viable within the tissues, which was most probably assisted by the lack 
of blood vessels and immune response in the ex vivo slices.  DPSCs survival after 
Chapter 5: General Discussion 
229 
implantation in the CNS in in vivo models has already been demonstrated (Huang et 
al. 2008; Leong et al. 2012; Sakai et al. 2012).  In fact, DPSCs have been demonstrated 
to possess immunomodulatory properties that could help decrease the risk of cell 
death in cases of allo- or xenotransplantation (Zhao et al. 2012).  The neuronal marker 
expression of the encapsulated cells after transplantation was also studied in this 
thesis.  It was hypothesized that the pre-differentiation of DPSCs into neuronal-like 
cells prior to encapsulation and further implantation could restrict the differentiation 
lineage, thereby avoiding the differentiation towards glial cells.  However, this was 
demonstrated to be limited since the expression of GFAP was observed by this group 
of cells.  However, map2 and nestin was also expressed by both undifferentiated and 
pre-differentiated DPSCs.  In contrast, NSCs stained positive for nestin and map2 but 
no expression of GFAP was observed.  
An emerging idea to control cell differentiation is based on the effect on cells 
of biomaterial behaviour.  As cells acquire information from their environment, (e.g. 
the materials that surround them) the biomaterials in which cells are encapsulated 
can give messages to stem cells in the form of by-products upon degradation, 
swelling, compression, etc. (Place et al. 2009).  Khetan et al. (2013) demonstrated 
that the fate of human MSCs is guided by degradation-mediated cellular-traction.  
Whereas HA hydrogels that permit cell-mediated degradation favoured 
osteogenesis, the switch towards a hydrogel with restricted degradation caused 
adipogenesis.  Hence, the physico-chemical properties of hydrogels can be easily 
adjusted to guide differentiation.  Also, the incorporation of growth factors within 
the scaffolds that are released upon biomaterial degradation is an attractive 
approach for the control of cell behaviour.  In this sense, the co-encapsulation of 
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growth factors promoting neuronal differentiation along with stem cells might 
provide an area of investigation to further develop the work presented in this thesis.  
Because SCI results in the damage of different cell types, one single therapy would 
not provide completely functional recovery.  Hence, implantation of different stem 
cell types encapsulated along with appropriate “sets” of growth factors that promote 
differentiation down to different neuronal cell types, would provide a complete 
recovery after SCI.  It has been demonstrated that DPSCs release growth factors and 
neurotrophins that promotes endogenous axonal regeneration (Sakai et al. 2012).  
However, regenerating axons require remyelination to allow the transmission of 
electrical signals along the spinal cord.  Co-encapsulation of oligodendrocyte 
precursors along with specific growth factors that promotes their maturation would 
provide remyelination of the regenerating axons (Watkins et al. 2008).  Also, the 
replacement of non-activated astrocytes at the injury site would allow for the 
reestablishment of the homeostasis, providing trophic support to the repaired cells.  
Altogether, these wound healing mechanisms would allow for a complete functional 
recovery.  
In summary, the investigations presented in this project demonstrate the 
development of a microfluidic technique for the successful encapsulation of two 
different cell types (examples of adherent and non-adherent cells).  The method 
developed is compatible with cell survival and the maintenance of stem cell 
properties upon encapsulation and subsequent release from the ECM-based 
microcapsules.  Although neuronal differentiation of DPSCs have been extensively 
reported in 2D culture (Nosrat et al. 2004; Hisham et al. 2013; Young et al. 2016), to 
our knowledge, any protocol for the neuronal differentiation of DPSCs within 
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hydrogel microcapsules have been yet described.  Hence, DPSC’s ability for neuronal 
differentiation linked to the successful development of a cell encapsulation 
technique represent an opportunity for further studies beyond the findings of this 
thesis.   
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APPENDIX I : Tables of antibodies 
 
Table 1.  Primary antibodies 
Antibody Manufacturer Cat. No. 
Host 
Species 
Isotype 
Concentration 
(µg/ml) 
Nestin Sigma N5413 Rabbit Polyclonal 10 
Sox2 Abcam ab97959 Rabbit Polyclonal 10 
Oct4 Abcam ab18976 Rabbit Polyclonal 2.5 
GFAP 
Life 
Technologies 
PA5-16291 Rabbit  Polyclonal 2 
β-III tubulin Cell Signalling 5568S Rabbit IgG 5 
Map2 Cell Signalling 8707S Rabbit IgG 5 
 
 
Table 2.  Isotype control 
Antibody Manufacturer Cat. No. 
Concentration 
(µg/ml) 
Normal rabbit 
IgG 
Santa Cruz sc-2027 5 
 
 
Table 3.  Secondary antibodies 
Antibody Manufacturer 
Cat. 
No. 
Host 
Species 
Fluorophore 
Concentration 
(µg/ml) 
Anti-
rabbit 
IgG (H+L) 
Life 
Technologies 
A-
11008 
Goat 
Alexa Fluor 
488 
4 
Anti-
rabbit 
IgG (H+L) 
Life 
Technologies 
A-
11012 
Goat 
Alexa Fluor 
594 
4 
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APPENDIX II : ISOTYPE CONTROL IN MONOLAYER CULTURES 
 
Merged images for rabbit IgG as an isotype control for β-III tubulin and Map2 in DPSCs (A) 
and NSC (B) in monolayer culture.  Scale bars = 50μm.   
A B
DAPI/Isotype control
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APPENDIX III : APOPTOSIS TUNEL ASSAY POSITIVE CONTROL 
 
Merged images of apoptotic nuclei of spinal cord tissue (A) and encapsulated cells 
transplanted into the ex vivo SCI model (B).  Samples were DNAse treated prior to staining 
with Apoptosis Tunel Assay kit.  Scale bar = 50µm. 
   
A D
DAPI/GFP/Apoptotic nucleiDAPI/Apoptotic nuclei
B
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APPENDIX IV : EX VIVO ISOTYPE CONTROL 
 
Ex vivo spinal cord slice cultures from the three cell types investigated ((A) Undifferentiated 
DPSCs, (B) Pre-differentiated DPSCs and (C) Undifferentiated NSCs) were negatively stained 
A
B
C
DAPI/GFP/Isotype control
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with Rabbit IgG isotype, demonstrating specificity for monoclonal antibodies, Map2 and 
GFAP.  Scale bar = 50µm. 
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APPENDIX V : ENDOGENOUS PRODUCTION OF NEURONAL 
MARKERS 
 
Endogenous production of neuronal markers: (A) Nestin, (B) Map2 and (C) GFAP.   
Scale bar = 100µm.
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